Revvity (RVTY) 10-K 24 Feb 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 28, 2014	Feb. 19, 2015	Jun. 27, 2014
Document and Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Entity Registrant Name	PERKINELMER INC
Entity Central Index Key	31791
Current Fiscal Year End Date	-16
Document Period End Date	28-Dec-14
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		113,026,313
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$5,228,997,924

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Revenue
Product revenue	$1,540,075	$1,498,070	$1,474,674
Service revenue	697,144	659,516	630,514
Total revenue	2,237,219	2,157,586	2,105,188
Cost of product revenue	805,345	783,584	762,989
Cost of service revenue	427,266	397,860	380,670
Selling, general and administrative expenses	659,335	581,898	627,370
Research and development expenses	121,141	132,400	131,835
Restructuring and contract termination charges, net	13,390	33,892	25,051
Asset impairment	0	158	74,153
Operating income from continuing operations	210,742	227,794	103,120
Interest and other expense, net	41,139	64,110	47,956
Income from continuing operations before income taxes	169,603	163,684	55,164
Provision for (benefit from) income taxes	8,437	-10,583	-16,125
Income from continuing operations	161,166	174,267	71,289
Loss from discontinued operations before income taxes	-4,959	-10,352	-4,577
(Loss) gain on disposition of discontinued operations before income taxes	-260	-1,810	2,405
Benefit from income taxes on discontinued operations and dispositions	-1,831	-5,107	-823
Net loss from discontinued operations and dispositions	-3,388	-7,055	-1,349
Net income	$157,778	$167,212	$69,940
Basic earnings per share:
Continuing operations	$1.43	$1.55	$0.63
Discontinued operations	($0.03)	($0.06)	($0.01)
Net Income	$1.40	$1.49	$0.61
Diluted earnings per share:
Continuing operations	$1.42	$1.54	$0.62
Discontinued operations	($0.03)	($0.06)	($0.01)
Net income	$1.39	$1.47	$0.61

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Net income	$157,778	$167,212	$69,940
Other comprehensive income (loss)
Foreign currency translation adjustments, net of tax	-52,951	8,756	11,363
Other Comprehensive Income (Loss), Amortization Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service (Cost) Credit, Net of Tax	146	-658	-82
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax	0	2,892	1,196
Unrealized (losses) gains on securities, net of tax	14	8	30
Other comprehensive income (loss)	-52,791	10,998	12,507
Comprehensive income	$104,987	$178,210	$82,447

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 28, 2014	Dec. 29, 2013
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$174,821	$173,242
Accounts receivable, net	470,563	466,749
Inventories, net	285,457	260,858
Other current assets	137,710	140,342
Current assets of discontinued operations	0	3,647
Total current assets	1,068,551	1,044,838
Property, plant and equipment, net	176,194	183,188
Marketable securities and investments	1,568	1,319
Intangible assets, net	490,265	460,430
Goodwill	2,284,077	2,143,120
Other assets, net	113,420	111,633
Disposal Group, Including Discontinued Operation, Long Lived Assets	0	2,184
Total assets	4,134,075	3,946,712
Current liabilities:
Short-term debt	1,075	2,624
Accounts payable	173,953	166,881
Accrued restructuring and contract termination costs	17,124	26,374
Accrued expenses and other current liabilities	403,021	403,678
Current liabilities of discontinued operations	2,137	3,239
Total current liabilities	597,310	602,796
Long-term debt	1,051,892	932,104
Long-term liabilities	442,771	417,325
Total liabilities	2,091,973	1,952,225
Commitments and contingencies (see Note 18)
Stockholders' equity:
Preferred stock-$1 par value per share, authorized 1,000,000 shares; none issued or outstanding	0	0
Common stock-$1 par value per share, authorized 300,000,000 shares; issued and outstanding 112,626,000 shares and 115,036,000 shares at December 29, 2013 and December 30, 2012, respectively	112,481	112,626
Capital in excess of par value	94,276	119,906
Retained earnings	1,810,545	1,684,364
Accumulated other comprehensive income	24,800	77,591
Total stockholders' equity	2,042,102	1,994,487
Total liabilities and stockholders' equity	$4,134,075	$3,946,712

Consolidated_Balance_Sheet_Par

Consolidated Balance Sheet Parenthetical (USD $)	Dec. 28, 2014	Dec. 29, 2013
Balance Sheet Parenthetical [Abstract]
Preferred stock, par value	$1	$1
Preferred stock, authorized	1,000,000	1,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$1	$1
Common stock, authorized	300,000,000	300,000,000
Common stock, issued	112,481,000	112,626,000
Common stock, outstanding	112,481,000	112,626,000

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Common Stock Amount [Member]	Capital In Excess of Par Value [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
In Thousands
Beginning Balance at Jan. 01, 2012	$1,842,216	$113,157	$164,290	$1,510,683	$54,086
Net income	69,940			69,940
Other comprehensive income (loss)	12,507				12,507
Dividends	-32,050			-32,050
Exercise of employee stock options and related income tax benefits	34,006	1,611	32,395
Issuance of common stock for employee benefit plans	1,323	54	1,269
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations	2,104	82	2,022
Issuance of common stock for long-term incentive program	8,955	296	8,659
Stock compensation	5,019	0	5,019	0	0
Ending Balance at Dec. 30, 2012	1,939,812	115,036	209,610	1,548,573	66,593
Net income	167,212			167,212
Other comprehensive income (loss)	10,998				10,998
Dividends	-31,421			-31,421	0
Exercise of employee stock options and related income tax benefits	19,842	947	18,895
Issuance of common stock for employee benefit plans	2,732	90	2,642
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations	127,398	3,728	123,670
Issuance of common stock for long-term incentive program	8,257	281	7,976
Stock compensation	4,453	0	4,453	0	0
Ending Balance at Dec. 29, 2013	1,994,487	112,626	119,906	1,684,364	77,591
Net income	157,778			157,778
Other comprehensive income (loss)	-52,791				-52,791
Dividends	-31,597			-31,597
Exercise of employee stock options and related income tax benefits	24,455	1,024	23,431
Issuance of common stock for employee benefit plans	2,539	61	2,478
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations	65,529	1,448	64,081
Issuance of common stock for long-term incentive program	7,880	218	7,662
Stock compensation	4,880	0	4,880	0	0
Ending Balance at Dec. 28, 2014	$2,042,102	$112,481	$94,276	$1,810,545	$24,800

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Operating activities:
Net income	$157,778	$167,212	$69,940
Less: Loss from discontinued operations and dispositions	3,388	7,055	1,349
Income from continuing operations	161,166	174,267	71,289
Adjustments to reconcile net income from continuing operations to net cash provided by continuing operations:
Restructuring and contract termination charges, net	13,390	33,892	25,051
Depreciation and amortization	116,736	126,879	125,126
Stock-based compensation	14,464	14,053	20,625
Pension and other postretirement expense	77,669	-18,176	35,336
Deferred taxes	-33,351	-29,907	-65,551
Contingencies and prior year tax matters	-7,605	-34,455	1,382
Amortization of deferred debt issuance costs, interest rate hedge and accretion of discounts	1,434	6,502	3,517
Losses (gains) on step acquisitions and dispositions, net	108	-1,566	0
Amortization of acquired inventory revaluation	2,425	203	5,214
Asset impairment	0	158	74,153
Changes in assets and liabilities which (used) provided cash, excluding effects from companies purchased and divested:
Accounts receivable, net	-16,989	-14,071	-44,878
Inventories, net	-24,642	-14,171	-7,860
Accounts payable	8,103	-1,083	-8,083
Excess tax benefit from exercise of common stock options	0	0	1,767
Accrued expenses and other	-30,640	-85,277	-83,102
Net cash provided by operating activities of continuing operations	282,268	157,248	153,986
Net cash (used in) provided by operating activities of discontinued operations	-671	1,343	-1,816
Net cash provided by operating activities	281,597	158,591	152,170
Investing activities:
Capital expenditures	-29,072	-38,981	-42,401
Proceeds from dispositions of property, plant and equipment, net	2,531	52,202	0
Changes in restricted cash balances	0	0	487
Proceeds from surrender of life insurance policies	490	783	0
Payments for acquisitions and investments, net of cash and cash equivalents acquired	-271,477	-15,699	-40,858
Net cash used in investing activities of continuing operations	-297,528	-1,695	-82,772
Net cash provided by (used in) investing activities of discontinued operations	1,631	484	2,463
Net cash (used in) provided by investing activities	-295,897	-1,211	-80,309
Financing activities:
Payments on revolving credit facility	-356,000	-538,000	-435,850
Proceeds from revolving credit facility	475,000	677,000	395,000
Early Repayment of Senior Debt	0	-150,000	0
Payments of Debt Extinguishment Costs	0	-11,119	0
Payments of debt issuance costs	-1,845	0	-416
Proceeds from (payments on) other credit facilities	-12,675	5,281	5,274
Settlement of cash flow hedges	0	1,363	4,050
Payments for acquisition-related contingent consideration	-855	0	-12,459
Excess tax benefit from exercise of common stock options	0	0	1,767
Proceeds from issuance of common stock under stock plans	24,455	20,313	32,478
Purchases of common stock	-65,529	-127,398	-2,104
Dividends paid	-31,620	-31,600	-31,903
Net cash provided by (used in) financing activities	30,931	-154,160	-44,163
Effect of exchange rate changes on cash and cash equivalents	-15,052	-1,422	1,404
Net (decrease) increase in cash and cash equivalents	1,579	1,798	29,102
Cash and cash equivalents at beginning of year	173,242	171,444	142,342
Cash and cash equivalents at end of year	174,821	173,242	171,444
Supplemental disclosures of cash flow information
Interest	30,320	39,904	40,447
Income taxes	$40,638	$36,675	$53,281

Nature_of_Operations_and_Accou

Nature of Operations and Accounting Policies	12 Months Ended
	Dec. 28, 2014
Accounting Policies [Abstract]
Nature of Operations and Accounting Policies	Nature of Operations and Accounting Policies
	Nature of Operations:    PerkinElmer, Inc. is a leading provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. Through its advanced technologies, solutions and services, critical issues are addressed that help to improve the health and safety of people and their environment. The results are reported within two reporting segments: Human Health and Environmental Health.
	The consolidated financial statements include the accounts of PerkinElmer, Inc. and its subsidiaries (the “Company”). All intercompany balances and transactions have been eliminated in consolidation.
	The Company has two operating segments; Human Health and Environmental Health. The Company’s Human Health segment concentrates on developing diagnostics, tools and applications to help detect diseases earlier and more accurately and to accelerate the discovery and development of critical new therapies. Within the Human Health segment, the Company serves both the diagnostics and research markets. The Company’s Environmental Health segment provides products, services and solutions to facilitate the creation of safer food and consumer products, more secure surroundings and efficient energy resources. The Environmental Health segment serves the environmental, industrial and laboratory services markets.
	The Company’s fiscal year ends on the Sunday nearest December 31. The Company reports fiscal years under a 52/53 week format. Under this method, certain years will contain 53 weeks. Each of the fiscal years ended December 28, 2014, December 29, 2013 and December 30, 2012 included 52 weeks. The fiscal year ending January 3, 2016 will include 53 weeks. The extra week in fiscal year 2015 will be included in the third quarter.
	The Company has evaluated subsequent events from December 28, 2014 through the date of the issuance of these consolidated financial statements and has determined that no material subsequent events have occurred that would affect the information presented in these consolidated financial statements.
	Accounting Policies and Estimates:    The preparation of consolidated financial statements in accordance with United States (“U.S.”) Generally Accepted Accounting Principles (“GAAP”) requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.
	Revenue Recognition:    The Company’s product revenue is recorded when persuasive evidence of an arrangement exists, delivery has occurred, the price to the buyer is fixed or determinable, and collectability is reasonably assured. For products that include installation, and if the installation meets the criteria to be considered a separate element, product revenue is recognized upon delivery, and installation revenue is recognized when the installation is complete. For revenue that includes customer-specified acceptance criteria, revenue is recognized after the acceptance criteria have been met. Certain of the Company’s products require specialized installation. Revenue for these products is deferred until installation is completed. Revenue from services is deferred and recognized over the contractual period, or as services are rendered.
	In limited circumstances, the Company has arrangements that include multiple elements that are delivered at different points of time, such as revenue from products and services with a remaining service or storage component, including cord blood processing and storage. For these arrangements, the revenue is allocated to each of the deliverables based upon their relative selling prices as determined by a selling-price hierarchy. A deliverable in an arrangement qualifies as a separate unit of accounting if the delivered item has value to the customer on a stand-alone basis. A delivered item that does not qualify as a separate unit of accounting is combined with the other undelivered items in the arrangement and revenue is recognized for those combined deliverables as a single unit of accounting. The selling price used for each deliverable is based upon vendor-specific objective evidence ("VSOE") if such evidence is available, third-party evidence ("TPE") if VSOE is not available, and management's best estimate of selling price ("BESP") if neither VSOE nor TPE are available. TPE is the price of the Company's or any competitor's largely interchangeable products or services in stand-alone sales to similarly-situated customers. BESP is the price at which the Company would sell the deliverable if it were sold regularly on a stand-alone basis, considering market conditions and entity-specific factors.
	Revenue from software licenses and services was 5% of the Company's total revenue for fiscal year 2014, 5% of the Company's total revenue for fiscal year 2013, and 3% of the Company's total revenue for fiscal year 2012. The Company sells its software licenses with maintenance services and, in some cases, also with consulting services. For the undelivered elements, the Company determines VSOE of fair value to be the price charged when the undelivered element is sold separately. The Company determines VSOE for maintenance sold in connection with a software license based on the amount that will be separately charged for the maintenance renewal period. The Company determines VSOE for consulting services by reference to the amount charged for similar engagements when a software license sale is not involved.
	The Company recognizes revenue from software licenses sold together with maintenance and/or consulting services upon shipment using the residual method, provided that the above criteria have been met. If VSOE of fair value for the undelivered elements cannot be established, the Company defers all revenue from the arrangement until the earlier of the point at which such sufficient VSOE does exist or all elements of the arrangement have been delivered, or if the only undelivered element is maintenance, then the Company recognizes the entire fee ratably over the maintenance period.
	The Company recognizes revenue from the grant of certain intellectual property rights for patented technologies it owns. These rights typically include a combination of the following: the grant of a non-exclusive, retroactive and future license to patented technologies, a covenant-not-to-sue, the release of the licensee from certain claims, and the dismissal of any pending litigation. The intellectual property rights granted may be perpetual in nature, extending until the expiration of the related patents, or can be granted for a defined timeframe. For these arrangements, the revenue is allocated to each of the deliverables based upon their relative selling prices as determined by the selling-price hierarchy. In the case where the agreement includes the dismissal of any pending litigation, the Company allocates between revenue and litigation settlement using the residual method. The Company recognizes revenue when the earnings process is complete and upon the execution of the agreement, when collectability is reasonably assured, or upon receipt of the minimum upfront fee for term agreement renewals, and when all other revenue recognition criteria have been met.
	Service revenues represent the Company’s service offerings including service contracts, field service including related time and materials, diagnostic testing, cord blood processing and storage, and training. Service revenues are recognized as the service is performed. Revenues for service contracts and storage contracts are recognized over the contract period.
	The Company sells products and accessories predominantly through its direct sales force. As a result, the use of distributors is generally limited to geographic regions where the Company has no direct sales force. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including its distributors. Payment terms granted to distributors are the same as those granted to end-user customers and payments are not dependent upon the distributors’ receipt of payment from their end-user customers. Sales incentives related to distributor revenue are also the same as those for end-user customers.
	Warranty Costs:    The Company provides for estimated warranty costs for products at the time of their sale. Warranty liabilities are estimated using expected future repair costs based on historical labor and material costs incurred during the warranty period.
	Shipping and Handling Costs:    The Company reports shipping and handling revenue in revenue, to the extent they are billed to customers, and the associated costs in cost of product revenue.
	Inventories:    Inventories, which include material, labor and manufacturing overhead, are valued at the lower of cost or market. Inventories are accounted for using the first-in, first-out method of determining inventory costs. Inventory quantities on-hand are regularly reviewed, and where necessary, provisions for excess and obsolete inventory are recorded based primarily on the Company’s estimated forecast of product demand and production requirements.
	Income Taxes:    The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases. This method also requires the recognition of future tax benefits such as net operating loss carryforwards, to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established for any deferred tax asset for which realization is not more likely than not. With respect to earnings expected to be indefinitely reinvested offshore, the Company does not accrue tax for the repatriation of such foreign earnings.
	The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions and other issues. These reserves are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. Potential interest and penalties associated with such uncertain tax positions is recorded as a component of income tax expense. See Note 6, below, for additional details.
	Property, Plant and Equipment:    The Company depreciates plant and equipment using the straight-line method over its estimated useful lives, which generally fall within the following ranges: buildings- 10 to 40 years; leasehold improvements-estimated useful life or remaining term of lease, whichever is shorter; and machinery and equipment- 3 to 7 years. Certain tooling costs are capitalized and amortized over a 3-year life, while repairs and maintenance costs are expensed.
	Asset Retirement Obligations:    The Company records obligations associated with its lease obligations, the retirement of tangible long-lived assets and the associated asset-retirement costs in accordance with authoritative guidance on asset retirement obligations. The Company reviews legal obligations associated with the retirement of long-lived assets that result from contractual obligations or the acquisition, construction, development and/or normal use of the assets. If it is determined that a legal obligation exists, regardless of whether the obligation is conditional on a future event, the fair value of the liability for an asset retirement obligation is recognized in the period in which it is incurred, if a reasonable estimate of fair value can be made. The fair value of the liability is added to the carrying amount of the associated asset, and this additional carrying amount is depreciated over the life of the asset. The difference between the gross expected future cash flow and its present value is accreted over the life of the related lease as interest expense. The amounts recorded in the consolidated financial statements are not material to any year presented.
	Pension and Other Postretirement Benefits:    The Company sponsors both funded and unfunded U.S. and non-U.S. defined benefit pension plans and other postretirement benefits. The Company immediately recognizes actuarial gains and losses in operating results in the year in which the gains and losses occur. Actuarial gains and losses are measured annually as of fiscal year end and accordingly will be recorded in the fourth quarter, unless the Company is required to perform an interim remeasurement. The remaining components of pension expense, primarily service and interest costs and assumed return on plan assets, are recorded on a quarterly basis. The Company’s funding policy provides that payments to the U.S. pension trusts shall at least be equal to the minimum funding requirements of the Employee Retirement Income Security Act of 1974. Non-U.S. plans are accrued for, but generally not fully funded, and benefits are paid from operating funds.
	Translation of Foreign Currencies:    For foreign operations, asset and liability accounts are translated at current exchange rates; income and expenses are translated using weighted average exchange rates for the reporting period. Resulting translation adjustments, as well as translation gains and losses from certain intercompany transactions considered permanent in nature, are reported in accumulated other comprehensive income, a separate component of stockholders’ equity. Gains and losses arising from transactions and translation of period-end balances denominated in currencies other than the functional currency are included in other expense, net, and were not material for fiscal years 2014, 2013, and 2012.
	Business Combinations:    Business combinations are accounted for at fair value. Acquisition costs are expensed as incurred and recorded in selling, general and administrative expenses; previously held equity interests are valued at fair value upon the acquisition of a controlling interest; in-process research and development (“IPR&D”) is recorded at fair value as an intangible asset at the acquisition date; restructuring costs associated with a business combination are expensed subsequent to the acquisition date; and changes in deferred tax asset valuation allowances and income tax uncertainties after the acquisition date affect income tax expense. All changes that do not qualify as measurement period adjustments are included in current period earnings. The accounting for business combinations requires estimates and judgment as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair value for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. If the actual results differ from the estimates and judgments used in these estimates, the amounts recorded in the financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of finite-lived intangible assets, or the recognition of additional consideration which would be expensed.
	Goodwill and Other Intangible Assets:    The Company’s intangible assets consist of (i) goodwill, which is not being amortized; (ii) indefinite lived intangibles, which consist of certain trademarks and trade names that are not subject to amortization; and (iii) amortizing intangibles, which consist of patents, trade names and trademarks, licenses, customer relationships, and purchased technologies, which are being amortized over their estimated useful lives.
	The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of a two-step process. The first step is the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. The second step measures the amount of an impairment loss, and is only performed if the carrying value exceeds the fair value of the reporting unit. This annual impairment assessment is performed by the Company on the later of January 1 or the first day of each fiscal year. This same impairment test will be performed at other times during the course of the year, should an event occur which suggests that the recoverability of goodwill should be reconsidered. Non-amortizing intangibles are also subject to an annual impairment test. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized. In addition, the Company evaluates the remaining useful life of its non-amortizing intangible assets at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful lives of non-amortizing intangible assets are no longer indefinite, the assets will be tested for impairment. These intangible assets will then be amortized prospectively over their estimated remaining useful life and accounted for in the same manner as other intangible assets that are subject to amortization. Recoverability of amortizing intangible assets is assessed only when events have occurred that may give rise to impairment. When a potential impairment has been identified, forecasted undiscounted net cash flows of the operations to which the asset relates are compared to the current carrying value of the long-lived assets present in that operation. If such cash flows are less than such carrying amounts, long-lived assets, including such intangibles, are written down to their respective fair values. See Note 12, below, for additional details.
	Stock-Based Compensation:    The Company accounts for stock-based compensation expense based on estimated grant date fair value, generally using the Black-Scholes option-pricing model. The fair value is recognized, net of estimated forfeitures, as expense in the consolidated financial statements over the requisite service period. The determination of fair value and the timing of expense using option pricing models such as the Black-Scholes model require the input of highly subjective assumptions, including the expected forfeiture rate, life of the option and the expected price volatility of the underlying stock. The Company estimates the expected forfeiture and expected life assumptions based on historical experience. In determining the Company’s expected stock price volatility assumption, the Company reviews both the historical and implied volatility of the Company’s common stock, with implied volatility based on the implied volatility of publicly traded options on the Company’s common stock. The Company has one stock-based compensation plan from which it makes grants, which is described more fully in Note 18, below.
	Marketable Securities and Investments:    The cost of securities sold is based on the specific identification method. If securities are classified as available for sale, the Company records these investments at their fair values with unrealized gains and losses included in accumulated other comprehensive income. Under the cost method of accounting, equity investments in private companies are carried at cost and are adjusted for other-than-temporary declines in fair value, additional investments or distributions.
	Cash and Cash Equivalents:    The Company considers all highly liquid unrestricted instruments with a purchased maturity of three months or less to be cash equivalents. The carrying amount of cash equivalents approximates fair value due to the short maturities of these instruments.
	Environmental Matters:    The Company accrues for costs associated with the remediation of environmental pollution when it is probable that a liability has been incurred and the Company’s proportionate share of the amount can be reasonably estimated. The recorded liabilities have not been discounted.
	Research and Development:    Research and development costs are expensed as incurred. The fair value of acquired in-process research and development ("IPR&D") costs are recorded at fair value as an intangible asset at the acquisition date and amortized once the product is ready for sale or expensed if abandoned.
	Restructuring Charges:    In recent fiscal years, the Company has undertaken a series of restructuring actions related to the impact of acquisitions and divestitures, the alignment of its operations with its growth strategy, the integration of its business units and productivity initiatives. In connection with these initiatives, the Company has recorded restructuring charges, as more fully described in Note 4, below. Generally, costs associated with an exit or disposal activity are recognized when the liability is incurred. Prior to recording restructuring charges for employee separation agreements, the Company notifies all employees of termination. Costs related to employee separation arrangements requiring future service beyond a specified minimum retention period are recognized over the service period. Costs related to lease terminations are recorded at the fair value of the liability based on the remaining lease rental payments, reduced by estimated sublease rentals that could be reasonably obtained for the property, at the date the Company ceases use.
	Comprehensive Income:    In February 2013, the Financial Accounting Standards Board issued Accounting Standards Update No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, requiring the presentation of reclassifications out of accumulated other comprehensive income on the face of the financial statements or as a separate disclosure in the notes to the financial statements. The reclassifications out of accumulated other comprehensive income and into net income were not material for the fiscal years ending December 28, 2014, December 29, 2013 and December 30, 2012. See Note 19 for additional details.
	Comprehensive income is defined as net income or loss and other changes in stockholders’ equity from transactions and other events from sources other than stockholders. Comprehensive income is reflected in the consolidated statements of comprehensive income.
	Derivative Instruments and Hedging:    Derivatives are recorded on the consolidated balance sheets at fair value. Accounting for gains or losses resulting from changes in the values of those derivatives depends on the use of the derivative instrument and whether it qualifies for hedge accounting.
	For a cash flow hedge, the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income and subsequently amortized into net earnings when the hedged exposure affects net earnings. Cash flow hedges related to anticipated transactions are designated and documented at the inception of each hedge by matching the terms of the contract to the underlying transaction. The Company classifies the cash flows from hedging transactions in the same categories as the cash flows from the respective hedged items. Once established, cash flow hedges are generally recorded in other comprehensive income, unless an anticipated transaction is no longer likely to occur, and subsequently amortized into net earnings when the hedged exposure affects net earnings. Discontinued or dedesignated cash flow hedges are immediately settled with counterparties, and the related accumulated derivative gains or losses are recognized into net earnings on the consolidated financial statements. Settled cash flow hedges related to forecasted transactions that remain probable are recorded as a component of other comprehensive income and are subsequently amortized into net earnings when the hedged exposure affects net earnings. Forward contract effectiveness for cash flow hedges is calculated by comparing the fair value of the contract to the change in value of the anticipated transaction using forward rates on a monthly basis. As of December 28, 2014, the Company had five outstanding cash flow hedges with a Euro denominated notional amount of €238.2 million. As of December 29, 2013, the Company had no outstanding cash flow hedges. As of December 30, 2012, the Company had two outstanding cash flow hedges with Euro denominated notional amounts of €50.0 million. The Company also has entered into other foreign currency forward contracts that are not designated as hedging instruments for accounting purposes. These contracts are recorded at fair value, with the changes in fair value recognized into net earnings on the consolidated financial statements.
	Recently Issued Accounting Pronouncements:    From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations.
	In April 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. Under this new guidance, only disposals of components of an entity that represent strategic shifts that have, or will have, a major effect on an entity's operations and financial results will be presented as discontinued operations. The standard also requires new disclosures related to individually significant disposals that do not meet the definition of a discontinued operation. The provisions of this guidance are effective for interim and annual periods beginning after December 15, 2014. The Company will utilize this new guidance when reporting new discontinued operations or disclosing new disposals in its future filings.
	In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers. Under this new guidance, an entity should use a five-step process to recognize revenue, which depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard also requires new disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The provisions of this guidance are effective for interim and annual periods beginning after December 15, 2016. The Company is evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company’s consolidated financial position, results of operations and cash flows.

Business_Combinations_and_Asse

Business Combinations and Asset Purchases	12 Months Ended
	Dec. 28, 2014
Business Combinations [Abstract]
Business Combinations and Asset Purchases	Business Combinations
	Acquisitions in fiscal year 2014
	Acquisition of Perten Instruments Group AB. In December 2014, the Company acquired all of the outstanding stock of Perten Instruments Group AB ("Perten"). Perten is a provider of analytical instruments and services for quality control of food, grain, flour and feed. The Company expects this acquisition to enhance its industrial, environmental and safety business by expanding the Company's product offerings to the academic and industrial end markets. The Company paid the shareholders of Perten $269.9 million in cash for the stock of Perten. The excess of the purchase price over the fair value of the acquired net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired, and has been allocated to goodwill, none of which is tax deductible. The Company has reported the operations for this acquisition within the results of the Company’s Environmental Health segment from the acquisition date. Identifiable definite-lived intangible assets, such as core technology, customer relationships and trade names, acquired as part of this acquisition had weighted average amortization periods of approximately 5 to 10 years.
	Other acquisitions in fiscal year 2014. In addition to the Perten acquisition, the Company completed the acquisition of two businesses in fiscal year 2014 for total consideration of $18.0 million in cash and $4.3 million of assumed debt. The excess of the purchase price over the fair value of each of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired, and has been allocated to goodwill, none of which is tax deductible. The Company reported the operations for these acquisitions within the results of the Human Health and Environmental Health segments from the acquisition dates.
	The total purchase price for the acquisitions in fiscal year 2014 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows:
		Perten			Other
		(Preliminary)
		(In thousands)
	Fair value of business combination:
	Cash payments	$	269,937		$	17,898
	Working capital and other adjustments	—			151
	Less: cash acquired	(16,732		)	(124		)
	Total	$	253,205		$	17,925
	Identifiable assets acquired and liabilities assumed:
	Current assets	$	32,805		$	1,965
	Property, plant and equipment	1,485			125
	Other assets	—			364
	Identifiable intangible assets:
	Core technology	16,000			1,705
	Trade names	7,000			—
	Customer relationships	87,000			6,800
	IPR&D	—			1,266
	Goodwill	164,164			15,981
	Deferred taxes	(31,454		)	(3,072		)
	Deferred revenue	—			(589		)
	Liabilities assumed	(16,195		)	(2,333		)
	Debt assumed	(7,600		)	(4,287		)
	Total	$	253,205		$	17,925
	Acquisitions in fiscal year 2013
	During fiscal year 2013, the Company completed the acquisition of four businesses for total consideration of $11.4 million, in cash. As of the closing dates, the Company potentially had to pay additional contingent consideration for the four acquired businesses of up to $2.2 million, which at closing had an estimated fair value of $1.1 million. During fiscal year 2014, the Company paid $0.4 million in additional deferred consideration for one of these acquisitions. The excess of the purchase price over the fair value of each of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired, and has been allocated to goodwill, none of which is tax deductible. The Company reported the operations for these acquisitions within the results of the Human Health and Environmental Health segments from the acquisition dates.
	Acquisition in fiscal year 2012
	Acquisition of Shanghai Haoyuan Biotech Co., Ltd. In November 2012, the Company acquired all outstanding stock of Shanghai Haoyuan Biotech Co., Ltd. ("Haoyuan"). Haoyuan is a provider of nucleic acid-based blood screening solutions for the blood banking and clinical diagnostics markets. The Company expects this acquisition to extend the Company's capabilities into nucleic acid blood screening, as well as deepen its position in the growing molecular clinical diagnostics market in China. The Company paid the shareholders of Haoyuan $38.0 million in cash for the stock of Haoyuan. The Company recorded a receivable of $2.7 million from the shareholders of Haoyuan as a reduction of purchase price for the settlement of certain contingencies. This receivable was collected in fiscal year 2013. As of the closing date, the Company potentially had to pay the shareholders additional contingent consideration of up to $30.0 million, which at closing had an estimated fair value of $1.9 million. The excess of the purchase price over the fair value of the acquired net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired, and has been allocated to goodwill, none of which is tax deductible. The Company reported the operations for this acquisition within the results of the Company’s Human Health segment from the acquisition date. Identifiable definite-lived intangible assets, such as core technology and trade names, acquired as part of this acquisition had weighted average amortization periods of 8 years.
	The total purchase price has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows:
		Haoyuan
		(In thousands)
	Fair value of business combination:
	Cash payments	$	38,000
	Contingent consideration	1,900
	Working capital and other adjustments	(2,729		)
	Less: cash acquired	(175		)
	Total	$	36,996
	Identifiable assets acquired and liabilities assumed:
	Current assets	$	2,389
	Property, plant and equipment	2,906
	Identifiable intangible assets:
	Core technology	17,700
	Trade names	400
	IPR&D	300
	Goodwill	19,682
	Deferred taxes	(2,656		)
	Liabilities assumed	(3,725		)
	Total	$	36,996
	The Company does not consider the acquisitions completed during fiscal years 2014, 2013, and 2012 to be material to its consolidated results of operations; therefore, the Company is not presenting pro forma financial information of operations. The Company has also determined that the presentation of the results of operations for each of those acquisitions, from the date of acquisition, is impracticable due to the integration of the operations upon acquisition.
	As of December 28, 2014 the allocation of purchase prices for acquisitions completed in fiscal years 2013 and 2012 were final. The preliminary allocations of the purchase prices for acquisitions completed in fiscal year 2014 were based upon initial valuations. The Company's estimates and assumptions underlying the initial valuations are subject to the collection of information necessary to complete its valuations within the measurement periods, which are up to one year from the respective acquisition dates. The primary areas of the preliminary purchase price allocations that are not yet finalized relate to the fair value of certain tangible and intangible assets acquired and liabilities assumed, assets and liabilities related to income taxes and related valuation allowances, and residual goodwill. The Company expects to continue to obtain information to assist in determining the fair values of the net assets acquired at the acquisition dates during the measurement periods. During the measurement periods, the Company will adjust assets or liabilities if new information is obtained about facts and circumstances that existed as of the acquisition dates that, if known, would have resulted in the recognition of those assets and liabilities as of those dates. Adjustments to the preliminary allocation of the purchase prices during the measurement period require the revision of comparative prior period financial information when reissued in subsequent financial statements. The effect of adjustments to the allocation of the purchase prices made during the measurement periods would be as if the adjustments had been completed on the acquisition dates. The effects of any such adjustments, if material, may cause changes in depreciation, amortization, or other income or expense recognized in prior periods. All changes that do not qualify as adjustments made during the measurement periods are included in current period earnings.
	Allocations of the purchase price for acquisitions are based on estimates of the fair value of the net assets acquired and are subject to adjustment upon finalization of the purchase price allocations. The accounting for business combinations requires estimates and judgments as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair values for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash. Increases or decreases in the fair value of contingent consideration liabilities primarily result from changes in the estimated probabilities of achieving revenue thresholds or product development milestones during the earnout period. The Company may have to pay contingent consideration, related to all acquisitions with open contingency periods, of up to $31.4 million as of December 28, 2014. As of December 28, 2014, the Company has recorded contingent consideration obligations relating to its acquisition of Tetra Teknolojik Sistemler Limited Sirketi with an estimated fair value of $0.1 million. The earnout period for each of these acquisitions does not exceed three years from the respective acquisition date. If the actual results differ from the estimates and judgments used in these fair values, the amounts recorded in the consolidated financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of definite-lived intangible assets, or the recognition of additional consideration which would be expensed.
	In connection with the purchase price allocations for acquisitions, the Company estimates the fair value of deferred revenue assumed with its acquisitions. The estimated fair value of deferred revenue is determined by the legal performance obligation at the date of acquisition, and is generally based on the nature of the activities to be performed and the related costs to be incurred after the acquisition date. The fair value of an assumed liability related to deferred revenue is estimated based on the current market cost of fulfilling the obligation, plus a normal profit margin thereon. The estimated costs to fulfill the deferred revenue are based on the historical direct costs related to providing the services. The Company does not include any costs associated with selling effort, research and development, or the related fulfillment margins on these costs. In most acquisitions, profit associated with selling effort is excluded because the acquired businesses would have concluded the selling effort on the support contracts prior to the acquisition date. The estimated research and development costs are not included in the fair value determination, as these costs are not deemed to represent a legal obligation at the time of acquisition. The sum of the costs and operating income approximates, in theory, the amount that the Company would be required to pay a third-party to assume the obligation.
	Total transaction costs related to acquisition activities for fiscal years 2014, 2013, and 2012 were $3.1 million, $0.1 million and $1.2 million, respectively. These transaction costs were expensed as incurred and recorded in selling, general and administrative expenses in the Company's consolidated statements of operations.

Discontinued_Operations

Discontinued Operations	12 Months Ended
	Dec. 28, 2014
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Discontinued Operations
	As part of the Company’s continuing efforts to focus on higher growth opportunities, the Company has discontinued certain businesses. The Company has accounted for these businesses as discontinued operations and, accordingly, has presented the results of operations and related cash flows as discontinued operations for all periods presented. Any remaining assets and liabilities of these businesses have been presented separately, and are reflected within assets and liabilities from discontinued operations in the accompanying consolidated balance sheets as of December 28, 2014 and December 29, 2013.
	The Company recorded the following pre-tax gains and losses, which have been reported as a net gain or loss on disposition of discontinued operations during the three fiscal years ended:
		December 28,			December 29,			December 30,
		2014			2013			2012
		(In thousands)
	Loss on disposition of microarray-based diagnostic testing laboratory	$	(90	)	$	—		$	—
	(Loss) gain on disposition of Photoflash business	(14		)	493			2,459
	Loss on disposition of Technical Services business	(156		)	(2,100		)	—
	Loss on disposition of other discontinued operations	—			(203		)	(54		)
	Net (loss) gain on disposition of discontinued operations before income taxes	$	(260	)	$	(1,810	)	$	2,405
	In May 2014, the Company’s management approved the shutdown of its microarray-based diagnostic testing laboratory in the United States, which had been reported within the Human Health segment. The Company determined that, with the lack of adequate reimbursement from health care payers, the microarray-based diagnostic testing laboratory in the United States would need significant investment in its operations to reduce costs in order to effectively compete in the market. The shutdown of the microarray-based diagnostic testing laboratory in the United States resulted in a $0.1 million net pre-tax loss primarily related to the disposal of fixed assets, which was partially offset by the sale of a building in fiscal year 2014.
	In June 2010, the Company sold its Photoflash business, which was included in the Company's Environmental Health segment. The Company recognized a pre-tax loss of $0.01 million in fiscal year 2014, a pre-tax gain of $0.5 million in fiscal year 2013 and a pre-tax gain of $2.5 million in fiscal year 2012 for contingent consideration related to this sale. These gains and losses were recognized as a (loss) gain on disposition of discontinued operations.
	In August 1999, the Company sold the assets of its Technical Service business. During fiscal years 2014 and 2013, the Company recorded pre-tax losses of $0.2 million and $2.1 million, respectively, for a contingency related to this business. These losses were recognized as a (loss) gain on disposition of discontinued operations.
	During fiscal years 2014, 2013, and 2012, the Company settled various commitments related to the divestiture of other discontinued operations. The Company recognized net pre-tax losses during fiscal years 2013 and 2012. These losses were recognized as a (loss) gain on disposition of discontinued operations.
	Summary pre-tax operating results of the discontinued operations for the periods prior to disposition, which included a $1.0 million pre-tax restructuring charge related to workforce reductions in the microarray-based diagnostic testing laboratory in the United States during fiscal year 2014, were as follows during the three fiscal years ended:
		December 28,			December 29,			December 30,
		2014			2013			2012
		(In thousands)
	Revenue	$	348		$	8,646		$	10,017
	Costs and expenses	5,307			18,998			14,594
	Loss from discontinued operations before income taxes	$	(4,959	)	$	(10,352	)	$	(4,577	)
	The Company recorded a tax benefit of $1.8 million on discontinued operations in fiscal year 2014, a tax benefit of $5.1 million on discontinued operations in fiscal year 2013 and a tax benefit of $0.8 million on discontinued operations in fiscal year 2012.

Restructuring_and_Contract_Ter

Restructuring and Contract Termination Charges, Net	12 Months Ended
	Dec. 28, 2014
Restructuring and Related Activities [Abstract]
Restructuring and Contract Termination Charges, Net	Restructuring and Contract Termination Charges, Net
	The Company's management has approved a series of restructuring actions related to the impact of acquisitions and divestitures, the alignment of its operations with the Company's growth strategy, the integration of its business units and productivity initiatives. The current portion of restructuring and contract termination charges is recorded in accrued restructuring and contract termination charges and the long-term portion of restructuring and contract termination charges is recorded in long-term liabilities. The activities associated with these plans have been reported as restructuring and contract termination charges, net, and are included as a component of operating expenses from continuing operations.
	The Company implemented a restructuring plan in the third quarter of fiscal year 2014 consisting of workforce reductions principally intended to realign resources to emphasize growth initiatives (the "Q3 2014 Plan"). The Company implemented restructuring plans in the second and first quarters of fiscal year 2014, the first quarter of fiscal year 2013, and the fourth quarter of fiscal year 2012 consisting of workforce reductions principally intended to focus resources on higher growth end markets (the "Q2 2014 Plan", "Q1 2014 Plan", "Q1 2013 Plan" and "Q4 2012 Plan", respectively). The Company implemented restructuring plans in the fourth and third quarters of fiscal year 2013 consisting of workforce reductions and the closure of excess facility space principally intended to shift certain of the Company's research and development resources into a newly opened Center for Innovation (the "Q4 2013 Plan" and "Q3 2013 Plan", respectively). The Company implemented restructuring plans in the second quarter of fiscal year 2013, and the third, second and first quarters of fiscal year 2012 consisting of workforce reductions and the closure of excess facility space principally intended to shift certain of the Company's operations into a newly established shared service center, as well as realign operations, research and development resources, and production resources as a result of previous acquisitions (the "Q2 2013 Plan", "Q3 2012 Plan", "Q2 2012 Plan" and "Q1 2012 Plan", respectively). All other previous restructuring plans were workforce reductions or the closure of excess facility space principally intended to integrate the Company's businesses in order to realign operations, reduce costs, achieve operational efficiencies and shift resources into geographic regions and end markets that are more consistent with the Company's growth strategy (the "Previous Plans"). The Company also has terminated various contractual commitments in connection with certain disposal activities and has recorded charges, to the extent applicable, for the costs of terminating these contracts before the end of their terms and the costs that will continue to be incurred for the remaining terms without economic benefit to the Company.
	The following table summarizes the number of employees reduced, the initial restructuring and contract termination charges by operating segment, and the expected dates payments will be substantially completed for restructuring actions during fiscal years 2014, 2013, and 2012. The Company expects to make payments for the leases of the Previous Plans, of which the terms vary in length, through fiscal year 2022.
		Workforce Reductions										Closure of Excess Facility or Contract Termination Charges								Total				(Expected) Date Payments Substantially Completed by
		Headcount Reduction		Human Health				Environmental Health				Human Health				Environmental Health								Severance	Excess Facility or Contract Termination
		(In thousands, except headcount data)
	Q3 2014 Plan	152		$	6,863			$	6,188			$	—			$	—			$	13,051			Q3 FY2015	—
	Q2 2014 Plan	22		460				275				—				—				735				Q2 FY2015	—
	Q1 2014 Plan	17		370				197				—				—				567				Q4 FY2014	—
	2014 Contract Termination Charges	N/A		N/A				N/A				—				1,545				1,545				N/A	Q4 FY2015
	Q4 2013 Plan	73		902				3,006				7,271				—				11,179				Q4 FY2014	Q1 FY2019
	Q3 2013 Plan	29		394				—				138				—				532				Q1 FY2014	Q4 FY2013
	Q2 2013 Plan(1)	264		9,395				8,737				522				50				18,704				Q4 FY2014	Q3 FY2014
	Q1 2013 Plan	62		2,340				245				—				—				2,585				Q3 FY2013	—
	2013 Contract Termination Charges	N/A		N/A				N/A				—				696				696				N/A	Q4 FY2015
	Q4 2012 Plan	54		523				2,413				—				—				2,936				Q1 FY2014	—
	Q3 2012 Plan(2)	61		3,671				3,728				—				—				7,399				Q3 FY2014	—
	Q2 2012 Plan(3)	203		3,976				242				—				—				4,218				Q3 FY2014	—
	Q1 2012 Plan(4)	112		5,252				388				79				—				5,719				Q1 FY2013	Q2 FY2012
	2012 Contract Termination Charges	N/A		N/A				N/A				$	—			$	1,470			$	1,470			N/A	Q4 FY2015
	____________________________
	(1)	Subsequent to the initial charge, during fiscal year 2013, the Company recorded an additional $0.6 million pre-tax restructuring charge in the Human Health segment for the Q2 2013 Plan for services that were provided for one-time termination benefits in which the employee was required to render service beyond the legal notification period.
	-2	Local law required some severance for the Q3 2012 Plan to be paid in monthly installments through the fourth quarter of fiscal year 2014.
	(3)	Subsequent to the initial charge, during fiscal years 2013 and 2012, the Company recorded an additional $2.1 million and $3.2 million , respectively, pre-tax restructuring charges in the Human Health segment for the Q2 2012 Plan for services that were provided for one-time termination benefits in which the employee was required to render service beyond the legal notification period.
	(4)	Subsequent to the initial charge, during fiscal year 2012, the Company recorded an additional $0.7 million pre-tax restructuring charge primarily in the Environmental Health segment for the Q1 2012 Plan for services that were provided for one-time termination benefits in which the employee was required to render service beyond the legal notification period.
	At December 28, 2014, the Company had $23.8 million recorded for accrued restructuring and contract termination charges, of which $17.1 million was recorded in short-term accrued restructuring and $6.7 million was recorded in long-term liabilities. At December 29, 2013, the Company had $35.5 million recorded for accrued restructuring and contract termination charges, of which $26.4 million was recorded in short-accrued restructuring and $9.1 million was recorded in long-term liabilities. The following table summarizes the Company's restructuring and contract termination accrual balances and related activity by restructuring plan, as well as contract termination, during fiscal years 2014, 2013, and 2012:
		Balance at January 1, 2012				2012 Charges and Changes in Estimates, Net				2012 Amounts Paid				Balance at December 30, 2012				2013 Charges and Changes in Estimates, Net				2013 Amounts Paid			Balance at December 29, 2013		2014 Charges and Changes in Estimates, Net			2014 Amounts Paid			Balance at December 28, 2014
		(In thousands)
	Severance:
	Q3 2014 Plan	$	—			$	—			$	—			$	—			$	—			$	—		$	—	$	13,051		$	(2,992	)	$	10,059
	Q2 2014 Plan	—				—				—				—				—				—			—		735			(484		)	251
	Q1 2014 Plan	—				—				—				—				—				—			—		567			(475		)	92
	Q4 2013 Plan(1)	—				—				—				—				3,908				(1,921		)	1,987		(121		)	(1,541		)	325
	Q3 2013 Plan	—				—				—				—				394				(257		)	137		—			(137		)	—
	Q2 2013 Plan(2)	—				—				—				—				18,704				(5,954		)	12,750		(796		)	(10,373		)	1,581
	Q1 2013 Plan(3)	—				—				—				—				2,585				(2,377		)	208		(208		)	—			—
	Facility:
	Q4 2013 Plan(1)	—				—				—				—				7,271				(417		)	6,854		1,055			(2,106		)	5,803
	Q3 2013 Plan	—				—				—				—				138				(138		)	—		—			—			—
	Q2 2013 Plan(2)	—				—				—				—				572				(572		)	—		184			(184		)	—
	Previous Plans(4)	20,819				23,581				(17,249		)		27,151				(376		)		(13,476		)	13,299		(2,622		)	(5,262		)	5,415
	Restructuring	20,819				23,581				(17,249		)		27,151				33,196				(25,112		)	35,235		11,845			(23,554		)	23,526
	Contract Termination	2,067				1,470				(2,941		)		596				696				(992		)	300		1,545			(1,541		)	304
	Total Restructuring and Contract Termination	$	22,886			$	25,051			$	(20,190	)		$	27,747			$	33,892			$	(26,104	)	$	35,535	$	13,390		$	(25,095	)	$	23,830
	____________________________
	(1)	During fiscal year 2014, the Company recorded a pre-tax restructuring reversal of $0.1 million in the Environmental Health segment related to lower than expected costs associated with the remaining severance payments for the Q4 2013 Plan and recorded an additional pre-tax restructuring charge of $1.1 million in the Human Health segment related to higher than expected costs associated with the closure of the excess facility for the Q4 2013 Plan.
	(2)	During fiscal year 2014, the Company recorded pre-tax restructuring reversals of $0.3 million in the Human Health segment and $0.5 million in the Environmental Health segment related to lower than expected costs associated with the remaining severance payments for the Q2 2013 Plan. In addition during fiscal year 2014, the Company incurred an additional pre-tax restructuring charge of $0.1 million in each of the Human Health and Environmental Health segments related to higher than expected costs associated with the closure of the excess facility space for the Q2 2013 Plan.
	(3)	During fiscal year 2014, the Company recorded a pre-tax restructuring reversal of $0.2 million in the Human Health segment related to lower than expected costs associated with the remaining severance payments for the Q1 2013 Plan.
	(4)	During fiscal year 2014, the Company recognized pre-tax restructuring reversals of $1.6 million in the Human Health segment and $1.1 million in the Environmental Health segment related to lower than expected costs associated with workforce reductions for the previous restructuring plans. During fiscal year 2014, the Company recognized an additional pre-tax restructuring charge of $0.1 million in the Human Health segment related to higher than expected costs associated with the closure of the excess facility space for the previous restructuring plans.

Interest_and_Other_Expense_Inc

Interest and Other Expense (Income), Net	12 Months Ended
	Dec. 28, 2014
Other Income and Expenses [Abstract]
Interest and Other Expense (Income), Net	Interest and Other Expense, Net
	Interest and other expense, net, consisted of the following for the fiscal years ended:
		December 28,			December 29,			December 30,
		2014			2013			2012
		(In thousands)
	Interest income	$	(667	)	$	(650	)	$	(747	)
	Interest expense	36,270			49,924			45,787
	Other expense, net	5,536			14,836			2,916
	Total interest and other expense, net	$	41,139		$	64,110		$	47,956
	In December 2013, the Company redeemed all of its 6% senior unsecured notes due in 2015 (the “2015 Notes”) for a redemption price that included the outstanding principal amount of $150.0 million and a prepayment premium of $11.1 million, which is included in other expense, net. The transaction also resulted in the write-off of $2.8 million for the remaining unamortized derivative losses for previously settled cash flow hedges and the write-off of $0.2 million for the remaining deferred debt issuance costs. Both of these amounts are included in interest expense.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 28, 2014
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes
	The Company regularly reviews its tax positions in each significant taxing jurisdiction in the process of evaluating its unrecognized tax benefits. The Company makes adjustments to its unrecognized tax benefits when: (i) facts and circumstances regarding a tax position change, causing a change in management’s judgment regarding that tax position; (ii) a tax position is effectively settled with a tax authority at a differing amount; and/or (iii) the statute of limitations expires regarding a tax position.
	The tabular reconciliation of the total amounts of unrecognized tax benefits is as follows for the fiscal years ended:
		December 28,			December 29,			December 30,
		2014			2013			2012
		(In thousands)
	Unrecognized tax benefits, beginning of year	$	39,410		$	58,110		$	51,740
	Gross increases—tax positions in prior periods	—			325			10,653
	Gross decreases—tax positions in prior periods	(1,809		)	(10,539		)	(4,665		)
	Gross increases—current-period tax positions	239			2,222			3,343
	Settlements	(1,400		)	(3,643		)	(2,822		)
	Lapse of statute of limitations	(4,129		)	(6,495		)	(595		)
	Foreign currency translation adjustments	31			(570		)	456
	Unrecognized tax benefits, end of year	$	32,342		$	39,410		$	58,110
	The Company classifies interest and penalties as a component of income tax expense. At December 28, 2014, the Company had accrued interest and penalties of $3.4 million and $0.2 million, respectively. During fiscal year 2014, the Company recognized a net benefit of $0.7 million for interest and a benefit of $0.2 million for penalties in its total tax provision primarily due to settlements and statutes that had lapsed. During fiscal year 2013, the Company recognized a benefit of $3.9 million for interest and a benefit of $3.7 million for penalties in its total tax provision primarily due to settlements and statutes that had lapsed. During fiscal year 2012, the Company recognized a charge of $1.1 million for interest and a benefit of $2.2 million for penalties in its total tax provision. At December 28, 2014, the Company had gross tax effected unrecognized tax benefits of $32.3 million, of which $28.5 million, if recognized, would affect the continuing operations effective tax rate. The remaining amount, if recognized, would affect discontinued operations.
	The Company believes that it is reasonably possible that approximately $5.3 million of its uncertain tax positions at December 28, 2014, including accrued interest and penalties, and net of tax benefits, may be resolved over the next twelve months as a result of lapses in applicable statutes of limitations and potential settlements. Various tax years after 2007 remain open to examination by certain jurisdictions in which the Company has significant business operations, such as China, Finland, Germany, Italy, Netherlands, Singapore, the United Kingdom and the United States. The tax years under examination vary by jurisdiction.
	During fiscal years 2014, 2013, and 2012, the Company recorded net discrete income tax benefits of $7.0 million, $24.0 million and $7.0 million, respectively, primarily for reversals of uncertain tax position reserves and resolution of other tax matters.
	The components of income (loss) from continuing operations before income taxes were as follows for the fiscal years ended:
		December 28,			December 29,			December 30,
		2014			2013			2012
		(In thousands)
	U.S.	$	(37,758	)	$	(71,901	)	$	(113,969	)
	Non-U.S.	207,361			235,585			169,133
	Total	$	169,603		$	163,684		$	55,164
	On a U.S. income tax basis, the Company has reported significant taxable income over the three year period ended December 28, 2014. The Company has utilized tax attributes to minimize cash taxes paid on that taxable income.
	The components of the provision for (benefit from) income taxes for continuing operations were as follows:
		Current Expense (Benefit)			Deferred Expense			Total
					(Benefit)
		(In thousands)
	Fiscal year ended December 28, 2014
	Federal	$	(262	)	$	(19,169	)	$	(19,431	)
	State	2,416			(3,842		)	(1,426		)
	Non-U.S.	39,634			(10,340		)	29,294
	Total	$	41,788		$	(33,351	)	$	8,437
	Fiscal year ended December 29, 2013
	Federal	$	2,331		$	(29,961	)	$	(27,630	)
	State	1,968			(2,147		)	(179		)
	Non-U.S.	15,025			2,201			17,226
	Total	$	19,324		$	(29,907	)	$	(10,583	)
	Fiscal year ended December 30, 2012
	Federal	$	(3,640	)	$	(34,920	)	$	(38,560	)
	State	2,752			(2,794		)	(42		)
	Non-U.S.	50,314			(27,837		)	22,477
	Total	$	49,426		$	(65,551	)	$	(16,125	)
	The total provision for (benefit from) income taxes included in the consolidated financial statements is as follows for the fiscal years ended:
		December 28,			December 29,			December 30,
		2014			2013			2012
		(In thousands)
	Continuing operations	$	8,437		$	(10,583	)	$	(16,125	)
	Discontinued operations	(1,831		)	(5,107		)	(823		)
	Total	$	6,606		$	(15,690	)	$	(16,948	)
	A reconciliation of income tax expense at the U.S. federal statutory income tax rate to the recorded tax provision is as follows for the fiscal years ended:
		December 28,			December 29,			December 30,
		2014			2013			2012
		(In thousands)
	Tax at statutory rate	$	59,361		$	57,289		$	19,302
	Non-U.S. rate differential, net	(36,616		)	(36,377		)	(26,652		)
	U.S. taxation of multinational operations	2,367			3,658			1,727
	State income taxes, net	1,970			(1,762		)	3,400
	Prior year tax matters	(7,009		)	(23,534		)	3,389
	Federal tax credits	(3,399		)	(5,452		)	(1,657		)
	Change in valuation allowance	(7,679		)	(4,675		)	(14,446		)
	Other, net	(558		)	270			(1,188		)
	Total	$	8,437		$	(10,583	)	$	(16,125	)
The Company’s provision for (benefit from) income taxes for fiscal years 2014, 2013, and 2012 included $7.1 million, $7.4 million and $5.2 million, respectively, of benefits derived from tax holidays in China and Singapore. The tax holidays in China and Singapore are scheduled to expire in fiscal years 2017 and 2018, respectively.
The tax effects of temporary differences and attributes that gave rise to deferred income tax assets and liabilities as of December 28, 2014 and December 29, 2013 were as follows:
	December 28,			December 29,
	2014			2013
	(In thousands)
Deferred tax assets:
Inventory	$	9,041		$	9,850
Reserves and accruals	30,641			30,269
Accrued compensation	22,915			15,920
Net operating loss and credit carryforwards	106,020			132,710
Accrued pension	44,342			23,353
Restructuring reserve	7,522			6,853
Deferred revenue	46,413			42,687
All other, net	824			1,666
Total deferred tax assets	267,718			263,308
Deferred tax liabilities:
Postretirement health benefits	(4,472		)	(3,894		)
Depreciation and amortization	(176,043		)	(163,269		)
Total deferred tax liabilities	(180,515		)	(167,163		)
Valuation allowance	(55,460		)	(63,139		)
Net deferred tax assets	$	31,743		$	33,006
At December 28, 2014, the Company had state net operating loss carryforwards of $197.4 million, foreign net operating loss carryforwards of $160.5 million, state tax credit carryforwards of $11.9 million, general business tax credit carryforwards of $30.8 million, and foreign tax credit carryforwards of $12.4 million. These are subject to expiration in years ranging from 2015 to 2033, and without expiration for certain foreign net operating loss carryforwards and certain state credit carryforwards. At December 28, 2014, the Company also had U.S. federal net operating loss carryforwards of $45.8 million as a result of acquisitions. The Company acquired estimated utilizable U.S. federal loss carryforwards of $223.4 million as a result of the Caliper acquisition during fiscal year 2011, of which $25.8 million remain at December 28, 2014. The utilization of these losses and credits is subject to annual limitations based on Section 382 of the Internal Revenue Code of 1986, as amended. These federal losses and credits will expire in fiscal years 2015 through 2031.
Valuation allowances take into consideration limitations imposed upon the use of the tax attributes and reduce the value of such items to the likely net realizable amount. The Company regularly evaluates positive and negative evidence available to determine if valuation allowances are required or if existing valuation allowances are no longer required. Valuation allowances have been provided on state net operating loss and state tax credit carryforwards and on certain foreign tax attributes that the Company has determined are not more likely than not to be realized. The decrease in the valuation allowance in fiscal years 2014 and 2013 is primarily due to the anticipated utilization of attributes in certain foreign and state jurisdictions. The valuation allowance at December 30, 2012 and January 1, 2012 was $67.8 million and $82.3 million, respectively, and the change in the valuation allowance during fiscal year 2012 was primarily due to the reversal of valuation allowances for two of the Company’s non-U.S. subsidiaries when it became more likely than not that the subsidiaries’ deferred tax assets would be realized.
Current deferred tax assets of $62.0 million and $78.3 million were included in other current assets at December 28, 2014 and December 29, 2013, respectively. Long-term deferred tax liabilities of $30.3 million and $45.3 million were included in other long-term liabilities at December 28, 2014 and December 29, 2013, respectively.
The components of net deferred tax assets (liabilities) as of December 28, 2014 and December 29, 2013 were as follows:
	December 28,			December 29,
	2014			2013
	(In thousands)
U.S.	$	44,073		$	22,565
Non-U.S.	(12,330		)	10,441
Total	$	31,743		$	33,006
Taxes have not been provided on unremitted earnings of international subsidiaries that the Company considers indefinitely reinvested because the Company plans to keep these amounts indefinitely reinvested overseas except for instances where the Company can remit such earnings to the U.S. without an associated net tax cost. The Company's indefinite reinvestment determination is based on the future operational and capital requirements of its U.S. and non-U.S. operations. As of December 28, 2014, the amount of foreign earnings that the Company has the intent and ability to keep invested outside the U.S. indefinitely and for which no U.S. tax cost has been provided was approximately $675.0 million. It is not practical to calculate the unrecognized deferred tax liability on those earnings.

Earnings_Per_Share

Earnings Per Share	12 Months Ended
	Dec. 28, 2014
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share
	Basic earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding during the period less restricted unvested shares. Diluted earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding plus all potentially dilutive common stock equivalents, primarily shares issuable upon the exercise of stock options using the treasury stock method. The following table reconciles the number of shares utilized in the earnings per share calculations for the fiscal years ended:
		December 28,	December 29,	December 30,
		2014	2013	2012
		(In thousands)
	Number of common shares—basic	112,593	112,254	113,728
	Effect of dilutive securities:
	Stock options	922	982	847
	Restricted stock awards	224	267	285
	Number of common shares—diluted	113,739	113,503	114,860
	Number of potentially dilutive securities excluded from calculation due to antidilutive impact	475	485	1,288
	Antidilutive securities include outstanding stock options with exercise prices and average unrecognized compensation cost in excess of the average fair market value of common stock for the related period. Antidilutive options were excluded from the calculation of diluted net income per share and could become dilutive in the future.

Accounts_Receivable_Net

Accounts Receivable, Net	12 Months Ended
	Dec. 28, 2014
Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]
Accounts Receivable, Net	Accounts Receivable, Net
	Accounts receivable were net of reserves for doubtful accounts of $32.9 million and $28.3 million as of December 28, 2014 and December 29, 2013, respectively.

Inventories_Net

Inventories, Net	12 Months Ended
	Dec. 28, 2014
Inventory Disclosure [Abstract]
Inventories, Net	Inventories
	Inventories as of December 28, 2014 and December 29, 2013 consisted of the following:
		December 28,		December 29,
		2014		2013
		(In thousands)
	Raw materials	$	96,169	$	92,713
	Work in progress	18,783		15,505
	Finished goods	170,505		152,640
	Total inventories	$	285,457	$	260,858

Property_Plant_and_Equipment_N

Property, Plant and Equipment, Net	12 Months Ended
	Dec. 28, 2014
Property, Plant and Equipment, Net [Abstract]
Property, Plant and Equipment, Net	Property, Plant and Equipment, Net
	Property, plant and equipment, at cost, as of December 28, 2014 and December 29, 2013, consisted of the following:
		December 28,			December 29,
		2014			2013
		(In thousands)
	Land	$	906		$	1,019
	Building and leasehold improvements	175,040			171,393
	Machinery and equipment	316,868			325,699
	Total property, plant and equipment	492,814			498,111
	Accumulated depreciation	(316,620		)	(314,923		)
	Total property, plant and equipment, net	$	176,194		$	183,188
	Depreciation expense on property, plant and equipment for the fiscal years ended December 28, 2014, December 29, 2013 and December 30, 2012 was $33.3 million, $37.6 million and $35.0 million, respectively.

Marketable_Securities_and_Inve

Marketable Securities and Investments	12 Months Ended
	Dec. 28, 2014
Marketable Securities [Abstract]
Marketable Securities and Investments	Marketable Securities and Investments
	Investments as of December 28, 2014 and December 29, 2013 consisted of the following:
		December 28,		December 29,
		2014		2013
		(In thousands)
	Marketable securities	$	1,568	$	1,319
	Marketable securities include equity and fixed-income securities held to meet obligations associated with the Company’s supplemental executive retirement plan and other deferred compensation plans. The Company has, accordingly, classified these securities as long-term.
	The net unrealized holding gain and loss on marketable securities, net of deferred income taxes, reported as a component of other comprehensive income in stockholders’ equity, was a $0.01 million gain in both fiscal years 2014 and 2013. The proceeds from the sales of securities and the related gains and losses are not material for any period presented.
	Marketable securities classified as available for sale as of December 28, 2014 and December 29, 2013 consisted of the following:
		Market		Gross Unrealized Holding
		Value		Cost		Gains		(Losses)
				(In thousands)
	December 28, 2014
	Equity securities	$	1,002	$	1,110	$	7	$	(115	)
	Fixed-income securities	88		88		—		—
	Other	478		541		—		(63		)
		$	1,568	$	1,739	$	7	$	(178	)
	December 29, 2013
	Equity securities	$	740	$	871	$	—	$	(131	)
	Fixed-income securities	308		308		—		—
	Other	271		334		—		(63		)
		$	1,319	$	1,513	$	—	$	(194	)

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets, Net	12 Months Ended
	Dec. 28, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Net
		Goodwill and Intangible Assets, Net
	The Company tests goodwill and non-amortizing intangible assets at least annually for possible impairment. Accordingly, the Company completes the annual testing of impairment for goodwill and non-amortizing intangible assets on the later of January 1 or the first day of each fiscal year. In addition to its annual test, the Company regularly evaluates whether events or circumstances have occurred that may indicate a potential impairment of goodwill or non-amortizing intangible assets.
	The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of a two-step process. The first step is the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. The second step measures the amount of an impairment loss, and is only performed if the carrying value exceeds the fair value of the reporting unit. The Company performed its annual impairment testing for its reporting units as of January 1, 2014, its annual impairment date for fiscal year 2014. The Company concluded based on the first step of the process that there was no goodwill impairment, and the fair value exceeded the carrying value by more than 90.0% for each reporting unit, with the exception of the life sciences and technology reporting unit where the fair value exceeded the carrying value by approximately 11.0%. The carrying value of the goodwill for the life sciences and technology reporting unit was $796.3 million, at the annual impairment date for fiscal year 2014. The long-term terminal growth rates for the Company’s reporting units were 3.0% to 6.0% for the fiscal year 2014 impairment analysis. The range for the discount rates for the reporting units was 10.0% to 11.5%. Keeping all other variables constant, a 10.0% change in any one of the input assumptions for the various reporting units would still allow the Company to conclude, based on the first step of the process, that there was no impairment of goodwill.
	During the second quarter of fiscal year 2014, the Company realigned its organization which resulted in a change in the composition of the Company's reporting units within the Human Health segment. The Company's informatics business was moved from the life sciences and technology reporting unit to its own reporting unit. As a result of the new alignment, the Company reallocated goodwill based on the relative fair value, determined using the income approach, of each of these businesses. During the third quarter of 2014, the Company finalized this analysis and the realignment resulted in $220.3 million of goodwill being reallocated from the life sciences and technology reporting unit to the informatics reporting unit. The Company concluded based on the first step of the process that there was no goodwill impairment for either the life sciences and technology reporting unit or the informatics reporting unit as the fair value exceeded the carrying value for each of these reporting units as of the date of the realignment.
	The Company has consistently employed the income approach to estimate the current fair value when testing for impairment of goodwill. A number of significant assumptions and estimates are involved in the application of the income approach to forecast operating cash flows, including markets and market share, sales volumes and prices, costs to produce, tax rates, capital spending, discount rates and working capital changes. Cash flow forecasts are based on approved business unit operating plans for the early years’ cash flows and historical relationships in later years. The income approach is sensitive to changes in long-term terminal growth rates and the discount rates. The long-term terminal growth rates are consistent with the Company’s historical long-term terminal growth rates, as the current economic trends are not expected to affect the long-term terminal growth rates of the Company. The Company corroborates the income approach with a market approach.
	The Company has consistently employed the relief from royalty model to estimate the current fair value when testing for impairment of non-amortizing intangible assets. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized. In addition, the Company evaluates the remaining useful lives of its non-amortizing intangible assets at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful lives of non-amortizing intangible assets are no longer indefinite, the assets will be tested for impairment. These intangible assets will then be amortized prospectively over their estimated remaining useful lives and accounted for in the same manner as other intangible assets that are subject to amortization. The Company performed its annual impairment testing as of January 1, 2014, and concluded that there was no impairment of non-amortizing intangible assets.
	As part of integrating the Company's acquisitions, in the fourth quarter of fiscal year 2012, the Company decided that prospectively it would primarily focus on the PerkinElmer trade name. Accordingly, the Company undertook a review of certain of its trade names within its portfolio as part of a realignment of its marketing strategy. The process resulted in the Company determining that the lives of certain trade names that it intends to phase out should be shortened, and in certain cases non-amortizing trade names were determined to no longer be indefinite-lived. Accordingly, the Company tested the recoverability of these identified indefinite-lived and definite-lived intangibles and concluded that the fair values of certain trade name intangible assets were less than the carrying amounts of those assets. For non-amortizing trade names the Company compared the fair values, which was determined using a relief from royalty method, to the carrying values, considering the revised useful lives. For amortizing trade names, the Company first determined if the undiscounted cash flows associated with the intangibles exceeded the carrying values. If the undiscounted cash flows did not exceed the carrying values, the Company determined the fair values of the trade names using a relief from royalty method, considering the revised useful lives. As a result, the remaining adjusted fair values of $6.1 million for trade names are being amortized over the period of time until the trade names are expected to be phased out, having weighted average remaining useful lives of 3 years.
	Additionally during fiscal year 2012, the Company recorded an intangible asset impairment charge of $74.2 million which was equal to the excess of the carrying amounts of the intangible assets over the fair value of such assets. The Company recognized $73.4 million pre-tax impairment charges in the Human Health segment and also recognized $0.7 million pre-tax impairment charges in the Environmental Health segment.
	An assessment of the recoverability of amortizing intangible assets takes place when events have occurred that may give rise to an impairment. During fiscal year 2013, the Company recorded a charge of $0.2 million for the impairment of certain long-lived assets within the Human Health segment, as the carrying amounts of the long-lived assets were not recoverable and exceeded their fair value. These non-cash impairments of long-lived assets, including intangible assets, have been recorded as a separate component of operating expenses.
	The changes in the carrying amount of goodwill for fiscal years 2014 and 2013 are as follows:
		Human			Environmental			Consolidated
		Health			Health
		(In thousands)
	Balance at December 30, 2012	$	1,632,487		$	490,301		$	2,122,788
	Foreign currency translation	12,867			2,300			15,167
	Acquisitions, earnouts and other	2,978			2,187			5,165
	Balance at December 29, 2013	1,648,332			494,788			2,143,120
	Foreign currency translation	(29,145		)	(8,741		)	(37,886		)
	Acquisitions, earnouts and other	2,408			176,435			178,843
	Balance at December 28, 2014	$	1,621,595		$	662,482		$	2,284,077
	Identifiable intangible asset balances at December 28, 2014 by category and by business segment were as follows:
		Human			Environmental			Consolidated
		Health			Health
		(In thousands)
	Patents	$	36,760		$	3,193		$	39,953
	Less: Accumulated amortization	(24,652		)	(2,548		)	(27,200		)
	Net patents	12,108			645			12,753
	Trade names and trademarks	33,069			7,000			40,069
	Less: Accumulated amortization	(16,878		)	(58		)	(16,936		)
	Net trade names and trademarks	16,191			6,942			23,133
	Licenses	59,631			—			59,631
	Less: Accumulated amortization	(41,792		)	—			(41,792		)
	Net licenses	17,839			—			17,839
	Core technology	169,864			128,627			298,491
	Less: Accumulated amortization	(98,798		)	(85,899		)	(184,697		)
	Net core technology	71,066			42,728			113,794
	Customer relationships	292,627			109,558			402,185
	Less: Accumulated amortization	(148,820		)	(8,174		)	(156,994		)
	Net customer relationships	143,807			101,384			245,191
	IPR&D	5,079			5,024			10,103
	Less: Accumulated amortization	(998		)	(2,134		)	(3,132		)
	Net IPR&D	4,081			2,890			6,971
	Net amortizable intangible assets	265,092			154,589			419,681
	Non-amortizable intangible assets:
	Trade names and trademarks	—			70,584			70,584
	Total	$	265,092		$	225,173		$	490,265
	Identifiable intangible asset balances at December 29, 2013 by category and business segment were as follows:
		Human			Environmental			Consolidated
		Health			Health
		(In thousands)
	Patents	$	36,791		$	2,800		$	39,591
	Less: Accumulated amortization	(22,205		)	(2,002		)	(24,207		)
	Net patents	14,586			798			15,384
	Trade names and trademarks	35,723			86			35,809
	Less: Accumulated amortization	(16,122		)	(86		)	(16,208		)
	Net trade names and trademarks	19,601			—			19,601
	Licenses	71,580			7,600			79,180
	Less: Accumulated amortization	(45,835		)	(7,095		)	(52,930		)
	Net licenses	25,745			505			26,250
	Core technology	187,387			114,683			302,070
	Less: Accumulated amortization	(88,811		)	(80,515		)	(169,326		)
	Net core technology	98,576			34,168			132,744
	Customer relationships	305,038			16,357			321,395
Less: Accumulated amortization	(127,397		)	(5,436		)	(132,833		)
Net customer relationships	177,641			10,921			188,562
IPR&D	4,257			5,226			9,483
Less: Accumulated amortization	(695		)	(1,483		)	(2,178		)
Net IPR&D	3,562			3,743			7,305
Net amortizable intangible assets	339,711			50,135			389,846
Non-amortizable intangible assets:
Trade names and trademarks	—			70,584			70,584
Total	$	339,711		$	120,719		$	460,430
Total amortization expense related to definite-lived intangible assets was $83.4 million in fiscal year 2014, $89.3 million in fiscal year 2013 and $90.1 million in fiscal year 2012. Estimated amortization expense related to definite-lived intangible assets for each of the next five years is $80.4 million in fiscal year 2015, $71.4 million in fiscal year 2016, $61.9 million in fiscal year 2017, $48.7 million in fiscal year 2018, and $37.2 million in fiscal year 2019.
The Company entered into a strategic agreement in fiscal year 2012 under which it acquired certain intangible assets and received a license to certain core technology for an analytics and data discovery platform, as well as the exclusive right to distribute the platform in certain scientific research and development markets. During fiscal year 2012, the Company paid $6.8 million for net intangible assets and $25.0 million for prepaid royalties. During fiscal year 2013, the Company extended the existing agreement for an additional year. In addition, the Company entered into a new agreement to expand the distribution rights to the clinical and other related markets and acquired additional intangible assets. During fiscal year 2013, the Company paid $7.0 million for net intangible assets and $40.3 million for prepaid royalties. The prepaid royalties have been recorded primarily as other long-term assets. The Company expects to pay $10.0 million of additional prepaid royalties within the next twelve months. The Company expenses royalties as revenue is recognized. These intangible assets are being amortized over their estimated useful lives. The Company has reported the amortization of these intangible assets within the results of the Company's Human Health segment from the execution date.

Debt

Debt	12 Months Ended
	Dec. 28, 2014
Debt Disclosure [Abstract]
Debt	Debt
	Senior Unsecured Revolving Credit Facility. On January 8, 2014, the Company refinanced its debt held under a previous senior unsecured revolving credit facility and entered into a new senior unsecured revolving credit facility. The new senior unsecured revolving credit facility provides for $700.0 million of revolving loans and has an initial maturity of January 8, 2019. As of December 28, 2014, undrawn letters of credit in the aggregate amount of $12.2 million were treated as issued and outstanding under the new senior unsecured revolving credit facility. As of December 28, 2014, the Company had $171.8 million available for additional borrowing under the new facility. The Company uses the new senior unsecured revolving credit facility for general corporate purposes, which may include working capital, refinancing existing indebtedness, capital expenditures, share repurchases, acquisitions and strategic alliances. The interest rates under the new senior unsecured revolving credit facility are based on the Eurocurrency rate or the base rate at the time of borrowing, plus a margin. The base rate is the higher of (i) the rate of interest in effect for such day as publicly announced from time to time by JP Morgan Chase Bank, N.A. as its "prime rate," (ii) the Federal Funds rate plus 50 basis points or (iii) one-month Libor plus 1.00%. At December 28, 2014, borrowings under the new senior unsecured revolving credit facility were accruing interest primarily based on the Eurocurrency rate. The Eurocurrency margin as of December 28, 2014 was 108 basis points. The weighted average Eurocurrency interest rate as of December 28, 2014 was 0.18%, resulting in a weighted average effective Eurocurrency rate, including the margin, of 1.26%. At December 28, 2014, the Company had $516.0 million of borrowings in U.S. dollars outstanding under the new senior unsecured revolving credit facility. The credit agreement for the facility contains affirmative, negative and financial covenants and events of default similar to those contained in the Company's credit agreement for its previous facility. The financial covenants in the Company's new senior unsecured revolving credit facility include a debt-to-capital ratio, and two contingent covenants, a maximum consolidated leverage ratio and a minimum consolidated interest coverage ratio, applicable if the Company's credit rating is downgraded below investment grade. During fiscal year 2014, the Company capitalized $1.8 million of debt financing costs for the refinancing of debt held under its previous senior unsecured revolving credit facility. These debt financing costs are being amortized into interest and other expense, net, on a straight-line basis, over the term of the new senior unsecured revolving credit facility.
	The Company's previous senior unsecured revolving credit facility provided for $700.0 million of revolving loans and had an initial maturity of December 16, 2016. At December 29, 2013, the Company had $397.0 million of borrowings in U.S. dollars outstanding under the previous senior unsecured revolving credit facility. The credit agreement for the previous facility contained affirmative, negative and financial covenants and events of default similar to those contained in the Company's new credit facility.
	5% Senior Unsecured Notes due in 2021. On October 25, 2011, the Company issued $500.0 million aggregate principal amount of senior unsecured notes due in 2021 in a registered public offering and received $496.9 million of net proceeds from the issuance. The 2021 Notes were issued at 99.372% of the principal amount, which resulted in a discount of $3.1 million. As of December 28, 2014, the 2021 Notes had an aggregate carrying value of $497.7 million, net of $2.3 million of unamortized original issue discount. As of December 29, 2013, the 2021 Notes had an aggregate carrying value of $497.4 million, net of $2.6 million of unamortized original issue discount. The 2021 Notes mature in November 2021 and bear interest at an annual rate of 5%. Interest on the 2021 Notes is payable semi-annually on May 15th and November 15th each year. Prior to August 15, 2021 (three months prior to their maturity date), the Company may redeem the 2021 Notes in whole or in part, at its option, at a redemption price equal to the greater of (i) 100% of the principal amount of the 2021 Notes to be redeemed, plus accrued and unpaid interest, or (ii) the sum of the present values of the remaining scheduled payments of principal and interest in respect to the 2021 Notes being redeemed, discounted on a semi-annual basis, at the Treasury Rate plus 45 basis points, plus accrued and unpaid interest. At any time on or after August 15, 2021 (three months prior to their maturity date), the Company may redeem the 2021 Notes, at its option, at a redemption price equal to 100% of the principal amount of the 2021 Notes to be redeemed plus accrued and unpaid interest. Upon a change of control (as defined in the indenture governing the 2021 Notes ) and a contemporaneous downgrade of the 2021 Notes below investment grade, each holder of 2021 Notes will have the right to require the Company to repurchase such holder's 2021 Notes for 101% of their principal amount, plus accrued and unpaid interest.
	Financing Lease Obligations. In fiscal year 2012, the Company entered into agreements with the lessors of certain buildings that the Company is currently occupying and leasing to expand those buildings. The Company provided a portion of the funds needed for the construction of the additions to the buildings, and as a result the Company is considered the owner of the buildings during the construction period. At the end of the construction period, the Company was not reimbursed by the lessors for all of the construction costs. The Company is therefore deemed to have continuing involvement and the leases qualify as financing leases under sale-leaseback accounting guidance, representing debt obligations for the Company and non-cash investing and financing activities. As a result, the Company capitalized $29.3 million in property and equipment, net, representing the fair value of the buildings with a corresponding increase to debt. The Company has also capitalized $11.5 million in additional construction costs necessary to complete the renovations to the buildings, which were funded by the lessors, with a corresponding increase to debt. At December 28, 2014, the Company had $39.3 million recorded for these financing lease obligations, of which $1.1 million was recorded as short-term debt and $38.2 million was recorded as long-term debt. At December 29, 2013, the Company had $40.3 million recorded for these financing lease obligations, of which $2.6 million was recorded as short-term debt and $37.7 million was recorded as long-term debt. The buildings are being depreciated on a straight-line basis over the terms of the leases to their estimated residual values, which will equal the remaining financing obligation at the end of the lease term. At the end of the lease term, the remaining balances in property, plant and equipment, net and debt will be reversed against each other.
	The following table summarizes the maturities of the Company’s indebtedness as of December 28, 2014:
		Sr. Unsecured		5.0% Sr. Notes			Financing Lease Obligations		Total
		Revolving		Maturing 2021
		Credit Facility
		Maturing 2019
		(In thousands)
	2015	$	—	$	—		$	1,075	$	1,075
	2016	—		—			1,120		1,120
	2017	—		—			1,169		1,169
	2018	—		—			1,367		1,367
	2019	516,000		—			1,532		517,532
	2020 and thereafter	—		500,000			33,009		533,009
	Total before unamortized discount	516,000		500,000			39,272		1,055,272
	Unamortized discount	—		(2,305		)	—		(2,305		)
	Total	$	516,000	$	497,695		$	39,272	$	1,052,967

Accrued_Expenses_and_Other_Cur

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 28, 2014
Accounts Payable and Accrued Liabilities, Current [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued Expenses and Other Current Liabilities
	Accrued expenses and other current liabilities as of December 28, 2014 and December 29, 2013 consisted of the following:
		December 28,		December 29,
		2014		2013
		(In thousands)
	Payroll and incentives	$	61,018	$	52,865
	Employee benefits	40,318		40,965
	Deferred revenue	168,928		164,723
	Federal, non-U.S. and state income taxes	9,801		11,783
	Other accrued operating expenses	122,956		133,342
	Total accrued expenses and other current liabilities	$	403,021	$	403,678

Employee_Benefit_Plans

Employee Benefit Plans	12 Months Ended
	Dec. 28, 2014
Compensation and Retirement Disclosure [Abstract]
Employee Benefit Plans	Employee Benefit Plans
	Savings Plan:    The Company has a 401(k) Savings Plan for the benefit of all qualified U.S. employees, with such employees receiving matching contributions in the amount equal to 100.0% of the first 5.0% of eligible compensation up to applicable Internal Revenue Service limits. Such matching contributions have been in effect since February 1, 2011 for all employees except former employees of Caliper, who received matching contributions of 50.0% of the first 5.0% of eligible compensation up to applicable Internal Revenue Service limits until December 31, 2012, and received matching contributions of 100.0% of the first 5.0% of eligible compensation up to applicable Internal Revenue Service limits after December 31, 2012. Savings plan expense was $12.2 million in fiscal year 2014, $12.8 million in fiscal year 2013 and $12.3 million in fiscal year 2012.
	Pension Plans:    The Company has a defined benefit pension plan covering certain U.S. employees and non-U.S. pension plans for certain non-U.S. employees. The principal U.S. defined benefit pension plan was closed to new hires effective January 31, 2001, and benefits for those employed by the Company’s former Life Sciences businesses were frozen as of that date. Plan benefits were frozen as of March 2003 for those employed by the Company’s former Analytical Instruments business and corporate employees. Plan benefits were frozen as of January 31, 2011 for all remaining employees that were still actively accruing in the plan. The plans provide benefits that are based on an employee’s years of service and compensation near retirement.
	Net periodic pension cost (credit) for U.S. and non-U.S. plans included the following components for fiscal years ended:
		December 28,				December 29,				December 30,
		2014				2013				2012
		(In thousands)
	Service cost	$	4,070			$	3,664			$	3,852
	Interest cost	23,475				21,334				23,164
	Expected return on plan assets	(25,007		)		(25,106		)		(20,768		)
	Actuarial loss (gain)	71,700				(16,464		)		28,355
	Amortization of prior service cost	(281		)		(267		)		(242		)
	Net periodic pension cost (credit)	$	73,957			$	(16,839	)		$	34,361
	In the third quarter of fiscal year 2014, the Company notified employees of its intention to terminate their employment as part of the Q3 2014 restructuring plan. The removal of these participants may decrease the expected future service lives in excess of the curtailment limit for one of the Company's pension plans, which would result in a curtailment gain. If the curtailment occurs, the curtailment will be measured and recorded when the notified employees are separated from the Company. As part of a curtailment, the Company is required to remeasure the pension plan's assets and liabilities based upon current discount rates and the fair value of the pension plan's assets as of the curtailment date, which may result in an additional gain or (loss) in addition to the curtailment gain. Employee separation is expected to be completed during the first half of fiscal year 2015.
	The following table sets forth the changes in the funded status of the principal U.S. pension plan and the principal non-U.S. pension plans and the amounts recognized in the Company’s consolidated balance sheets as of December 28, 2014 and December 29, 2013.
		December 28, 2014								December 29, 2013
		Non-U.S.				U.S.				Non-U.S.			U.S.
		(In thousands)
	Actuarial present value of benefit obligations:
	Accumulated benefit obligations	$	291,640			$	327,632			$	277,125		$	279,299
	Change in benefit obligations:
	Projected benefit obligations at beginning of year	$	288,216			$	279,299			$	278,707		$	301,770
	Service cost	2,670				1,400				2,589			1,075
	Interest cost	10,575				12,900				9,834			11,500
	Benefits paid and plan expenses	(12,280		)		(19,282		)		(11,218		)	(17,817		)
	Participants’ contributions	394				—				391			—
	Plan settlement	—				—				(918		)	—
	Actuarial loss (gain)	42,095				53,315				1,678			(17,229		)
	Effect of exchange rate changes	(27,861		)		—				7,153			—
	Projected benefit obligations at end of year	$	303,809			$	327,632			$	288,216		$	279,299
	Change in plan assets:
	Fair value of plan assets at beginning of year	$	143,704			$	249,756			$	114,515		$	221,755
	Actual return on plan assets	22,939				25,780				17,201			8,818
	Benefits paid and plan expenses	(12,280		)		(19,282		)		(11,218		)	(17,817		)
	Employer’s contributions	11,195				—				20,200			37,000
	Participants’ contributions	394				—				391			—
	Plan settlement	—				—				(918		)	—
	Effect of exchange rate changes	(9,185		)		—				3,533			—
	Fair value of plan assets at end of year	156,767				256,254				143,704			249,756
	Net liabilities recognized in the consolidated balance sheets	$	(147,042	)		$	(71,378	)		$	(144,512	)	$	(29,543	)
	Net amounts recognized in the consolidated balance sheets consist of:
	Noncurrent assets	$	9,825			$	—			$	6,879		$	—
	Current liabilities	(6,786		)		—				(7,360		)	—
	Noncurrent liabilities	(150,081		)		(71,378		)		(144,031		)	(29,543		)
	Net liabilities recognized in the consolidated balance sheets	$	(147,042	)		$	(71,378	)		$	(144,512	)	$	(29,543	)
	Net amounts recognized in accumulated other comprehensive income consist of:
	Prior service cost	$	(1,371	)		$	—			$	(1,745	)	$	—
	Net amounts recognized in accumulated other comprehensive income	$	(1,371	)		$	—			$	(1,745	)	$	—
	Actuarial assumptions as of the year-end measurement date:
	Discount rate	2.75		%		4.08		%		3.77		%	4.77		%
	Rate of compensation increase	3.07		%		None				3.23		%	None
	Actuarial assumptions used to determine net periodic pension cost during the year were as follows:
		December 28, 2014						December 29, 2013					December 30, 2012
		Non-U.S.			U.S.			Non-U.S.			U.S.		Non-U.S.			U.S.
	Discount rate	3.77	%		4.77	%		3.62	%		3.92	%	4.91	%		4.1	%
	Rate of compensation increase	3.23	%		None			2.88	%		None		3.22	%		3.5	%
	Expected rate of return on assets	5.3	%		7.25	%		5.5	%		7.5	%	5.4	%		7.75	%
	The following table provides a breakdown of the non-U.S. benefit obligations and fair value of assets for pension plans that have benefit obligations in excess of plan assets:
		December 28,				December 29,
		2014				2013
		(In thousands)
	Pension Plans with Projected Benefit Obligations in Excess of Plan Assets
	Projected benefit obligations	$	156,867			$	151,391
	Fair value of plan assets	—				—
Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets
Accumulated benefit obligations	$	153,239			$	148,235
Fair value of plan assets	—				—
Assets of the defined benefit pension plans are primarily equity and debt securities. Asset allocations as of December 28, 2014 and December 29, 2013, and target asset allocations for fiscal year 2015 are as follows:
	Target Allocation						Percentage of Plan Assets at
	January 3, 2016						December 28, 2014					December 29, 2013
Asset Category	Non-U.S.			U.S.			Non-U.S.			U.S.		Non-U.S.			U.S.
Equity securities	45-55%			40-50%			49	%		39	%	51	%		43	%
Debt securities	45-55%			50-60%			50	%		61	%	48	%		57	%
Other	0-5%			0-5%			1	%		—	%	1	%		—	%
Total	100	%		100	%		100	%		100	%	100	%		100	%
The Company maintains target allocation percentages among various asset classes based on investment policies established for the pension plans which are designed to maximize the total rate of return (income and appreciation) after inflation within the limits of prudent risk taking, while providing for adequate near-term liquidity for benefit payments.
The Company’s expected returns on assets assumptions are derived from management’s estimates, as well as other information compiled by management, including studies that utilize customary procedures and techniques. The studies include a review of anticipated future long-term performance of individual asset classes and consideration of the appropriate asset allocation strategy given the anticipated requirements of the plans to determine the average rate of earnings expected on the funds invested to provide for the pension plans benefits. While the study gives appropriate consideration to recent fund performance and historical returns, the assumption is primarily a long-term, prospective rate.
The Company's discount rate assumptions are derived from a range of factors, including a yield curve composed of the rates of return on high-quality fixed-income corporate bonds available at the measurement date and the related expected duration for the obligations.
For the plans in the United States, as of December 28, 2014 the Company adopted the new mortality base table, RP-2014, with projection scale, MP-2014, that was published by the Society of Actuaries in 2014. The adoption of the new mortality base table resulted in a $32.1 million increase to the projected benefit obligation at December 28, 2014 and is included within "Actuarial loss (gain)" in the Change in Benefit Obligation for fiscal year 2014 above.
The target allocations for plan assets are listed in the above table. Equity securities primarily include investments in large-cap and mid-cap companies located in the United States and abroad, and equity index funds. Debt securities include corporate bonds of companies from diversified industries, high-yield bonds, and U.S. government securities. Other types of investments include investments in non-U.S. government index linked bonds, multi-strategy hedge funds and venture capital funds that follow several different strategies.
The fair values of the Company’s pension plan assets as of December 28, 2014 and December 29, 2013 by asset category, classified in the three levels of inputs described in Note 21 to the consolidated financial statements are as follows:
					Fair Value Measurements at December 28, 2014 Using:
	Total Carrying				Quoted Prices in				Significant Other			Significant
	Value at				Active Markets				Observable Inputs			Unobservable
	December 28, 2014				(Level 1)				(Level 2)			Inputs
												(Level 3)
	(In thousands)
Cash	$	4,971			$	4,971			$	—		$	—
Equity Securities:
U.S. large-cap	28,602				28,602				—			—
International large-cap value	25,202				25,202				—			—
Emerging markets growth	13,010				13,010				—			—
Equity index funds	77,432				—				77,432			—
Domestic real estate funds	2,860				2,860				—			—
Commodity funds	7,423				7,423				—			—
Fixed income securities:
Non-U.S. Treasury Securities	22,025				—				22,025			—
Corporate and U.S. debt instruments	147,834				53,813				94,021			—
Corporate bonds	25,164				—				25,164			—
High yield bond funds	3,614				3,614				—			—
Other types of investments:
Multi-strategy hedge funds	23,332				—				—			23,332
Venture capital funds	1				—				—			1
Non-U.S. government index linked bonds	31,551				—				31,551			—
Total assets measured at fair value	$	413,021			$	139,495			$	250,193		$	23,333
					Fair Value Measurements at December 29, 2013 Using:
	Total Carrying				Quoted Prices in				Significant Other			Significant
	Value at				Active Markets				Observable Inputs			Unobservable
	December 29, 2013				(Level 1)				(Level 2)			Inputs
												(Level 3)
	(In thousands)
Cash	$	4,458			$	4,458			$	—		$	—
Equity Securities:
U.S. large-cap	34,127				34,127				—			—
International large-cap value	27,595				27,595				—			—
Emerging markets growth	12,517				12,517				—			—
Equity index funds	73,796				—				73,796			—
Domestic real estate funds	2,471				2,471				—			—
Commodity funds	8,179				8,179				—			—
Fixed income securities:
Non-U.S. Treasury Securities	18,344				—				18,344			—
Corporate and U.S. debt instruments	132,828				45,215				87,613			—
Corporate bonds	22,619				—				22,619			—
High yield bond funds	6,170				6,170				—			—
Other types of investments:
Multi-strategy hedge funds	22,689				—				—			22,689
Venture capital funds	8				—				—			8
Non-U.S. government index linked bonds	27,659				—				27,659			—
Total assets measured at fair value	$	393,460			$	140,732			$	230,031		$	22,697
Valuation Techniques:    Valuation techniques utilized need to maximize the use of observable inputs and minimize the use of unobservable inputs. There have been no changes in the methodologies utilized at December 28, 2014 compared to December 29, 2013. The following is a description of the valuation techniques utilized to measure the fair value of the assets shown in the table above.
Equity Securities:    Shares of registered investment companies that are publicly traded are categorized as Level 1 assets; they are valued at quoted market prices that represent the net asset value of the fund. These instruments have active markets.
Equity index funds are mutual funds that are not publicly traded and are comprised primarily of underlying equity securities that are publicly traded on exchanges. Price quotes for the assets held by these funds are readily observable and available. Equity index funds are categorized as Level 2 assets.
Fixed Income Securities:    Fixed income mutual funds that are publicly traded are valued at quoted market prices that represent the net asset value of securities held by the fund and are categorized as Level 1 assets.
Fixed income index funds that are not publicly traded are stated at net asset value as determined by the issuer of the fund based on the fair value of the underlying investments and are categorized as Level 2 assets.
Individual fixed income bonds are categorized as Level 2 assets except where sufficient quoted prices exist in active markets, in which case such securities are categorized as Level 1 assets. These securities are valued using third-party pricing services. These services may use, for example, model-based pricing methods that utilize observable market data as inputs. Broker dealer bids or quotes of securities with similar characteristics may also be used.
Other Types of Investments:    Non-U.S. government index link bond funds are not publicly traded and are stated at net asset value as determined by the issuer of the fund based on the fair value of the underlying investments. Underlying investments consist of bonds in which payment of income on the principal is related to a specific price index and are categorized as Level 2 assets.
Hedge funds, private equity funds and venture capital funds are valued at fair value by using the net asset values provided by the investment managers and are updated, if necessary, using analytical procedures, appraisals, public market data and/or inquiry of the investment managers. The net asset values are determined based upon the fair values of the underlying investments in the funds. These other investments invest primarily in readily available marketable securities and allocate gains, losses, and expense to the investor based on the ownership percentage as described in the fund agreements. They are categorized as Level 3 assets.
The Company's policy is to recognize significant transfers between levels at the actual date of the event.
A reconciliation of the beginning and ending Level 3 assets for fiscal years 2014, 2013, and 2012 is as follows:
	Fair Value Measurements Using
	Significant Unobservable Inputs
	(Level 3):
	Common				Venture				Multi-strategy			Total
	Collective				Capital				Hedge
	Trusts/Private Funds				Funds				Funds
	(In thousands)
Balance at January 1, 2012	$	—			$	7			$	19,285		$	19,292
Realized losses	1,162				—				—			1,162
Unrealized gains	19				—				977			996
Purchases	9,448				—				—			9,448
Issuances, Sales and Settlements	(10,467		)		—				—			(10,467		)
Balance at December 30, 2012	162				7				20,262			20,431
Realized gains	7				—				—			7
Unrealized (losses) gains	(19		)		1				2,427			2,409
Issuances, Sales and Settlements	(150		)		—				—			(150		)
Balance at December 29, 2013	—				8				22,689			22,697
Realized gains	—				—				—			—
Unrealized (losses) gains	—				(7		)		643			636
Purchases	—				—				—			—
Issuances, Sales and Settlements	—				—				—			—
Balance at December 28, 2014	$	—			$	1			$	23,332		$	23,333
The Company expects to contribute $20.0 million, in the aggregate, during the first quarter of fiscal year 2015, for the 2014 plan year to one of its plans within the United States. With respect to plans outside of the United States, the Company expects to contribute $10.2 million in the aggregate during fiscal year 2015. During fiscal year 2014, the Company made contributions of $11.2 million, in the aggregate, to plans outside of the United States. During fiscal year 2013, the Company made contributions of $37.0 million for the 2012 plan year to its defined benefit pension plan in the United States. During fiscal year 2013, the Company contributed $20.2 million, in the aggregate, to plans outside of the United States, which includes an additional contribution of $10.0 million to its defined benefit pension plan in the United Kingdom. During fiscal year 2012, the Company contributed $17.0 million for the 2011 plan year to its defined benefit pension plans in the United States, and $10.9 million in the aggregate to its defined benefit pension plans outside of the United States.
The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:
	Non-U.S.				U.S.
	(In thousands)
2015	$	11,320			$	18,169
2016	11,832				18,268
2017	12,028				18,363
2018	12,475				18,657
2019	13,067				18,857
2020-2024	70,926				97,713
The Company also sponsors a supplemental executive retirement plan to provide senior management with benefits in excess of normal pension benefits. Effective July 31, 2000, this plan was closed to new entrants. At December 28, 2014 and December 29, 2013, the projected benefit obligations were $24.5 million and $21.1 million, respectively. Assets with a fair value of $0.5 million and $0.3 million, segregated in a trust (which is included in marketable securities and investments on the consolidated balance sheets), were available to meet this obligation as of December 28, 2014 and December 29, 2013, respectively. Pension income and expenses for this plan netted to an expense of $4.8 million in fiscal year 2014, income of $0.4 million in fiscal year 2013 and an expense of $2.5 million in fiscal year 2012.
Postretirement Medical Plans:    The Company provides healthcare benefits for eligible retired U.S. employees under a comprehensive major medical plan or under health maintenance organizations where available. Eligible U.S. employees qualify for retiree health benefits if they retire directly from the Company and have at least ten years of service. Generally, the major medical plan pays stated percentages of covered expenses after a deductible is met and takes into consideration payments by other group coverage and by Medicare. The plan requires retiree contributions under most circumstances and has provisions for cost-sharing charges. Effective January 1, 2000, this plan was closed to new hires. For employees retiring after 1991, the Company has capped its medical premium contribution based on employees’ years of service. The Company funds the amount allowable under a 401(h) provision in the Company’s defined benefit pension plan. Assets of the plan are primarily equity and debt securities and are available only to pay retiree health benefits.
Net periodic postretirement medical benefit credit included the following components for the fiscal years ended:
	December 28,				December 29,				December 30,
	2014				2013				2012
	(In thousands)
Service cost	$	95			$	106			$	106
Interest cost	155				135				144
Expected return on plan assets	(964		)		(965		)		(877		)
Actuarial gain	(384		)		(182		)		(929		)
Net periodic postretirement medical benefit credit	$	(1,098	)		$	(906	)		$	(1,556	)
The following table sets forth the changes in the postretirement medical plan’s funded status and the amounts recognized in the Company’s consolidated balance sheets as of December 28, 2014 and December 29, 2013.
	December 28,				December 29,
	2014				2013
	(In thousands)
Actuarial present value of benefit obligations:
Retirees	$	1,159			$	1,331
Active employees eligible to retire	388				470
Other active employees	1,795				2,009
Accumulated benefit obligations at beginning of year	3,342				3,810
Service cost	95				106
Interest cost	155				135
Benefits paid	(157		)		(189		)
Actuarial loss (gain)	141				(520		)
Change in accumulated benefit obligations during the year	234				(468		)
Retirees	1,033				1,159
Active employees eligible to retire	424				388
Other active employees	2,119				1,795
Accumulated benefit obligations at end of year	3,576				3,342
Change in plan assets:
Fair value of plan assets at beginning of year	13,396				12,958
Actual return on plan assets	1,332				438
Fair value of plan assets at end of year	14,728				13,396
Net assets recognized in the consolidated balance sheets	$	11,152			$	10,054
Net amounts recognized in the consolidated balance sheets consist of:
Noncurrent assets	$	11,152			$	10,054
Net assets recognized in the consolidated balance sheets	$	11,152			$	10,054
Net amounts recognized in accumulated other comprehensive income consist of:
Prior service cost	$	—			$	—
Net amounts recognized in accumulated other comprehensive income	$	—			$	—
Actuarial assumptions as of the year-end measurement date:
Discount rate	4.1		%		4.77		%
Actuarial assumptions used to determine net cost during the year are as follows:
	December 28,			December 29,			December 30,
	2014			2013			2012
Discount rate	4.77	%		3.86	%		4	%
Expected rate of return on assets	7.25	%		7.5	%		7.75	%
The Company maintains a master trust for plan assets related to the U.S. defined benefit plans and the U.S. postretirement medical plan. Accordingly, investment policies, target asset allocations and actual asset allocations are the same as those disclosed for the U.S. defined benefit plans.
The fair values of the Company’s plan assets at December 28, 2014 and December 29, 2013 by asset category, classified in the three levels of inputs described in Note 21, are as follows:
					Fair Value Measurements at December 28, 2014 Using:
	Total Carrying				Quoted Prices in				Significant Other			Significant
	Value at				Active Markets				Observable Inputs			Unobservable
	December 28, 2014				(Level 1)				(Level 2)			Inputs
												(Level 3)
	(In thousands)
Cash	$	248			$	248			$	—		$	—
Equity Securities:
U.S. large-cap	1,644				1,644				—			—
International large-cap value	1,449				1,449				—			—
Emerging markets growth	748				748				—			—
Domestic real estate funds	164				164				—			—
Commodity funds	427				427				—			—
Fixed income securities:
Corporate debt instruments	8,499				3,094				5,405			—
High yield bond funds	208				208				—			—
Other types of investments:
Multi-strategy hedge funds	1,341				—				—			1,341
Total assets measured at fair value	$	14,728			$	7,982			$	5,405		$	1,341
					Fair Value Measurements at December 29, 2013 Using:
	Total Carrying				Quoted Prices in				Significant Other			Significant
	Value at				Active Markets				Observable Inputs			Unobservable
	December 29, 2013				(Level 1)				(Level 2)			Inputs
												(Level 3)
	(In thousands)
Cash	$	167			$	167			$	—		$	—
Equity Securities:
U.S large-cap	1,831				1,831				—			—
International large-cap value	1,480				1,480				—			—
Emerging markets growth	672				672				—			—
Domestic real estate funds	133				133				—			—
Commodity funds	439				439				—			—
Fixed income securities:
Corporate debt instruments	7,126				2,426				4,700			—
High yield bond funds	331				331				—			—
Other types of investments:
Multi-strategy hedge funds	1,217				—				—			1,217
Total assets measured at fair value	$	13,396			$	7,479			$	4,700		$	1,217
Valuation Techniques:    Valuation techniques are the same as those disclosed for the U.S. defined benefit plans above.
A reconciliation of the beginning and ending Level 3 assets for fiscal years 2014, 2013, and 2012 is as follows:
	Fair Value Measurements Using
	Significant Unobservable Inputs
	(Level 3):
	Common				Venture				Multi-strategy			Total
	Collective				Capital				Hedge
	Trusts/Private Funds				Funds				Funds
	(In thousands)
Balance at January 1, 2012	$	—			$	1			$	1,129		$	1,130
Realized gains	68				—				—			68
Unrealized gains	1				—				55			56
Purchases	552				—				—			552
Issuances, Sales and Settlements	(612		)		—				—			(612		)
Balance at December 30, 2012	9				1				1,184			1,194
Realized gains	—				—				—			—
Unrealized (losses) gains	(1		)		(1		)		33			31
Purchases	—				—				—			—
Issuances, Sales and Settlements	(8		)		—				—			(8		)
Balance at December 29, 2013	—				—				1,217			1,217
Realized gains	—				—				—			—
Unrealized gains	—				—				124			124
Purchases	—				—				—			—
Issuances, Sales and Settlements	—				—				—			—
Balance at December 28, 2014	$	—			$	—			$	1,341		$	1,341
The Company does not expect to make any contributions to the postretirement medical plan during fiscal year 2015.
The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:
Postretirement Medical Plan
	(In thousands)
2015	$	167
2016	174
2017	182
2018	192
2019	200
2020-2024	1,159
Deferred Compensation Plans:    During fiscal year 1998, the Company implemented a nonqualified deferred compensation plan that provides benefits payable to officers and certain key employees or their designated beneficiaries at specified future dates, or upon retirement or death. The plan was amended to eliminate deferral elections, with the exception of Company 401(k) excess contributions for eligible participants, for plan years beginning January 1, 2011. Benefit payments under the plan are funded by contributions from participants, and for certain participants, contributions by the Company. The obligations related to the deferred compensation plan totaled $1.0 million for both December 28, 2014 and December 29, 2013.

Contingencies

Contingencies	12 Months Ended
	Dec. 28, 2014
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies
	The Company is conducting a number of environmental investigations and remedial actions at current and former locations of the Company and, along with other companies, has been named a potentially responsible party (“PRP”) for certain waste disposal sites. The Company accrues for environmental issues in the accounting period that the Company's responsibility is established and when the cost can be reasonably estimated. The Company has accrued $12.3 million and $13.5 million as of December 28, 2014 and December 29, 2013, respectively, which represents its management’s estimate of the cost of the remediation of known environmental matters, and does not include any potential liability for related personal injury or property damage claims. These amounts are recorded in accrued expenses and other current liabilities. During fiscal year 2014, the Company recorded a benefit of $2.3 million for cost reimbursements related to a particular site for monitoring and mitigation activities. During fiscal year 2013, the Company accrued an additional $5.7 million related to a particular site for increased monitoring and mitigation activities. The Company's environmental accrual is not discounted and does not reflect the recovery of any material amounts through insurance or indemnification arrangements. The cost estimates are subject to a number of variables, including the stage of the environmental investigations, the magnitude of the possible contamination, the nature of the potential remedies, possible joint and several liability, the time period over which remediation may occur, and the possible effects of changing laws and regulations. For sites where the Company has been named a PRP, management does not currently anticipate any additional liability to result from the inability of other significant named parties to contribute. The Company expects that the majority of such accrued amounts could be paid out over a period of up to ten years. As assessment and remediation activities progress at each individual site, these liabilities are reviewed and adjusted to reflect additional information as it becomes available. There have been no environmental problems to date that have had, or are expected to have, a material adverse effect on the Company’s consolidated financial statements. While it is possible that a loss exceeding the amounts recorded in the consolidated financial statements may be incurred, the potential exposure is not expected to be materially different from those amounts recorded.
	The Company is subject to various claims, legal proceedings and investigations covering a wide range of matters that arise in the ordinary course of its business activities. Although the Company has established accruals for potential losses that it believes are probable and reasonably estimable, in the opinion of the Company’s management, based on its review of the information available at this time, the total cost of resolving these contingencies at December 28, 2014 should not have a material adverse effect on the Company’s consolidated financial statements. However, each of these matters is subject to uncertainties, and it is possible that some of these matters may be resolved unfavorably to the Company.

Warranty_Reserves

Warranty Reserves	12 Months Ended
	Dec. 28, 2014
Product Warranties Disclosures [Abstract]
Warranty Reserves	Warranty Reserves
	The Company provides warranty protection for certain products usually for a period of one year beyond the date of sale. The majority of costs associated with warranty obligations include the replacement of parts and the time for service personnel to respond to repair and replacement requests. A warranty reserve is recorded based upon historical results, supplemented by management’s expectations of future costs. Warranty reserves are included in “Accrued expenses and other current liabilities” on the consolidated balance sheets.
	A summary of warranty reserve activity for the fiscal years ended December 28, 2014, December 29, 2013 and December 30, 2012 is as follows:
		(In thousands)
	Balance at January 1, 2012	$	10,412
	Provision charged to income	17,750
	Payments	(18,022		)
	Adjustments to previously provided warranties, net	801
	Foreign currency translation and acquisitions	62
	Balance at December 30, 2012	11,003
	Provision charged to income	17,291
	Payments	(17,116		)
	Adjustments to previously provided warranties, net	(693		)
	Foreign currency translation and acquisitions	49
	Balance at December 29, 2013	10,534
	Provision charged to income	17,447
	Payments	(16,750		)
	Adjustments to previously provided warranties, net	73
	Foreign currency translation and acquisitions	(521		)
	Balance at December 28, 2014	$	10,783

Stock_Plans

Stock Plans	12 Months Ended
	Dec. 28, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Plans	Stock Plans
	Stock-Based Compensation:
	In addition to the Company’s Employee Stock Purchase Plan, the Company utilizes one stock-based compensation plan, the 2009 Incentive Plan (the “2009 Plan”). Under the 2009 Plan, 10.7 million shares of the Company's common stock are authorized for stock option grants, restricted stock awards, performance units and stock grants as part of the Company’s compensation programs. In addition to shares of the Company’s common stock originally authorized for issuance under the 2009 Plan, the 2009 Plan includes shares of the Company’s common stock previously granted under the Amended and Restated 2001 Incentive Plan and the 2005 Incentive Plan that were canceled or forfeited without the shares being issued.
	The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock options, restricted stock, restricted stock units, performance units and stock grants, net of estimated forfeitures, included in the Company’s consolidated statements of operations for fiscal years 2014, 2013, and 2012:
		December 28,			December 29,				December 30,
		2014			2013				2012
		(In thousands)
	Cost of product and service revenue	$	1,456		$	1,304			$	1,247
	Research and development expenses	546			853				747
	Selling, general and administrative expenses	12,462			11,896				18,631
	Continuing operations stock-based compensation expense	14,464			14,053				20,625
	Discontinued operations stock-based compensation expense	—			—				406
	Total stock-based compensation expense	$	14,464		$	14,053			$	21,031
	The total income tax benefit recognized in the consolidated statements of operations for stock-based compensation was $5.4 million in fiscal year 2014, $4.4 million in fiscal year 2013 and $6.8 million in fiscal year 2012. Stock-based compensation costs capitalized as part of inventory were $0.3 million and $0.4 million as of December 28, 2014 and December 29, 2013, respectively. The excess tax benefit recognized from stock compensation, classified as a financing cash activity, was zero in both fiscal years 2014 and 2013, and $1.8 million in fiscal year 2012.
	Stock Options:    The Company has granted options to purchase common shares at prices equal to the market price of the common shares on the date the option is granted. Conditions of vesting are determined at the time of grant. Options are generally exercisable in equal annual installments over a period of three years, and will generally expire seven years after the date of grant. Options replaced in association with business combination transactions are generally issued with the same terms of the respective plans under which they were originally issued.
	The fair value of each option grant is estimated using the Black-Scholes option pricing model. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was calculated primarily based on the historical volatility of the Company’s stock. The average expected life was based on the contractual term of the option and historic exercise experience. The risk-free interest rate is based on United States Treasury zero-coupon issues with a remaining term equal to the expected life assumed at the date of grant. Forfeitures are estimated based on voluntary termination behavior, as well as an analysis of actual option forfeitures. The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows for the fiscal years ended:
		December 28,		December 29,			December 30,
		2014		2013			2012
	Risk-free interest rate	1.5	%	0.9	%		0.6	%
	Expected dividend yield	0.7	%	0.8	%		1.2	%
	Expected lives	5 years		5 years			4 years
	Expected stock volatility	30.9	%	38.5	%		38.7	%
	The following table summarizes stock option activity for the three fiscal years ended December 28, 2014:
		December 28, 2014						December 29, 2013					December 30, 2012
		Number		Weighted-				Number			Weighted-		Number		Weighted-
		of		Average Exercise				of			Average Exercise		of		Average Exercise
		Shares		Price				Shares			Price		Shares		Price
		(Shares in thousands)
	Outstanding at beginning of year	3,494		$	23.34			4,266			$	21.64	5,346		$	20.57
	Granted	520		43.12				518			33.62		756		26.28
	Exercised	(1,024	)	23.89				(947	)		21.45		(1,611	)	20.16
	Canceled	(4	)	20.97				(8	)		22.88		(210	)	22.34
	Forfeited	(158	)	35.33				(335	)		23.04		(15	)	21.98
	Outstanding at end of year	2,828		$	26.11			3,494			$	23.34	4,266		$	21.64
	Exercisable at end of year	1,900		$	21.13			2,392			$	20.66	2,677		$	20
	The aggregate intrinsic value for stock options outstanding at December 28, 2014 was $48.0 million with a weighted-average remaining contractual term of 3.4 years. The aggregate intrinsic value for stock options exercisable at December 28, 2014 was $41.7 million with a weighted-average remaining contractual term of 2.4 years. At December 28, 2014, there were 2.8 million stock options that were vested, and expected to vest in the future, with an aggregate intrinsic value of $47.7 million and a weighted-average remaining contractual term of 3.4 years.
	The weighted-average per-share grant-date fair value of options granted during fiscal years 2014, 2013, and 2012 was $11.86, $10.82, and $7.36, respectively. The total intrinsic value of options exercised during fiscal years 2014, 2013, and 2012 was $22.0 million, $13.8 million, and $13.1 million, respectively. Cash received from option exercises for fiscal years 2014, 2013, and 2012 was $24.5 million, $20.3 million, and $32.5 million, respectively. The total compensation expense recognized related to the Company’s outstanding options was $5.0 million in fiscal year 2014, $4.4 million in fiscal year 2013 and $5.1 million in fiscal year 2012.
	There was $5.6 million of total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock options granted as of December 28, 2014. This cost is expected to be recognized over a weighted-average period of 1.8 years, and will be adjusted for any future changes in estimated forfeitures.
	Restricted Stock Awards:    The Company has awarded shares of restricted stock and restricted stock units to certain employees at no cost to them, which cannot be sold, assigned, transferred or pledged during the restriction period. The restricted stock and restricted stock units vest through the passage of time, assuming continued employment. The fair value of the award at the time of the grant is expensed on a straight line basis primarily in selling, general and administrative expenses over the vesting period, which is generally three years. These awards were granted under the Company’s 2009 Plan. Recipients of the restricted stock have the right to vote such shares and receive dividends.
	The following table summarizes restricted stock award activity for the three fiscal years ended December 28, 2014:
		December 28, 2014						December 29, 2013					December 30, 2012
		Number		Weighted-				Number			Weighted-		Number		Weighted-
		of		Average				of			Average		of		Average
		Shares		Grant-				Shares			Grant-		Shares		Grant-
				Date Fair							Date Fair				Date Fair
				Value							Value				Value
		(Shares in thousands)
	Nonvested at beginning of year	649		$	29.24			781			$	24.71	672		$	23.62
	Granted	261		42.61				289			33.87		358		25.86
	Vested	(258	)	27.64				(346	)		22.98		(184	)	23.19
	Forfeited	(94	)	33.58				(75	)		28.76		(65	)	24.03
	Nonvested at end of year	558		$	33.51			649			$	29.24	781		$	24.71
	The fair value of restricted stock awards vested during fiscal years 2014, 2013, and 2012 was $7.1 million, $8.0 million, and $4.3 million, respectively. The total compensation expense recognized related to the restricted stock awards was $7.1 million in fiscal year 2014, $7.5 million in fiscal year 2013 and $8.2 million in fiscal year 2012.
	As of December 28, 2014, there was $10.0 million of total unrecognized compensation cost, net of forfeitures, related to nonvested restricted stock awards. That cost is expected to be recognized over a weighted-average period of 1.2 fiscal years.
	Performance Units:    The Company’s performance unit program provides a cash award based on the achievement of specific performance criteria. A target number of units are granted at the beginning of a three-year performance period. The number of units earned at the end of the performance period is determined by multiplying the number of units granted by a performance factor ranging from 0% to 200%. Awards are determined by multiplying the number of units earned by the stock price at the end of the performance period, and are paid in cash and accounted for as a liability based award. The compensation expense associated with these units is recognized over the period that the performance targets are expected to be achieved. The Company granted 79,463 performance units, 98,056 performance units, and 122,675 performance units during fiscal years 2014, 2013, and 2012, respectively. The weighted-average per-share grant-date fair value of performance units granted during fiscal years 2014, 2013, and 2012 was $42.84, $34.06, and $26.18, respectively. During fiscal years 2014, 2013, and 2012, 35,954, 28,515 and zero performance units were forfeited, respectively. The total compensation expense related to performance units was $1.6 million, $1.4 million, and $7.1 million for fiscal years 2014, 2013, and 2012, respectively. As of December 28, 2014, there were 235,725 performance units outstanding subject to forfeiture, with a corresponding liability of $4.1 million recorded in accrued expenses and long-term liabilities.
	Stock Awards:    The Company’s stock award program provides non-employee Directors an annual equity award. For fiscal years 2014, 2013, and 2012 the award equaled the number of shares of the Company’s common stock which has an aggregate fair market value of $100,000 on the date of the award. The stock award is prorated for non-employee Directors who serve for only a portion of the year. The compensation expense associated with these stock awards is recognized when the stock award is granted. In fiscal years 2014, 2013, and 2012, each non-employee Director was awarded 2,373 shares, 3,263 shares, and 3,580 shares, respectively. The Company also granted 955 shares to a new non-employee Director during fiscal year 2012. The weighted-average per-share grant-date fair value of stock awards granted during fiscal years 2014, 2013, and 2012 was $42.14, $30.65, and $27.87, respectively. In fiscal years 2014, 2013, and 2012, the total compensation expense recognized related to these stock awards was $0.7 million.
	Employee Stock Purchase Plan:
	In April 1999, the Company’s shareholders approved the 1998 Employee Stock Purchase Plan. In April 2005, the Compensation and Benefits Committee of the Board voted to amend the Employee Stock Purchase Plan, effective July 1, 2005, whereby participating employees have the right to purchase common stock at a price equal to 95% of the closing price on the last day of each six-month offering period. The number of shares which an employee may purchase, subject to certain aggregate limits, is determined by the employee’s voluntary contribution, which may not exceed 10% of the employee’s base compensation. During fiscal year 2014, the Company issued 60,870 shares of common stock under the Company’s Employee Stock Purchase Plan at a weighted-average price of $41.71 per share. During fiscal year 2013, the Company issued 89,521 shares under this plan at a weighted-average price of $30.51 per share. During fiscal year 2012, the Company issued 53,961 shares under this plan at a weighted-average price of $24.51 per share. At December 28, 2014 there remains available for sale to employees an aggregate of 1.0 million shares of the Company’s common stock out of the 5.0 million shares authorized by shareholders for issuance under this plan.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 28, 2014
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders’ Equity
	Comprehensive Income:
	The components of accumulated other comprehensive income consisted of the following:
		Foreign			Unrecognized			Unrealized			Unrealized and Realized (Losses) Gains on Derivatives, net of tax			Accumulated
		Currency			Prior Service			(Losses)						Other
		Translation			Costs, net of			Gains on						Comprehensive
		Adjustment,			tax			Securities,						Income
		net of tax						net of tax
		(In thousands)
	Balance, January 1, 2012	$	56,164		$	2,169		$	(159	)	$	(4,088	)	$	54,086
	Current year change	11,363			(82		)	30			1,196			12,507
	Balance, December 30, 2012	67,527			2,087			(129		)	(2,892		)	66,593
	Current year change	8,756			(658		)	8			2,892			10,998
	Balance, December 29, 2013	76,283			1,429			(121		)	—			77,591
	Current year change	(52,951		)	146			14			—			(52,791		)
	Balance, December 28, 2014	$	23,332		$	1,575		$	(107	)	$	—		$	24,800
	During fiscal year 2013, pre-tax losses of $4.8 million were reclassified from accumulated other comprehensive income into interest and other expense, net, related to previously settled cash flow hedges, which includes $2.8 million for the remaining unamortized derivative losses that were reclassified when the Company redeemed all of its 2015 Notes. The Company recognized a tax provision of $1.9 million related to these amounts reclassified out of accumulated other comprehensive income for fiscal year 2013. During fiscal year 2012, pre-tax losses of $2.0 million were reclassified from accumulated other comprehensive income into interest and other expense, net related to previously settled cash flow hedges. The Company recognized a tax provision of $0.8 million related to this amount reclassified out of accumulated other comprehensive income during fiscal year 2012. During fiscal years 2014, 2013, and 2012, pre-tax income of $0.1 million, pre-tax expenses of $0.7 million, and pre-tax expenses of $0.1 million, respectively, were reclassified from accumulated other comprehensive income into selling, general and administrative expenses as a component of net periodic benefit cost.
	Stock Repurchase Program:
	On October 24, 2012, the Board of Directors (the "Board") authorized the Company to repurchase up to 6.0 million shares of common stock under a stock repurchase program (the "Repurchase Program"). The Repurchase Program expired on October 24, 2014. On October 23, 2014, the Board authorized the Company to repurchase up to 8.0 million shares of common stock under a new stock repurchase program (the "New Repurchase Program"). The New Repurchase Program will expire on October 23, 2016 unless terminated earlier by the Board, and may be suspended or discontinued at any time. During fiscal year 2014, the Company repurchased 1.4 million shares of common stock in the open market at an aggregate cost of $61.3 million, including commissions, under these repurchase programs. During fiscal year 2013, the Company repurchased approximately 3.6 million shares of common stock in the open market at an aggregate cost of $123.0 million, including commissions, under the Repurchase Program. During fiscal year 2012, the Company did not repurchase any shares of common stock under any stock repurchase program. As of December 28, 2014, approximately 7.4 million shares authorized by the Board under the New Repurchase Program remained available for repurchase.
	The Board has authorized the Company to repurchase shares of common stock to satisfy minimum statutory tax withholding obligations in connection with the vesting of restricted stock awards and restricted stock unit awards granted pursuant to the Company’s equity incentive plans and to satisfy obligations related to the exercise of stock options made pursuant to the Company's equity incentive plans. During fiscal year 2014, the Company repurchased 98,269 shares of common stock for this purpose at an aggregate cost of $4.3 million. During fiscal year 2013, the Company repurchased 127,544 shares of common stock for this purpose at an aggregate cost of $4.4 million. During fiscal year 2012, the Company repurchased 82,186 shares of common stock for this purpose at an aggregate cost of $2.1 million.
	The repurchased shares have been reflected as additional authorized but unissued shares, with the payments reflected in common stock and capital in excess of par value.
	Dividends:
	The Board declared a regular quarterly cash dividend of $0.07 per share in each quarter of fiscal years 2014 and 2013. At December 28, 2014, the Company has accrued $7.9 million for dividends declared on October 23, 2014 for the fourth quarter of fiscal year 2014 payable in February 2015. On January 23, 2015, the Company announced that the Board had declared a quarterly dividend of $0.07 per share for the first quarter of fiscal year 2015 that will be payable in May 2015. In the future, the Board may determine to reduce or eliminate the Company’s common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.

Derivatives_And_Hedging_Activi

Derivatives And Hedging Activities	12 Months Ended
	Dec. 28, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Hedging Activities	Derivatives and Hedging Activities
	The Company uses derivative instruments as part of its risk management strategy only, and includes derivatives utilized as economic hedges that are not designated as hedging instruments. By nature, all financial instruments involve market and credit risks. The Company enters into derivative instruments with major investment grade financial institutions and has policies to monitor the credit risk of those counterparties. The Company does not enter into derivative contracts for trading or other speculative purposes, nor does the Company use leveraged financial instruments. Approximately 60% of the Company’s business is conducted outside of the United States, generally in foreign currencies. The fluctuations in foreign currency can increase the costs of financing, investing and operating the business. The intent of these economic hedges is to offset gains and losses that occur on the underlying exposures from these currencies, with gains and losses resulting from the forward currency contracts that hedge these exposures.
	In the ordinary course of business, the Company enters into foreign exchange contracts for periods consistent with its committed exposures to mitigate the effect of foreign currency movements on transactions denominated in foreign currencies. Transactions covered by hedge contracts include intercompany and third-party receivables and payables. The contracts are primarily in European and Asian currencies, have maturities that do not exceed 12 months, have no cash requirements until maturity, and are recorded at fair value on the Company’s consolidated balance sheets. Unrealized gains and losses on the Company’s foreign currency contracts are recognized immediately in earnings for hedges designated as fair value and, for hedges designated as cash flow, the related unrealized gains or losses are deferred as a component of other comprehensive income in the accompanying consolidated balance sheets. Deferred gains and losses are recognized in income in the period in which the underlying anticipated transaction occurs and impacts earnings.
	Principal hedged currencies include the British Pound, Euro, Japanese Yen and Singapore Dollar. The Company held forward foreign exchange contracts, designated as fair value hedges, with U.S. dollar equivalent notional amounts totaling $95.0 million at December 28, 2014, $138.4 million at December 29, 2013, and $64.3 million at December 30, 2012, and the fair value of these foreign currency derivative contracts was insignificant. The gains and losses realized on foreign currency derivative contracts are not material. The duration of these contracts was generally 30 days or less during each of fiscal years 2014, 2013, and 2012.
	During fiscal year 2014, the Company entered into five forward foreign exchange contracts with settlement dates in fiscal year 2015 and combined Euro denominated notional amounts of €238.2 million, designated as cash flow hedges, that were intended to hedge movements in foreign exchange rates prior to settlement of certain intercompany loan agreements. The fair value of these currency derivative contracts at December 28, 2014 was not material. The unrealized gain, which was recorded in other comprehensive income, will be recognized in interest and other expense, net, in the period in which the underlying hedged transaction occurs and impacts earnings. Such amounts were not material for fiscal year 2014. During December 2012, the Company entered into forward foreign exchange contracts with settlement dates in fiscal year 2013 and combined Euro denominated notional amounts of €50.0 million, designated as cash flow hedges. During fiscal year 2013, the Company settled these Euro denominated forward foreign exchange contracts. The derivative gains were recognized in the period in which the underlying hedged exposures occurred and impacted earnings, and were recorded in interest and other expense, net. Such amounts were not material for fiscal year 2013.
	In May 2008, the Company settled forward interest rate contracts with notional amounts totaling $150.0 million upon the issuance of its 2015 Notes, and recognized $8.4 million, net of taxes of $5.4 million, of accumulated derivative losses in other comprehensive income. During each of fiscal years 2013 and 2012, the Company amortized a pre-tax loss of $2.0 million into interest and other expense, net. In addition, during fiscal year 2013, the Company redeemed all of its 2015 Notes and recognized a pre-tax loss of $2.8 million for the remaining unamortized derivative losses into interest and other expense, net.
	The Company does not expect any material net pre-tax gains or losses to be reclassified from accumulated other comprehensive income into interest and other expense, net within the next twelve months.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 28, 2014
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements
	Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents, derivatives, marketable securities and accounts receivable. The Company believes it had no significant concentrations of credit risk as of December 28, 2014.
	The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during fiscal years 2014 and 2013. The Company’s financial assets and liabilities carried at fair value are primarily comprised of marketable securities, derivative contracts used to hedge the Company’s currency risk, and acquisition related contingent consideration. The Company has not elected to measure any additional financial instruments or other items at fair value.
	Valuation Hierarchy: The following summarizes the three levels of inputs required to measure fair value. For Level 1 inputs, the Company utilizes quoted market prices as these instruments have active markets. For Level 2 inputs, the Company utilizes quoted market prices in markets that are not active, broker or dealer quotations, or utilizes alternative pricing sources with reasonable levels of price transparency. For Level 3 inputs, the Company utilizes unobservable inputs based on the best information available, including estimates by management primarily based on information provided by third-party fund managers, independent brokerage firms and insurance companies. A financial asset’s or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.
	The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of December 28, 2014 and December 29, 2013 classified in one of the three classifications described above:
					Fair Value Measurements at December 28, 2014 Using:
		Total Carrying			Quoted Prices in		Significant Other			Significant
		Value at			Active Markets		Observable Inputs			Unobservable Inputs
		December 28,			(Level 1)		(Level 2)			(Level 3)
		2014
		(In thousands)
	Marketable securities	$	1,568		$	1,568	$	—		$	—
	Foreign exchange derivative assets	3,205			—		3,205			—
	Foreign exchange derivative liabilities	(302		)	—		(302		)	—
	Contingent consideration	(91		)	—		—			(91		)
					Fair Value Measurements at December 29, 2013 Using:
		Total Carrying			Quoted Prices in		Significant Other			Significant
		Value at			Active Markets		Observable Inputs			Unobservable Inputs
		December 29,			(Level 1)		(Level 2)			(Level 3)
		2013
		(In thousands)
	Marketable securities	$	1,319		$	1,319	$	—		$	—
	Foreign exchange derivative assets	293			—		293			—
	Foreign exchange derivative liabilities, net	(396		)	—		(396		)	—
	Contingent consideration	(4,926		)	—		—			(4,926		)
	Level 1 and Level 2 Valuation Techniques:    The Company’s Level 1 and Level 2 assets and liabilities are comprised of investments in equity and fixed-income securities as well as derivative contracts. For financial assets and liabilities that utilize Level 1 and Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including common stock price quotes, foreign exchange forward prices and bank price quotes. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities.
	Marketable securities:    Include equity and fixed-income securities measured at fair value using the quoted market prices in active markets at the reporting date.
	Foreign exchange derivative assets and liabilities:    Include foreign exchange derivative contracts that are valued using quoted forward foreign exchange prices at the reporting date. The Company’s foreign exchange derivative contracts are subject to master netting arrangements that allow the Company and its counterparties to net settle amounts owed to each other. Derivative assets and liabilities that can be net settled under these arrangements have been presented in the Company's consolidated balance sheet on a net basis and are recorded in other assets. As of both December 28, 2014 and December 29, 2013, none of the master netting arrangements involved collateral.
	Level 3 Valuation Techniques:    The Company’s Level 3 liabilities are comprised of contingent consideration related to acquisitions. For liabilities that utilize Level 3 inputs, the Company uses significant unobservable inputs. Below is a summary of valuation techniques for Level 3 liabilities.
	Contingent consideration:    The Company has classified its net liabilities for contingent consideration relating to its acquisitions within Level 3 of the fair value hierarchy because the fair value is determined using significant unobservable inputs, which included probability weighted cash flows. Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period. Increases or decreases in the fair value of contingent consideration liabilities primarily result from changes in the estimated probabilities of achieving revenue thresholds or product development milestones during the earnout period. The Company may have to pay contingent consideration, related to all acquisitions with open contingency periods, of up to $31.4 million as of December 28, 2014. As of December 28, 2014, the Company has recorded contingent consideration obligations relating to its acquisition of Tetra Teknolojik Sistemler Limited Sirketi with an estimated fair value of $0.1 million. The earnout period for each of these acquisitions does not exceed three years from the respective acquisition date, and the remaining weighted average earnout period at December 28, 2014 was one year.
	A reconciliation of the beginning and ending Level 3 net liabilities for contingent consideration is as follows:
		(In thousands)
	Balance at January 1, 2012	$	(20,298	)
	Additions	(1,900		)
	Amounts paid and foreign currency translation	17,433
	Change in fair value (included within selling, general and administrative expenses)	1,748
	Balance at December 30, 2012	(3,017		)
	Additions	(1,100		)
	Amounts paid and foreign currency translation	135
	Change in fair value (included within selling, general and administrative expenses)	(944		)
	Balance at December 29, 2013	(4,926		)
	Additions	—
	Amounts paid and foreign currency translation	2,074
	Change in fair value (included within selling, general and administrative expenses)	2,761
	Balance at December 28, 2014	$	(91	)
	During the fourth quarter of fiscal year 2012, the Company recorded $74.2 million of pre-tax intangible asset impairment charges related to certain trade names. A description of these impairment charges is included within Note 12. The fair value measurements were determined using a relief from royalty method, which incorporates unobservable inputs, thereby classifying the fair value measurements as a Level 3 measurement within the fair value hierarchy. The primary inputs used in the relief from royalty method, an income-based approach, included estimated prospective cash flows considering the revised useful lives and an estimated royalty rate that would be used by a market participant. The royalty rates ranged from 0.5% to 1.0%, the discount rates ranged from 11.0% to 12.0%, and the useful lives ranged from 1 to 8 years. The identified indefinite-lived intangibles related to the above impairment charges, had a carrying value of $76.4 million and a fair value of $4.5 million as of the impairment date, resulting in an impairment loss of $71.9 million. The identified definite-lived intangibles related to the above impairment charges, had a carrying value of $3.8 million and a fair value of $1.5 million as of the impairment date, resulting in an impairment loss of $2.3 million.
	The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturities of these assets and liabilities. If measured at fair value, cash and cash equivalents would be classified as Level 1.
	The Company’s new senior unsecured revolving credit facility, which provides for $700.0 million of revolving loans, had amounts outstanding, excluding letters of credit, of $516.0 million as of December 28, 2014. The Company’s previous senior unsecured revolving credit facility had amounts outstanding, excluding letters of credit, of $397.0 million as of December 29, 2013. The interest rate on the Company’s senior unsecured revolving credit facility is reset at least monthly to correspond to variable rates that reflect currently available terms and conditions for similar debt. The Company had no change in credit standing during fiscal year 2014. Consequently, the carrying value of the current year and prior year credit facilities approximate fair value and would be classified as Level 2.
	The Company's 2021 Notes, with a face value of $500.0 million, had an aggregate carrying value of $497.7 million, net of $2.3 million of unamortized original issue discount, and a fair value of $542.7 million as of December 28, 2014. The 2021 Notes had an aggregate carrying value of $497.4 million, net of $2.6 million of unamortized original issue discount, and a fair value of $513.0 million as of December 29, 2013. The fair value of the 2021 Notes is estimated using market quotes from brokers and is based on current rates offered for similar debt. The Company's financing lease obligations had an aggregate carrying value of $39.3 million and $40.3 million as of December 28, 2014 and December 29, 2013, respectively, and approximated the fair value as there has been minimal change in the Company's incremental borrowing rate. As of December 28, 2014, the 2021 Notes and financing lease obligations were classified as Level 2.
	As of December 28, 2014, there has not been any significant impact to the fair value of the Company’s derivative liabilities due to credit risk. Similarly, there has not been any significant adverse impact to the Company’s derivative assets based on the evaluation of its counterparties’ credit risks.

Leases

Leases	12 Months Ended
	Dec. 28, 2014
Leases [Abstract]
Leases	Leases
	The Company leases certain property and equipment under operating leases. Rental expense charged to continuing operations for fiscal years 2014, 2013, and 2012 amounted to $54.8 million, $52.6 million, and $60.2 million, respectively. Minimum rental commitments under noncancelable operating leases are as follows: $54.8 million in fiscal year 2015, $36.3 million in fiscal year 2016, $28.1 million in fiscal year 2017, $23.9 million in fiscal year 2018, $20.7 million in fiscal year 2019 and $77.2 million in fiscal year 2020 and thereafter.
	On August 22, 2013, the Company sold one of its facilities located in Boston, Massachusetts for net proceeds of $47.6 million. Simultaneously with the closing of the sale of the property, the Company entered into a lease agreement to lease back the property for its continued use. The lease has an initial term of 15 years and the Company has the right to extend the term of the lease for two additional periods of ten years each. The lease is accounted for as an operating lease and at the transaction date the Company had deferred $26.5 million of gains which are being amortized in operating expenses over the initial lease term of 15 years. During fiscal years 2014 and 2013, the Company amortized $1.8 million and $0.6 million, respectively, of deferred gains related to the lease. The deferred gains remaining to be amortized were $24.1 million at December 28, 2014 and $25.9 million at December 29, 2013, which were recorded in long-term liabilities.

Industry_Segment_and_Geographi

Industry Segment and Geographic Area Information	12 Months Ended
	Dec. 28, 2014
Segment Reporting [Abstract]
Industry Segment Information	Industry Segment and Geographic Area Information
	The Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The Company evaluates the performance of its operating segments based on revenue and operating income. Intersegment revenue and transfers are not significant. The Company’s management reviews the results of the Company’s operations by the Human Health and Environmental Health operating segments. The accounting policies of the operating segments are the same as those described in Note 1. The principal products and services of these two operating segments are:
	•	Human Health.    Develops diagnostics, tools and applications to help detect diseases earlier and more accurately and to accelerate the discovery and development of critical new therapies. The Human Health segment serves both the diagnostics and research markets.
	•	Environmental Health.    Provides products, services and solutions to facilitate the creation of safer food and consumer products, more secure surroundings and efficient energy resources. The Environmental Health segment serves the environmental, industrial and laboratory services markets.
	The Company has included the expenses for its corporate headquarters, such as legal, tax, audit, human resources, information technology, and other management and compliance costs, as well as the activity related to the mark-to-market adjustment on postretirement benefit plans, as “Corporate” below. The Company has a process to allocate and recharge expenses to the reportable segments when these costs are administered or paid by the corporate headquarters based on the extent to which the segment benefited from the expenses. These amounts have been calculated in a consistent manner and are included in the Company’s calculations of segment results to internally plan and assess the performance of each segment for all purposes, including determining the compensation of the business leaders for each of the Company’s operating segments.
	Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below for the fiscal years ended:
		December 28,			December 29,			December 30,
		2014			2013			2012
		(In thousands)
	Human Health
	Product revenue	$	996,767		$	957,022		$	926,733
	Service revenue	246,635			244,088			237,892
	Total revenue	1,243,402			1,201,110			1,164,625
	Operating income from continuing operations(1)	220,165			156,452			63,773
	Environmental Health
	Product revenue	543,308			541,048			547,941
	Service revenue	450,509			415,428			392,622
	Total revenue	993,817			956,476			940,563
	Operating income from continuing operations(1)	109,129			97,052			111,844
	Corporate
	Operating loss from continuing operations(2)(3)	(118,552		)	(25,710		)	(72,497		)
	Continuing Operations
	Product revenue	$	1,540,075		$	1,498,070		$	1,474,674
	Service revenue	697,144			659,516			630,514
	Total revenue	2,237,219			2,157,586			2,105,188
	Operating income from continuing operations	210,742			227,794			103,120
	Interest and other expense, net (see Note 5)	41,139			64,110			47,956
	Income from continuing operations before income taxes	$	169,603		$	163,684		$	55,164
	____________________________
	(1)	Pre-tax impairment charges have been included in the Human Health and Environmental Health operating income from continuing operations. The Company had no pre-tax impairment charges in fiscal year 2014. The Company recognized a $0.2 million pre-tax impairment charge in the Human Health segment in fiscal year 2013. The Company recognized $73.4 million of pre-tax impairment charges in the Human Health segment and also recognized $0.7 million of pre-tax impairment charges in the Environmental Health segment in fiscal year 2012.
	(2)	Activity related to the mark-to-market adjustment on postretirement benefit plans has been included in the Corporate operating loss from continuing operations, and in the aggregate constituted a pre-tax loss of $75.9 million in fiscal year 2014, pre-tax income of $17.6 million in fiscal year 2013, and a pre-tax loss of $31.8 million in fiscal year 2012.
	(3)	Includes expenses related to litigation with Enzo Biochem, Inc. and Enzo Life Sciences, Inc. (collectively, “Enzo”). Enzo filed a complaint in 2002 alleging that the Company separately and together with other defendants breached distributorship and settlement agreements with Enzo, infringed Enzo's patents, engaged in unfair competition and fraud, and committed torts against Enzo by, among other things, engaging in commercial development and exploitation of Enzo's patented products and technology. The Company entered into a settlement agreement with Enzo dated June 20, 2014 and during fiscal year 2014 paid $7.0 million into a designated escrow account to resolve this matter, of which $3.7 million had been accrued in previous years and $3.3 million was recorded during fiscal year 2014. In addition, $3.4 million of expenses were incurred and recorded in preparation for the trial during fiscal year 2014.
	Additional information relating to the Company’s reporting segments is as follows for the three fiscal years ended December 28, 2014:
		Depreciation and Amortization									Capital Expenditures
		Expense
		December 28,			December 29,			December 30,			December 28,		December 29,		December 30,
		2014			2013			2012			2014		2013		2012
		(In thousands)									(In thousands)
	Human Health	$	89,969		$	98,582		$	99,597		$	15,201	$	20,900	$	24,518
	Environmental Health	24,736			25,915			23,001			12,149		16,532		14,488
	Corporate	2,031			2,382			2,528			1,722		1,549		3,395
	Continuing operations	116,736			126,879			125,126			29,072		38,981		42,401
	Discontinued operations	$	339		$	1,590		$	1,741		$	213	$	10	$	7
		Total Assets
		December 28,			December 29,			December 30,
		2014			2013			2012
		(In thousands)
	Human Health	$	2,645,411		$	2,692,809		$	2,700,565
	Environmental Health	1,453,683			1,213,801			1,153,444
	Corporate	34,981			34,271			33,952
	Net current and long-term assets of discontinued operations	—			5,831			13,801
	Total assets	$	4,134,075		$	3,946,712		$	3,901,762
	The following geographic area information for continuing operations includes revenue based on location of external customer for the three fiscal years ended December 28, 2014 and net long-lived assets based on physical location as of December 28, 2014 and December 29, 2013:
		Revenue
		December 28,			December 29,			December 30,
		2014			2013			2012
		(In thousands)
	U.S.	$	849,356		$	826,991		$	812,934
	International:
	China	276,230			254,838			216,425
	United Kingdom	134,614			133,611			118,611
	Germany	107,081			99,153			105,735
	Japan	93,811			95,676			114,300
	Italy	85,433			78,120			69,599
France	84,946			81,719			84,395
Other international	605,748			587,478			583,189
Total international	1,387,863			1,330,595			1,292,254
Total sales	$	2,237,219		$	2,157,586		$	2,105,188
	Net Long-Lived Assets
	December 28,			December 29,			December 30,
	2014			2013			2012
	(In thousands)
U.S.	$	198,675		$	214,721		$	200,539
International:
China	36,797			30,682			30,134
United Kingdom	13,033			9,882			2,960
Finland	12,758			13,635			11,851
Singapore	7,041			6,812			6,366
Italy	4,107			2,735			3,303
Netherlands	3,614			4,037			3,900
Germany	2,493			2,591			2,353
Brazil	2,099			1,967			1,515
Mexico	1,938			1,016			1,353
Other international	8,627			8,062			8,889
Total international	92,507			81,419			72,624
Total net long-lived assets	$	291,182		$	296,140		$	273,163

Quarterly_Financial_Informatio

Quarterly Financial Information (Unaudited)	12 Months Ended
	Dec. 28, 2014
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information (Unaudited)	Quarterly Financial Information (Unaudited)
	Selected quarterly financial information is as follows for the fiscal years ended:
		First		Second		Third		Fourth			Year
		Quarter		Quarter		Quarter		Quarter(1)(2)
		(In thousands, except per share data)
	December 28, 2014
	Revenue	$	530,610	$	556,170	$	542,049	$	608,390		$	2,237,219
	Gross profit	235,713		247,984		243,309		277,602			1,004,608
	Restructuring and contract termination charges, net	2,135		742		11,092		(579		)	13,390
	Operating income from continuing operations	51,762		69,637		58,776		30,567			210,742
	Income from continuing operations before income taxes	40,473		60,673		47,810		20,647			169,603
	Income from continuing operations	34,951		52,003		42,898		31,314			161,166
	Net income	34,224		50,490		42,277		30,787			157,778
	Basic earnings per share:
	Income from continuing operations	$	0.31	$	0.46	$	0.38	$	0.28		$	1.43
	Net income	0.3		0.45		0.38		0.27			1.4
	Diluted earnings per share:
	Income from continuing operations	$	0.31	$	0.46	$	0.38	$	0.28		$	1.42
	Net income	0.3		0.44		0.37		0.27			1.39
	Cash dividends declared per common share	0.07		0.07		0.07		0.07			0.28
	December 29, 2013
	Revenue	$	502,943	$	540,673	$	522,100	$	591,870		$	2,157,586
	Gross profit	224,442		241,662		233,268		276,770			976,142
	Restructuring and contract termination charges, net	3,310		19,247		1,124		10,211			33,892
	Operating income from continuing operations	36,694		40,216		57,954		92,930			227,794
	Income from continuing operations before income taxes	24,654		27,351		45,614		66,065			163,684
	Income from continuing operations	32,775		27,274		40,763		73,455			174,267
	Net income	32,216		27,925		40,198		66,873			167,212
	Basic earnings per share:
	Income from continuing operations	$	0.29	$	0.24	$	0.36	$	0.65		$	1.55
	Net income	0.28		0.25		0.36		0.6			1.49
	Diluted earnings per share:
	Income continuing operations	$	0.29	$	0.24	$	0.36	$	0.65		$	1.54
	Net income	0.28		0.25		0.36		0.59			1.47
	Cash dividends declared per common share	0.07		0.07		0.07		0.07			0.28
	____________________________
	-1	The fourth quarter of fiscal year 2014 includes a pre-tax loss of $75.9 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy.
	-2	The fourth quarter of fiscal year 2013 includes pre-tax income of $17.6 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2013 also includes a tax benefit of $9.2 million related to discrete items primarily for lapses in statutes of limitations and audit settlements.

Nature_of_Operations_and_Accou1

Nature of Operations and Accounting Policies Nature of Operations and Accounting Policies (Policies)	12 Months Ended
	Dec. 28, 2014
Accounting Policies [Abstract]
Consolidation [Policy Text Block]	The consolidated financial statements include the accounts of PerkinElmer, Inc. and its subsidiaries (the “Company”). All intercompany balances and transactions have been eliminated in consolidation.
Segment Reporting [Policy Text Block]	The Company has two operating segments; Human Health and Environmental Health. The Company’s Human Health segment concentrates on developing diagnostics, tools and applications to help detect diseases earlier and more accurately and to accelerate the discovery and development of critical new therapies. Within the Human Health segment, the Company serves both the diagnostics and research markets. The Company’s Environmental Health segment provides products, services and solutions to facilitate the creation of safer food and consumer products, more secure surroundings and efficient energy resources. The Environmental Health segment serves the environmental, industrial and laboratory services markets.
Fiscal Periods [Policy Text Block]	The Company’s fiscal year ends on the Sunday nearest December 31. The Company reports fiscal years under a 52/53 week format. Under this method, certain years will contain 53 weeks. Each of the fiscal years ended December 28, 2014, December 29, 2013 and December 30, 2012 included 52 weeks. The fiscal year ending January 3, 2016 will include 53 weeks. The extra week in fiscal year 2015 will be included in the third quarter.
Subsequent Events [Policy Text Block]	The Company has evaluated subsequent events from December 28, 2014 through the date of the issuance of these consolidated financial statements and has determined that no material subsequent events have occurred that would affect the information presented in these consolidated financial statements.
Accounting Policies and Estimates [Policy Text Block]	Accounting Policies and Estimates:    The preparation of consolidated financial statements in accordance with United States (“U.S.”) Generally Accepted Accounting Principles (“GAAP”) requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.
Revenue Recognition [Policy Text Block]	Revenue Recognition:    The Company’s product revenue is recorded when persuasive evidence of an arrangement exists, delivery has occurred, the price to the buyer is fixed or determinable, and collectability is reasonably assured. For products that include installation, and if the installation meets the criteria to be considered a separate element, product revenue is recognized upon delivery, and installation revenue is recognized when the installation is complete. For revenue that includes customer-specified acceptance criteria, revenue is recognized after the acceptance criteria have been met. Certain of the Company’s products require specialized installation. Revenue for these products is deferred until installation is completed. Revenue from services is deferred and recognized over the contractual period, or as services are rendered.
	In limited circumstances, the Company has arrangements that include multiple elements that are delivered at different points of time, such as revenue from products and services with a remaining service or storage component, including cord blood processing and storage. For these arrangements, the revenue is allocated to each of the deliverables based upon their relative selling prices as determined by a selling-price hierarchy. A deliverable in an arrangement qualifies as a separate unit of accounting if the delivered item has value to the customer on a stand-alone basis. A delivered item that does not qualify as a separate unit of accounting is combined with the other undelivered items in the arrangement and revenue is recognized for those combined deliverables as a single unit of accounting. The selling price used for each deliverable is based upon vendor-specific objective evidence ("VSOE") if such evidence is available, third-party evidence ("TPE") if VSOE is not available, and management's best estimate of selling price ("BESP") if neither VSOE nor TPE are available. TPE is the price of the Company's or any competitor's largely interchangeable products or services in stand-alone sales to similarly-situated customers. BESP is the price at which the Company would sell the deliverable if it were sold regularly on a stand-alone basis, considering market conditions and entity-specific factors.
	Revenue from software licenses and services was 5% of the Company's total revenue for fiscal year 2014, 5% of the Company's total revenue for fiscal year 2013, and 3% of the Company's total revenue for fiscal year 2012. The Company sells its software licenses with maintenance services and, in some cases, also with consulting services. For the undelivered elements, the Company determines VSOE of fair value to be the price charged when the undelivered element is sold separately. The Company determines VSOE for maintenance sold in connection with a software license based on the amount that will be separately charged for the maintenance renewal period. The Company determines VSOE for consulting services by reference to the amount charged for similar engagements when a software license sale is not involved.
	The Company recognizes revenue from software licenses sold together with maintenance and/or consulting services upon shipment using the residual method, provided that the above criteria have been met. If VSOE of fair value for the undelivered elements cannot be established, the Company defers all revenue from the arrangement until the earlier of the point at which such sufficient VSOE does exist or all elements of the arrangement have been delivered, or if the only undelivered element is maintenance, then the Company recognizes the entire fee ratably over the maintenance period.
	The Company recognizes revenue from the grant of certain intellectual property rights for patented technologies it owns. These rights typically include a combination of the following: the grant of a non-exclusive, retroactive and future license to patented technologies, a covenant-not-to-sue, the release of the licensee from certain claims, and the dismissal of any pending litigation. The intellectual property rights granted may be perpetual in nature, extending until the expiration of the related patents, or can be granted for a defined timeframe. For these arrangements, the revenue is allocated to each of the deliverables based upon their relative selling prices as determined by the selling-price hierarchy. In the case where the agreement includes the dismissal of any pending litigation, the Company allocates between revenue and litigation settlement using the residual method. The Company recognizes revenue when the earnings process is complete and upon the execution of the agreement, when collectability is reasonably assured, or upon receipt of the minimum upfront fee for term agreement renewals, and when all other revenue recognition criteria have been met.
	Service revenues represent the Company’s service offerings including service contracts, field service including related time and materials, diagnostic testing, cord blood processing and storage, and training. Service revenues are recognized as the service is performed. Revenues for service contracts and storage contracts are recognized over the contract period.
	The Company sells products and accessories predominantly through its direct sales force. As a result, the use of distributors is generally limited to geographic regions where the Company has no direct sales force. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including its distributors. Payment terms granted to distributors are the same as those granted to end-user customers and payments are not dependent upon the distributors’ receipt of payment from their end-user customers. Sales incentives related to distributor revenue are also the same as those for end-user customers.
Warranty Costs [Policy Text Block]	Warranty Costs:    The Company provides for estimated warranty costs for products at the time of their sale. Warranty liabilities are estimated using expected future repair costs based on historical labor and material costs incurred during the warranty period.
Shipping and Handling Costs [Policy Text Block]	Shipping and Handling Costs:    The Company reports shipping and handling revenue in revenue, to the extent they are billed to customers, and the associated costs in cost of product revenue.
Inventories [Policy Text Block]	Inventories:    Inventories, which include material, labor and manufacturing overhead, are valued at the lower of cost or market. Inventories are accounted for using the first-in, first-out method of determining inventory costs. Inventory quantities on-hand are regularly reviewed, and where necessary, provisions for excess and obsolete inventory are recorded based primarily on the Company’s estimated forecast of product demand and production requirements.
Income Taxes [Policy Text Block]	Income Taxes:    The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases. This method also requires the recognition of future tax benefits such as net operating loss carryforwards, to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established for any deferred tax asset for which realization is not more likely than not. With respect to earnings expected to be indefinitely reinvested offshore, the Company does not accrue tax for the repatriation of such foreign earnings.
	The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions and other issues. These reserves are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. Potential interest and penalties associated with such uncertain tax positions is recorded as a component of income tax expense. See Note 6, below, for additional details.
Property, Plant and Equipment [Policy Text Block]	Property, Plant and Equipment:    The Company depreciates plant and equipment using the straight-line method over its estimated useful lives, which generally fall within the following ranges: buildings- 10 to 40 years; leasehold improvements-estimated useful life or remaining term of lease, whichever is shorter; and machinery and equipment- 3 to 7 years. Certain tooling costs are capitalized and amortized over a 3-year life, while repairs and maintenance costs are expensed.
Asset Retirement Obligations [Policy Text Block]	Asset Retirement Obligations:    The Company records obligations associated with its lease obligations, the retirement of tangible long-lived assets and the associated asset-retirement costs in accordance with authoritative guidance on asset retirement obligations. The Company reviews legal obligations associated with the retirement of long-lived assets that result from contractual obligations or the acquisition, construction, development and/or normal use of the assets. If it is determined that a legal obligation exists, regardless of whether the obligation is conditional on a future event, the fair value of the liability for an asset retirement obligation is recognized in the period in which it is incurred, if a reasonable estimate of fair value can be made. The fair value of the liability is added to the carrying amount of the associated asset, and this additional carrying amount is depreciated over the life of the asset. The difference between the gross expected future cash flow and its present value is accreted over the life of the related lease as interest expense. The amounts recorded in the consolidated financial statements are not material to any year presented.
Change in Accounting for Pension and Other Postretirement Benefits [Policy Text Block]	Pension and Other Postretirement Benefits:    The Company sponsors both funded and unfunded U.S. and non-U.S. defined benefit pension plans and other postretirement benefits. The Company immediately recognizes actuarial gains and losses in operating results in the year in which the gains and losses occur. Actuarial gains and losses are measured annually as of fiscal year end and accordingly will be recorded in the fourth quarter, unless the Company is required to perform an interim remeasurement. The remaining components of pension expense, primarily service and interest costs and assumed return on plan assets, are recorded on a quarterly basis. The Company’s funding policy provides that payments to the U.S. pension trusts shall at least be equal to the minimum funding requirements of the Employee Retirement Income Security Act of 1974. Non-U.S. plans are accrued for, but generally not fully funded, and benefits are paid from operating funds
Translation of Foreign Currencies [Policy Text Block]	Translation of Foreign Currencies:    For foreign operations, asset and liability accounts are translated at current exchange rates; income and expenses are translated using weighted average exchange rates for the reporting period. Resulting translation adjustments, as well as translation gains and losses from certain intercompany transactions considered permanent in nature, are reported in accumulated other comprehensive income, a separate component of stockholders’ equity. Gains and losses arising from transactions and translation of period-end balances denominated in currencies other than the functional currency are included in other expense, net, and were not material for fiscal years 2014, 2013, and 2012.
Business Combinations [Policy Text Block]	Business Combinations:    Business combinations are accounted for at fair value. Acquisition costs are expensed as incurred and recorded in selling, general and administrative expenses; previously held equity interests are valued at fair value upon the acquisition of a controlling interest; in-process research and development (“IPR&D”) is recorded at fair value as an intangible asset at the acquisition date; restructuring costs associated with a business combination are expensed subsequent to the acquisition date; and changes in deferred tax asset valuation allowances and income tax uncertainties after the acquisition date affect income tax expense. All changes that do not qualify as measurement period adjustments are included in current period earnings. The accounting for business combinations requires estimates and judgment as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair value for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. If the actual results differ from the estimates and judgments used in these estimates, the amounts recorded in the financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of finite-lived intangible assets, or the recognition of additional consideration which would be expensed.
Goodwill and Other Intangible Assets [Policy Text Block]	Goodwill and Other Intangible Assets:    The Company’s intangible assets consist of (i) goodwill, which is not being amortized; (ii) indefinite lived intangibles, which consist of certain trademarks and trade names that are not subject to amortization; and (iii) amortizing intangibles, which consist of patents, trade names and trademarks, licenses, customer relationships, and purchased technologies, which are being amortized over their estimated useful lives.
	The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of a two-step process. The first step is the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. The second step measures the amount of an impairment loss, and is only performed if the carrying value exceeds the fair value of the reporting unit. This annual impairment assessment is performed by the Company on the later of January 1 or the first day of each fiscal year. This same impairment test will be performed at other times during the course of the year, should an event occur which suggests that the recoverability of goodwill should be reconsidered. Non-amortizing intangibles are also subject to an annual impairment test. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized. In addition, the Company evaluates the remaining useful life of its non-amortizing intangible assets at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful lives of non-amortizing intangible assets are no longer indefinite, the assets will be tested for impairment. These intangible assets will then be amortized prospectively over their estimated remaining useful life and accounted for in the same manner as other intangible assets that are subject to amortization. Recoverability of amortizing intangible assets is assessed only when events have occurred that may give rise to impairment. When a potential impairment has been identified, forecasted undiscounted net cash flows of the operations to which the asset relates are compared to the current carrying value of the long-lived assets present in that operation. If such cash flows are less than such carrying amounts, long-lived assets, including such intangibles, are written down to their respective fair values. See Note 12, below, for additional details.
Stock-Based Compensation [Policy Text Block]	Stock-Based Compensation:    The Company accounts for stock-based compensation expense based on estimated grant date fair value, generally using the Black-Scholes option-pricing model. The fair value is recognized, net of estimated forfeitures, as expense in the consolidated financial statements over the requisite service period. The determination of fair value and the timing of expense using option pricing models such as the Black-Scholes model require the input of highly subjective assumptions, including the expected forfeiture rate, life of the option and the expected price volatility of the underlying stock. The Company estimates the expected forfeiture and expected life assumptions based on historical experience. In determining the Company’s expected stock price volatility assumption, the Company reviews both the historical and implied volatility of the Company’s common stock, with implied volatility based on the implied volatility of publicly traded options on the Company’s common stock. The Company has one stock-based compensation plan from which it makes grants, which is described more fully in Note 18, below.
Marketable Securities and Investments [Policy Text Block]	Marketable Securities and Investments:    The cost of securities sold is based on the specific identification method. If securities are classified as available for sale, the Company records these investments at their fair values with unrealized gains and losses included in accumulated other comprehensive income. Under the cost method of accounting, equity investments in private companies are carried at cost and are adjusted for other-than-temporary declines in fair value, additional investments or distributions.
Cash Flows [Policy Text Block]	Cash and Cash Equivalents:    The Company considers all highly liquid unrestricted instruments with a purchased maturity of three months or less to be cash equivalents. The carrying amount of cash equivalents approximates fair value due to the short maturities of these instruments.
Environmental Matters [Policy Text Block]	Environmental Matters:    The Company accrues for costs associated with the remediation of environmental pollution when it is probable that a liability has been incurred and the Company’s proportionate share of the amount can be reasonably estimated. The recorded liabilities have not been discounted.
Research and Development Expense, Policy [Policy Text Block]	Research and Development:    Research and development costs are expensed as incurred. The fair value of acquired in-process research and development ("IPR&D") costs are recorded at fair value as an intangible asset at the acquisition date and amortized once the product is ready for sale or expensed if abandoned.
Restructuring Charges [Policy Text Block]	Restructuring Charges:    In recent fiscal years, the Company has undertaken a series of restructuring actions related to the impact of acquisitions and divestitures, the alignment of its operations with its growth strategy, the integration of its business units and productivity initiatives. In connection with these initiatives, the Company has recorded restructuring charges, as more fully described in Note 4, below. Generally, costs associated with an exit or disposal activity are recognized when the liability is incurred. Prior to recording restructuring charges for employee separation agreements, the Company notifies all employees of termination. Costs related to employee separation arrangements requiring future service beyond a specified minimum retention period are recognized over the service period. Costs related to lease terminations are recorded at the fair value of the liability based on the remaining lease rental payments, reduced by estimated sublease rentals that could be reasonably obtained for the property, at the date the Company ceases use.
New Accounting Pronouncement or Change in Accounting Principle, Description	Comprehensive Income:    In February 2013, the Financial Accounting Standards Board issued Accounting Standards Update No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, requiring the presentation of reclassifications out of accumulated other comprehensive income on the face of the financial statements or as a separate disclosure in the notes to the financial statements. The reclassifications out of accumulated other comprehensive income and into net income were not material for the fiscal years ending December 28, 2014, December 29, 2013 and December 30, 2012. See Note 19 for additional details.
	Comprehensive income is defined as net income or loss and other changes in stockholders’ equity from transactions and other events from sources other than stockholders. Comprehensive income is reflected in the consolidated statements of comprehensive income.
Derivative Instruments and Hedging [Policy Text Block]	Derivative Instruments and Hedging:    Derivatives are recorded on the consolidated balance sheets at fair value. Accounting for gains or losses resulting from changes in the values of those derivatives depends on the use of the derivative instrument and whether it qualifies for hedge accounting.
	For a cash flow hedge, the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income and subsequently amortized into net earnings when the hedged exposure affects net earnings. Cash flow hedges related to anticipated transactions are designated and documented at the inception of each hedge by matching the terms of the contract to the underlying transaction. The Company classifies the cash flows from hedging transactions in the same categories as the cash flows from the respective hedged items. Once established, cash flow hedges are generally recorded in other comprehensive income, unless an anticipated transaction is no longer likely to occur, and subsequently amortized into net earnings when the hedged exposure affects net earnings. Discontinued or dedesignated cash flow hedges are immediately settled with counterparties, and the related accumulated derivative gains or losses are recognized into net earnings on the consolidated financial statements. Settled cash flow hedges related to forecasted transactions that remain probable are recorded as a component of other comprehensive income and are subsequently amortized into net earnings when the hedged exposure affects net earnings. Forward contract effectiveness for cash flow hedges is calculated by comparing the fair value of the contract to the change in value of the anticipated transaction using forward rates on a monthly basis. As of December 28, 2014, the Company had five outstanding cash flow hedges with a Euro denominated notional amount of €238.2 million. As of December 29, 2013, the Company had no outstanding cash flow hedges. As of December 30, 2012, the Company had two outstanding cash flow hedges with Euro denominated notional amounts of €50.0 million. The Company also has entered into other foreign currency forward contracts that are not designated as hedging instruments for accounting purposes. These contracts are recorded at fair value, with the changes in fair value recognized into net earnings on the consolidated financial statements.
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	Recently Issued Accounting Pronouncements:    From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations.
	In April 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. Under this new guidance, only disposals of components of an entity that represent strategic shifts that have, or will have, a major effect on an entity's operations and financial results will be presented as discontinued operations. The standard also requires new disclosures related to individually significant disposals that do not meet the definition of a discontinued operation. The provisions of this guidance are effective for interim and annual periods beginning after December 15, 2014. The Company will utilize this new guidance when reporting new discontinued operations or disclosing new disposals in its future filings.
	In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers. Under this new guidance, an entity should use a five-step process to recognize revenue, which depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard also requires new disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The provisions of this guidance are effective for interim and annual periods beginning after December 15, 2016. The Company is evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company’s consolidated financial position, results of operations and cash flows.

Business_Combinations_and_Asse1

Business Combinations and Asset Purchases (Tables)	12 Months Ended
	Dec. 28, 2014
Business Acquisition [Line Items]
Fair Values of the Business Combinations and Allocations for the Acquisitions Completed	The total purchase price has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows:
		Haoyuan
		(In thousands)
	Fair value of business combination:
	Cash payments	$	38,000
	Contingent consideration	1,900
	Working capital and other adjustments	(2,729		)
	Less: cash acquired	(175		)
	Total	$	36,996
	Identifiable assets acquired and liabilities assumed:
	Current assets	$	2,389
	Property, plant and equipment	2,906
	Identifiable intangible assets:
	Core technology	17,700
	Trade names	400
	IPR&D	300
	Goodwill	19,682
	Deferred taxes	(2,656		)
	Liabilities assumed	(3,725		)
	Total	$	36,996
	The total purchase price for the acquisitions in fiscal year 2014 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows:
		Perten			Other
		(Preliminary)
		(In thousands)
	Fair value of business combination:
	Cash payments	$	269,937		$	17,898
	Working capital and other adjustments	—			151
	Less: cash acquired	(16,732		)	(124		)
	Total	$	253,205		$	17,925
	Identifiable assets acquired and liabilities assumed:
	Current assets	$	32,805		$	1,965
	Property, plant and equipment	1,485			125
	Other assets	—			364
	Identifiable intangible assets:
	Core technology	16,000			1,705
	Trade names	7,000			—
	Customer relationships	87,000			6,800
	IPR&D	—			1,266
	Goodwill	164,164			15,981
	Deferred taxes	(31,454		)	(3,072		)
	Deferred revenue	—			(589		)
	Liabilities assumed	(16,195		)	(2,333		)
	Debt assumed	(7,600		)	(4,287		)
	Total	$	253,205		$	17,925

Discontinued_Operations_Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 28, 2014
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Gains and Losses on Disposition of Discontinued Operations	The Company recorded the following pre-tax gains and losses, which have been reported as a net gain or loss on disposition of discontinued operations during the three fiscal years ended:
		December 28,			December 29,			December 30,
		2014			2013			2012
		(In thousands)
	Loss on disposition of microarray-based diagnostic testing laboratory	$	(90	)	$	—		$	—
	(Loss) gain on disposition of Photoflash business	(14		)	493			2,459
	Loss on disposition of Technical Services business	(156		)	(2,100		)	—
	Loss on disposition of other discontinued operations	—			(203		)	(54		)
	Net (loss) gain on disposition of discontinued operations before income taxes	$	(260	)	$	(1,810	)	$	2,405
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]	Summary pre-tax operating results of the discontinued operations for the periods prior to disposition, which included a $1.0 million pre-tax restructuring charge related to workforce reductions in the microarray-based diagnostic testing laboratory in the United States during fiscal year 2014, were as follows during the three fiscal years ended:
		December 28,			December 29,			December 30,
		2014			2013			2012
		(In thousands)
	Revenue	$	348		$	8,646		$	10,017
	Costs and expenses	5,307			18,998			14,594
	Loss from discontinued operations before income taxes	$	(4,959	)	$	(10,352	)	$	(4,577	)

Restructuring_and_Contract_Ter1

Restructuring and Contract Terminaiton Charges, Net (Tables)	12 Months Ended
	Dec. 28, 2014
Restructuring and Related Activities [Abstract]
Restructuring and Related Costs [Table Text Block]	The following table summarizes the number of employees reduced, the initial restructuring and contract termination charges by operating segment, and the expected dates payments will be substantially completed for restructuring actions during fiscal years 2014, 2013, and 2012. The Company expects to make payments for the leases of the Previous Plans, of which the terms vary in length, through fiscal year 2022.
		Workforce Reductions										Closure of Excess Facility or Contract Termination Charges								Total				(Expected) Date Payments Substantially Completed by
		Headcount Reduction		Human Health				Environmental Health				Human Health				Environmental Health								Severance	Excess Facility or Contract Termination
		(In thousands, except headcount data)
	Q3 2014 Plan	152		$	6,863			$	6,188			$	—			$	—			$	13,051			Q3 FY2015	—
	Q2 2014 Plan	22		460				275				—				—				735				Q2 FY2015	—
	Q1 2014 Plan	17		370				197				—				—				567				Q4 FY2014	—
	2014 Contract Termination Charges	N/A		N/A				N/A				—				1,545				1,545				N/A	Q4 FY2015
	Q4 2013 Plan	73		902				3,006				7,271				—				11,179				Q4 FY2014	Q1 FY2019
	Q3 2013 Plan	29		394				—				138				—				532				Q1 FY2014	Q4 FY2013
	Q2 2013 Plan(1)	264		9,395				8,737				522				50				18,704				Q4 FY2014	Q3 FY2014
	Q1 2013 Plan	62		2,340				245				—				—				2,585				Q3 FY2013	—
	2013 Contract Termination Charges	N/A		N/A				N/A				—				696				696				N/A	Q4 FY2015
	Q4 2012 Plan	54		523				2,413				—				—				2,936				Q1 FY2014	—
	Q3 2012 Plan(2)	61		3,671				3,728				—				—				7,399				Q3 FY2014	—
	Q2 2012 Plan(3)	203		3,976				242				—				—				4,218				Q3 FY2014	—
	Q1 2012 Plan(4)	112		5,252				388				79				—				5,719				Q1 FY2013	Q2 FY2012
	2012 Contract Termination Charges	N/A		N/A				N/A				$	—			$	1,470			$	1,470			N/A	Q4 FY2015
	____________________________
	(1)	Subsequent to the initial charge, during fiscal year 2013, the Company recorded an additional $0.6 million pre-tax restructuring charge in the Human Health segment for the Q2 2013 Plan for services that were provided for one-time termination benefits in which the employee was required to render service beyond the legal notification period.
	-2	Local law required some severance for the Q3 2012 Plan to be paid in monthly installments through the fourth quarter of fiscal year 2014.
	(3)	Subsequent to the initial charge, during fiscal years 2013 and 2012, the Company recorded an additional $2.1 million and $3.2 million , respectively, pre-tax restructuring charges in the Human Health segment for the Q2 2012 Plan for services that were provided for one-time termination benefits in which the employee was required to render service beyond the legal notification period.
	(4)	Subsequent to the initial charge, during fiscal year 2012, the Company recorded an additional $0.7 million pre-tax restructuring charge primarily in the Environmental Health segment for the Q1 2012 Plan for services that were provided for one-time termination benefits in which the employee was required to render service beyond the legal notification period.
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	The following table summarizes the Company's restructuring and contract termination accrual balances and related activity by restructuring plan, as well as contract termination, during fiscal years 2014, 2013, and 2012:
		Balance at January 1, 2012				2012 Charges and Changes in Estimates, Net				2012 Amounts Paid				Balance at December 30, 2012				2013 Charges and Changes in Estimates, Net				2013 Amounts Paid			Balance at December 29, 2013		2014 Charges and Changes in Estimates, Net			2014 Amounts Paid			Balance at December 28, 2014
		(In thousands)
	Severance:
	Q3 2014 Plan	$	—			$	—			$	—			$	—			$	—			$	—		$	—	$	13,051		$	(2,992	)	$	10,059
	Q2 2014 Plan	—				—				—				—				—				—			—		735			(484		)	251
	Q1 2014 Plan	—				—				—				—				—				—			—		567			(475		)	92
	Q4 2013 Plan(1)	—				—				—				—				3,908				(1,921		)	1,987		(121		)	(1,541		)	325
	Q3 2013 Plan	—				—				—				—				394				(257		)	137		—			(137		)	—
	Q2 2013 Plan(2)	—				—				—				—				18,704				(5,954		)	12,750		(796		)	(10,373		)	1,581
	Q1 2013 Plan(3)	—				—				—				—				2,585				(2,377		)	208		(208		)	—			—
	Facility:
	Q4 2013 Plan(1)	—				—				—				—				7,271				(417		)	6,854		1,055			(2,106		)	5,803
	Q3 2013 Plan	—				—				—				—				138				(138		)	—		—			—			—
	Q2 2013 Plan(2)	—				—				—				—				572				(572		)	—		184			(184		)	—
	Previous Plans(4)	20,819				23,581				(17,249		)		27,151				(376		)		(13,476		)	13,299		(2,622		)	(5,262		)	5,415
	Restructuring	20,819				23,581				(17,249		)		27,151				33,196				(25,112		)	35,235		11,845			(23,554		)	23,526
	Contract Termination	2,067				1,470				(2,941		)		596				696				(992		)	300		1,545			(1,541		)	304
	Total Restructuring and Contract Termination	$	22,886			$	25,051			$	(20,190	)		$	27,747			$	33,892			$	(26,104	)	$	35,535	$	13,390		$	(25,095	)	$	23,830
	____________________________
	(1)	During fiscal year 2014, the Company recorded a pre-tax restructuring reversal of $0.1 million in the Environmental Health segment related to lower than expected costs associated with the remaining severance payments for the Q4 2013 Plan and recorded an additional pre-tax restructuring charge of $1.1 million in the Human Health segment related to higher than expected costs associated with the closure of the excess facility for the Q4 2013 Plan.
	(2)	During fiscal year 2014, the Company recorded pre-tax restructuring reversals of $0.3 million in the Human Health segment and $0.5 million in the Environmental Health segment related to lower than expected costs associated with the remaining severance payments for the Q2 2013 Plan. In addition during fiscal year 2014, the Company incurred an additional pre-tax restructuring charge of $0.1 million in each of the Human Health and Environmental Health segments related to higher than expected costs associated with the closure of the excess facility space for the Q2 2013 Plan.
	(3)	During fiscal year 2014, the Company recorded a pre-tax restructuring reversal of $0.2 million in the Human Health segment related to lower than expected costs associated with the remaining severance payments for the Q1 2013 Plan.
	(4)	During fiscal year 2014, the Company recognized pre-tax restructuring reversals of $1.6 million in the Human Health segment and $1.1 million in the Environmental Health segment related to lower than expected costs associated with workforce reductions for the previous restructuring plans. During fiscal year 2014, the Company recognized an additional pre-tax restructuring charge of $0.1 million in the Human Health segment related to higher than expected costs associated with the closure of the excess facility space for the previous restructuring plans.

Interest_and_Other_Expense_Inc1

Interest and Other Expense (Income), Net (Tables)	12 Months Ended
	Dec. 28, 2014
Other Income and Expenses [Abstract]
Interest and Other Expense (Income), Net	Interest and other expense, net, consisted of the following for the fiscal years ended:
		December 28,			December 29,			December 30,
		2014			2013			2012
		(In thousands)
	Interest income	$	(667	)	$	(650	)	$	(747	)
	Interest expense	36,270			49,924			45,787
	Other expense, net	5,536			14,836			2,916
	Total interest and other expense, net	$	41,139		$	64,110		$	47,956

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 28, 2014
Income Tax Disclosure [Abstract]
Summary of Income Tax Contingencies [Table Text Block]	The tabular reconciliation of the total amounts of unrecognized tax benefits is as follows for the fiscal years ended:
		December 28,			December 29,			December 30,
		2014			2013			2012
		(In thousands)
	Unrecognized tax benefits, beginning of year	$	39,410		$	58,110		$	51,740
	Gross increases—tax positions in prior periods	—			325			10,653
	Gross decreases—tax positions in prior periods	(1,809		)	(10,539		)	(4,665		)
	Gross increases—current-period tax positions	239			2,222			3,343
	Settlements	(1,400		)	(3,643		)	(2,822		)
	Lapse of statute of limitations	(4,129		)	(6,495		)	(595		)
	Foreign currency translation adjustments	31			(570		)	456
	Unrecognized tax benefits, end of year	$	32,342		$	39,410		$	58,110
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	The components of income (loss) from continuing operations before income taxes were as follows for the fiscal years ended:
		December 28,			December 29,			December 30,
		2014			2013			2012
		(In thousands)
	U.S.	$	(37,758	)	$	(71,901	)	$	(113,969	)
	Non-U.S.	207,361			235,585			169,133
	Total	$	169,603		$	163,684		$	55,164
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	The components of the provision for (benefit from) income taxes for continuing operations were as follows:
		Current Expense (Benefit)			Deferred Expense			Total
					(Benefit)
		(In thousands)
	Fiscal year ended December 28, 2014
	Federal	$	(262	)	$	(19,169	)	$	(19,431	)
	State	2,416			(3,842		)	(1,426		)
	Non-U.S.	39,634			(10,340		)	29,294
	Total	$	41,788		$	(33,351	)	$	8,437
	Fiscal year ended December 29, 2013
	Federal	$	2,331		$	(29,961	)	$	(27,630	)
	State	1,968			(2,147		)	(179		)
	Non-U.S.	15,025			2,201			17,226
	Total	$	19,324		$	(29,907	)	$	(10,583	)
	Fiscal year ended December 30, 2012
	Federal	$	(3,640	)	$	(34,920	)	$	(38,560	)
	State	2,752			(2,794		)	(42		)
	Non-U.S.	50,314			(27,837		)	22,477
	Total	$	49,426		$	(65,551	)	$	(16,125	)
Schedule of Income Tax Expense (Benefit), Continuing Operations and Discontinued Operations [Table Text Block]	The total provision for (benefit from) income taxes included in the consolidated financial statements is as follows for the fiscal years ended:
		December 28,			December 29,			December 30,
		2014			2013			2012
		(In thousands)
	Continuing operations	$	8,437		$	(10,583	)	$	(16,125	)
	Discontinued operations	(1,831		)	(5,107		)	(823		)
	Total	$	6,606		$	(15,690	)	$	(16,948	)
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	A reconciliation of income tax expense at the U.S. federal statutory income tax rate to the recorded tax provision is as follows for the fiscal years ended:
		December 28,			December 29,			December 30,
		2014			2013			2012
		(In thousands)
	Tax at statutory rate	$	59,361		$	57,289		$	19,302
	Non-U.S. rate differential, net	(36,616		)	(36,377		)	(26,652		)
	U.S. taxation of multinational operations	2,367			3,658			1,727
	State income taxes, net	1,970			(1,762		)	3,400
	Prior year tax matters	(7,009		)	(23,534		)	3,389
	Federal tax credits	(3,399		)	(5,452		)	(1,657		)
	Change in valuation allowance	(7,679		)	(4,675		)	(14,446		)
	Other, net	(558		)	270			(1,188		)
	Total	$	8,437		$	(10,583	)	$	(16,125	)
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The tax effects of temporary differences and attributes that gave rise to deferred income tax assets and liabilities as of December 28, 2014 and December 29, 2013 were as follows:
		December 28,			December 29,
		2014			2013
		(In thousands)
	Deferred tax assets:
	Inventory	$	9,041		$	9,850
	Reserves and accruals	30,641			30,269
	Accrued compensation	22,915			15,920
	Net operating loss and credit carryforwards	106,020			132,710
	Accrued pension	44,342			23,353
	Restructuring reserve	7,522			6,853
	Deferred revenue	46,413			42,687
	All other, net	824			1,666
	Total deferred tax assets	267,718			263,308
	Deferred tax liabilities:
	Postretirement health benefits	(4,472		)	(3,894		)
	Depreciation and amortization	(176,043		)	(163,269		)
	Total deferred tax liabilities	(180,515		)	(167,163		)
	Valuation allowance	(55,460		)	(63,139		)
	Net deferred tax assets	$	31,743		$	33,006
Schedule of Deferred Income Taxes, Domestic and Foreign [Table Text Block]	The components of net deferred tax assets (liabilities) as of December 28, 2014 and December 29, 2013 were as follows:
		December 28,			December 29,
		2014			2013
		(In thousands)
	U.S.	$	44,073		$	22,565
	Non-U.S.	(12,330		)	10,441
	Total	$	31,743		$	33,006

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	12 Months Ended
	Dec. 28, 2014
Earnings Per Share [Abstract]
Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations	The following table reconciles the number of shares utilized in the earnings per share calculations for the fiscal years ended:
		December 28,	December 29,	December 30,
		2014	2013	2012
		(In thousands)
	Number of common shares—basic	112,593	112,254	113,728
	Effect of dilutive securities:
	Stock options	922	982	847
	Restricted stock awards	224	267	285
	Number of common shares—diluted	113,739	113,503	114,860
	Number of potentially dilutive securities excluded from calculation due to antidilutive impact	475	485	1,288

Inventories_Net_Tables

Inventories, Net (Tables)	12 Months Ended
	Dec. 28, 2014
Inventory Disclosure [Abstract]
Schedule of Net Inventories	Inventories as of December 28, 2014 and December 29, 2013 consisted of the following:
		December 28,		December 29,
		2014		2013
		(In thousands)
	Raw materials	$	96,169	$	92,713
	Work in progress	18,783		15,505
	Finished goods	170,505		152,640
	Total inventories	$	285,457	$	260,858

Property_Plant_and_Equipment_N1

Property, Plant and Equipment, Net (Tables)	12 Months Ended
	Dec. 28, 2014
Property, Plant and Equipment, Net [Abstract]
Property, Plant and Equipment [Table Text Block]	Property, plant and equipment, at cost, as of December 28, 2014 and December 29, 2013, consisted of the following:
		December 28,			December 29,
		2014			2013
		(In thousands)
	Land	$	906		$	1,019
	Building and leasehold improvements	175,040			171,393
	Machinery and equipment	316,868			325,699
	Total property, plant and equipment	492,814			498,111
	Accumulated depreciation	(316,620		)	(314,923		)
	Total property, plant and equipment, net	$	176,194		$	183,188

Marketable_Securities_and_Inve1

Marketable Securities and Investments (Tables)	12 Months Ended
	Dec. 28, 2014
Marketable Securities [Abstract]
Schedule of Investments, Noncurrent [Table Text Block]	Investments as of December 28, 2014 and December 29, 2013 consisted of the following:
		December 28,		December 29,
		2014		2013
		(In thousands)
	Marketable securities	$	1,568	$	1,319
Available-for-sale Securities [Table Text Block]	Marketable securities classified as available for sale as of December 28, 2014 and December 29, 2013 consisted of the following:
		Market		Gross Unrealized Holding
		Value		Cost		Gains		(Losses)
				(In thousands)
	December 28, 2014
	Equity securities	$	1,002	$	1,110	$	7	$	(115	)
	Fixed-income securities	88		88		—		—
	Other	478		541		—		(63		)
		$	1,568	$	1,739	$	7	$	(178	)
	December 29, 2013
	Equity securities	$	740	$	871	$	—	$	(131	)
	Fixed-income securities	308		308		—		—
	Other	271		334		—		(63		)
		$	1,319	$	1,513	$	—	$	(194	)

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 28, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in the Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for fiscal years 2014 and 2013 are as follows:
		Human			Environmental			Consolidated
		Health			Health
		(In thousands)
	Balance at December 30, 2012	$	1,632,487		$	490,301		$	2,122,788
	Foreign currency translation	12,867			2,300			15,167
	Acquisitions, earnouts and other	2,978			2,187			5,165
	Balance at December 29, 2013	1,648,332			494,788			2,143,120
	Foreign currency translation	(29,145		)	(8,741		)	(37,886		)
	Acquisitions, earnouts and other	2,408			176,435			178,843
	Balance at December 28, 2014	$	1,621,595		$	662,482		$	2,284,077
Identifiable Intangible Asset Balances	Identifiable intangible asset balances at December 28, 2014 by category and by business segment were as follows:
		Human			Environmental			Consolidated
		Health			Health
		(In thousands)
	Patents	$	36,760		$	3,193		$	39,953
	Less: Accumulated amortization	(24,652		)	(2,548		)	(27,200		)
	Net patents	12,108			645			12,753
	Trade names and trademarks	33,069			7,000			40,069
	Less: Accumulated amortization	(16,878		)	(58		)	(16,936		)
	Net trade names and trademarks	16,191			6,942			23,133
	Licenses	59,631			—			59,631
	Less: Accumulated amortization	(41,792		)	—			(41,792		)
	Net licenses	17,839			—			17,839
	Core technology	169,864			128,627			298,491
	Less: Accumulated amortization	(98,798		)	(85,899		)	(184,697		)
	Net core technology	71,066			42,728			113,794
	Customer relationships	292,627			109,558			402,185
	Less: Accumulated amortization	(148,820		)	(8,174		)	(156,994		)
	Net customer relationships	143,807			101,384			245,191
	IPR&D	5,079			5,024			10,103
	Less: Accumulated amortization	(998		)	(2,134		)	(3,132		)
	Net IPR&D	4,081			2,890			6,971
	Net amortizable intangible assets	265,092			154,589			419,681
	Non-amortizable intangible assets:
	Trade names and trademarks	—			70,584			70,584
	Total	$	265,092		$	225,173		$	490,265
	Identifiable intangible asset balances at December 29, 2013 by category and business segment were as follows:
		Human			Environmental			Consolidated
		Health			Health
		(In thousands)
	Patents	$	36,791		$	2,800		$	39,591
	Less: Accumulated amortization	(22,205		)	(2,002		)	(24,207		)
	Net patents	14,586			798			15,384
	Trade names and trademarks	35,723			86			35,809
	Less: Accumulated amortization	(16,122		)	(86		)	(16,208		)
	Net trade names and trademarks	19,601			—			19,601
	Licenses	71,580			7,600			79,180
	Less: Accumulated amortization	(45,835		)	(7,095		)	(52,930		)
	Net licenses	25,745			505			26,250
	Core technology	187,387			114,683			302,070
	Less: Accumulated amortization	(88,811		)	(80,515		)	(169,326		)
	Net core technology	98,576			34,168			132,744
	Customer relationships	305,038			16,357			321,395
	Less: Accumulated amortization	(127,397		)	(5,436		)	(132,833		)
	Net customer relationships	177,641			10,921			188,562
	IPR&D	4,257			5,226			9,483
	Less: Accumulated amortization	(695		)	(1,483		)	(2,178		)
	Net IPR&D	3,562			3,743			7,305
	Net amortizable intangible assets	339,711			50,135			389,846
	Non-amortizable intangible assets:
	Trade names and trademarks	—			70,584			70,584
	Total	$	339,711		$	120,719		$	460,430

Debt_Tables

Debt (Tables)	12 Months Ended
	Dec. 28, 2014
Debt Disclosure [Abstract]
Schedule of Maturities of Long-term Debt [Table Text Block]	The following table summarizes the maturities of the Company’s indebtedness as of December 28, 2014:
		Sr. Unsecured		5.0% Sr. Notes			Financing Lease Obligations		Total
		Revolving		Maturing 2021
		Credit Facility
		Maturing 2019
		(In thousands)
	2015	$	—	$	—		$	1,075	$	1,075
	2016	—		—			1,120		1,120
	2017	—		—			1,169		1,169
	2018	—		—			1,367		1,367
	2019	516,000		—			1,532		517,532
	2020 and thereafter	—		500,000			33,009		533,009
	Total before unamortized discount	516,000		500,000			39,272		1,055,272
	Unamortized discount	—		(2,305		)	—		(2,305		)
	Total	$	516,000	$	497,695		$	39,272	$	1,052,967

Accrued_Expenses_and_Other_Cur1

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 28, 2014
Accounts Payable and Accrued Liabilities, Current [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses and other current liabilities as of December 28, 2014 and December 29, 2013 consisted of the following:
		December 28,		December 29,
		2014		2013
		(In thousands)
	Payroll and incentives	$	61,018	$	52,865
	Employee benefits	40,318		40,965
	Deferred revenue	168,928		164,723
	Federal, non-U.S. and state income taxes	9,801		11,783
	Other accrued operating expenses	122,956		133,342
	Total accrued expenses and other current liabilities	$	403,021	$	403,678

Employee_Benefit_Plans_Tables

Employee Benefit Plans (Tables)	12 Months Ended
	Dec. 28, 2014
Pension Plans, Defined Benefit
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Components of Net Periodic Benefit Cost (Credit)	Net periodic pension cost (credit) for U.S. and non-U.S. plans included the following components for fiscal years ended:
		December 28,				December 29,				December 30,
		2014				2013				2012
		(In thousands)
	Service cost	$	4,070			$	3,664			$	3,852
	Interest cost	23,475				21,334				23,164
	Expected return on plan assets	(25,007		)		(25,106		)		(20,768		)
	Actuarial loss (gain)	71,700				(16,464		)		28,355
	Amortization of prior service cost	(281		)		(267		)		(242		)
	Net periodic pension cost (credit)	$	73,957			$	(16,839	)		$	34,361
Schedule of Net Funded Status	The following table sets forth the changes in the funded status of the principal U.S. pension plan and the principal non-U.S. pension plans and the amounts recognized in the Company’s consolidated balance sheets as of December 28, 2014 and December 29, 2013.
		December 28, 2014								December 29, 2013
		Non-U.S.				U.S.				Non-U.S.			U.S.
		(In thousands)
	Actuarial present value of benefit obligations:
	Accumulated benefit obligations	$	291,640			$	327,632			$	277,125		$	279,299
	Change in benefit obligations:
	Projected benefit obligations at beginning of year	$	288,216			$	279,299			$	278,707		$	301,770
	Service cost	2,670				1,400				2,589			1,075
	Interest cost	10,575				12,900				9,834			11,500
	Benefits paid and plan expenses	(12,280		)		(19,282		)		(11,218		)	(17,817		)
	Participants’ contributions	394				—				391			—
	Plan settlement	—				—				(918		)	—
	Actuarial loss (gain)	42,095				53,315				1,678			(17,229		)
	Effect of exchange rate changes	(27,861		)		—				7,153			—
	Projected benefit obligations at end of year	$	303,809			$	327,632			$	288,216		$	279,299
	Change in plan assets:
	Fair value of plan assets at beginning of year	$	143,704			$	249,756			$	114,515		$	221,755
	Actual return on plan assets	22,939				25,780				17,201			8,818
	Benefits paid and plan expenses	(12,280		)		(19,282		)		(11,218		)	(17,817		)
	Employer’s contributions	11,195				—				20,200			37,000
	Participants’ contributions	394				—				391			—
	Plan settlement	—				—				(918		)	—
	Effect of exchange rate changes	(9,185		)		—				3,533			—
	Fair value of plan assets at end of year	156,767				256,254				143,704			249,756
	Net liabilities recognized in the consolidated balance sheets	$	(147,042	)		$	(71,378	)		$	(144,512	)	$	(29,543	)
	Net amounts recognized in the consolidated balance sheets consist of:
	Noncurrent assets	$	9,825			$	—			$	6,879		$	—
	Current liabilities	(6,786		)		—				(7,360		)	—
	Noncurrent liabilities	(150,081		)		(71,378		)		(144,031		)	(29,543		)
	Net liabilities recognized in the consolidated balance sheets	$	(147,042	)		$	(71,378	)		$	(144,512	)	$	(29,543	)
	Net amounts recognized in accumulated other comprehensive income consist of:
	Prior service cost	$	(1,371	)		$	—			$	(1,745	)	$	—
	Net amounts recognized in accumulated other comprehensive income	$	(1,371	)		$	—			$	(1,745	)	$	—
	Actuarial assumptions as of the year-end measurement date:
	Discount rate	2.75		%		4.08		%		3.77		%	4.77		%
	Rate of compensation increase	3.07		%		None				3.23		%	None
	Actuarial assumptions used to determine net periodic pension cost during the year were as follows:
		December 28, 2014						December 29, 2013					December 30, 2012
		Non-U.S.			U.S.			Non-U.S.			U.S.		Non-U.S.			U.S.
	Discount rate	3.77	%		4.77	%		3.62	%		3.92	%	4.91	%		4.1	%
	Rate of compensation increase	3.23	%		None			2.88	%		None		3.22	%		3.5	%
	Expected rate of return on assets	5.3	%		7.25	%		5.5	%		7.5	%	5.4	%		7.75	%
Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets [Table Text Block]	The following table provides a breakdown of the non-U.S. benefit obligations and fair value of assets for pension plans that have benefit obligations in excess of plan assets:
		December 28,				December 29,
		2014				2013
		(In thousands)
	Pension Plans with Projected Benefit Obligations in Excess of Plan Assets
	Projected benefit obligations	$	156,867			$	151,391
	Fair value of plan assets	—				—
	Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets
	Accumulated benefit obligations	$	153,239			$	148,235
	Fair value of plan assets	—				—
Schedule of Allocation of Plan Assets	Assets of the defined benefit pension plans are primarily equity and debt securities. Asset allocations as of December 28, 2014 and December 29, 2013, and target asset allocations for fiscal year 2015 are as follows:
		Target Allocation						Percentage of Plan Assets at
		January 3, 2016						December 28, 2014					December 29, 2013
	Asset Category	Non-U.S.			U.S.			Non-U.S.			U.S.		Non-U.S.			U.S.
	Equity securities	45-55%			40-50%			49	%		39	%	51	%		43	%
	Debt securities	45-55%			50-60%			50	%		61	%	48	%		57	%
	Other	0-5%			0-5%			1	%		—	%	1	%		—	%
	Total	100	%		100	%		100	%		100	%	100	%		100	%
Schedule of Changes in Fair Value of Plan Assets	The fair values of the Company’s pension plan assets as of December 28, 2014 and December 29, 2013 by asset category, classified in the three levels of inputs described in Note 21 to the consolidated financial statements are as follows:
						Fair Value Measurements at December 28, 2014 Using:
		Total Carrying				Quoted Prices in				Significant Other			Significant
		Value at				Active Markets				Observable Inputs			Unobservable
		December 28, 2014				(Level 1)				(Level 2)			Inputs
													(Level 3)
		(In thousands)
	Cash	$	4,971			$	4,971			$	—		$	—
	Equity Securities:
	U.S. large-cap	28,602				28,602				—			—
	International large-cap value	25,202				25,202				—			—
	Emerging markets growth	13,010				13,010				—			—
	Equity index funds	77,432				—				77,432			—
	Domestic real estate funds	2,860				2,860				—			—
	Commodity funds	7,423				7,423				—			—
	Fixed income securities:
	Non-U.S. Treasury Securities	22,025				—				22,025			—
	Corporate and U.S. debt instruments	147,834				53,813				94,021			—
	Corporate bonds	25,164				—				25,164			—
	High yield bond funds	3,614				3,614				—			—
	Other types of investments:
	Multi-strategy hedge funds	23,332				—				—			23,332
	Venture capital funds	1				—				—			1
	Non-U.S. government index linked bonds	31,551				—				31,551			—
	Total assets measured at fair value	$	413,021			$	139,495			$	250,193		$	23,333
						Fair Value Measurements at December 29, 2013 Using:
		Total Carrying				Quoted Prices in				Significant Other			Significant
		Value at				Active Markets				Observable Inputs			Unobservable
		December 29, 2013				(Level 1)				(Level 2)			Inputs
													(Level 3)
		(In thousands)
	Cash	$	4,458			$	4,458			$	—		$	—
	Equity Securities:
	U.S. large-cap	34,127				34,127				—			—
	International large-cap value	27,595				27,595				—			—
	Emerging markets growth	12,517				12,517				—			—
	Equity index funds	73,796				—				73,796			—
	Domestic real estate funds	2,471				2,471				—			—
	Commodity funds	8,179				8,179				—			—
	Fixed income securities:
	Non-U.S. Treasury Securities	18,344				—				18,344			—
	Corporate and U.S. debt instruments	132,828				45,215				87,613			—
	Corporate bonds	22,619				—				22,619			—
	High yield bond funds	6,170				6,170				—			—
	Other types of investments:
	Multi-strategy hedge funds	22,689				—				—			22,689
	Venture capital funds	8				—				—			8
	Non-U.S. government index linked bonds	27,659				—				27,659			—
	Total assets measured at fair value	$	393,460			$	140,732			$	230,031		$	22,697
Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets	A reconciliation of the beginning and ending Level 3 assets for fiscal years 2014, 2013, and 2012 is as follows:
		Fair Value Measurements Using
		Significant Unobservable Inputs
		(Level 3):
		Common				Venture				Multi-strategy			Total
		Collective				Capital				Hedge
		Trusts/Private Funds				Funds				Funds
		(In thousands)
	Balance at January 1, 2012	$	—			$	7			$	19,285		$	19,292
	Realized losses	1,162				—				—			1,162
	Unrealized gains	19				—				977			996
	Purchases	9,448				—				—			9,448
	Issuances, Sales and Settlements	(10,467		)		—				—			(10,467		)
	Balance at December 30, 2012	162				7				20,262			20,431
	Realized gains	7				—				—			7
	Unrealized (losses) gains	(19		)		1				2,427			2,409
	Issuances, Sales and Settlements	(150		)		—				—			(150		)
	Balance at December 29, 2013	—				8				22,689			22,697
	Realized gains	—				—				—			—
	Unrealized (losses) gains	—				(7		)		643			636
	Purchases	—				—				—			—
	Issuances, Sales and Settlements	—				—				—			—
	Balance at December 28, 2014	$	—			$	1			$	23,332		$	23,333
Schedule of Expected Benefit Payments	The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:
		Non-U.S.				U.S.
		(In thousands)
	2015	$	11,320			$	18,169
	2016	11,832				18,268
	2017	12,028				18,363
	2018	12,475				18,657
	2019	13,067				18,857
	2020-2024	70,926				97,713
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Components of Net Periodic Benefit Cost (Credit)	Net periodic postretirement medical benefit credit included the following components for the fiscal years ended:
		December 28,				December 29,				December 30,
		2014				2013				2012
		(In thousands)
	Service cost	$	95			$	106			$	106
	Interest cost	155				135				144
	Expected return on plan assets	(964		)		(965		)		(877		)
	Actuarial gain	(384		)		(182		)		(929		)
	Net periodic postretirement medical benefit credit	$	(1,098	)		$	(906	)		$	(1,556	)
Schedule of Net Funded Status	The following table sets forth the changes in the postretirement medical plan’s funded status and the amounts recognized in the Company’s consolidated balance sheets as of December 28, 2014 and December 29, 2013.
		December 28,				December 29,
		2014				2013
		(In thousands)
	Actuarial present value of benefit obligations:
	Retirees	$	1,159			$	1,331
	Active employees eligible to retire	388				470
	Other active employees	1,795				2,009
	Accumulated benefit obligations at beginning of year	3,342				3,810
	Service cost	95				106
	Interest cost	155				135
	Benefits paid	(157		)		(189		)
	Actuarial loss (gain)	141				(520		)
	Change in accumulated benefit obligations during the year	234				(468		)
	Retirees	1,033				1,159
	Active employees eligible to retire	424				388
	Other active employees	2,119				1,795
	Accumulated benefit obligations at end of year	3,576				3,342
	Change in plan assets:
	Fair value of plan assets at beginning of year	13,396				12,958
	Actual return on plan assets	1,332				438
	Fair value of plan assets at end of year	14,728				13,396
	Net assets recognized in the consolidated balance sheets	$	11,152			$	10,054
	Net amounts recognized in the consolidated balance sheets consist of:
	Noncurrent assets	$	11,152			$	10,054
	Net assets recognized in the consolidated balance sheets	$	11,152			$	10,054
	Net amounts recognized in accumulated other comprehensive income consist of:
	Prior service cost	$	—			$	—
	Net amounts recognized in accumulated other comprehensive income	$	—			$	—
	Actuarial assumptions as of the year-end measurement date:
	Discount rate	4.1		%		4.77		%
	Actuarial assumptions used to determine net cost during the year are as follows:
		December 28,			December 29,			December 30,
		2014			2013			2012
	Discount rate	4.77	%		3.86	%		4	%
	Expected rate of return on assets	7.25	%		7.5	%		7.75	%
Schedule of Changes in Fair Value of Plan Assets	The fair values of the Company’s plan assets at December 28, 2014 and December 29, 2013 by asset category, classified in the three levels of inputs described in Note 21, are as follows:
						Fair Value Measurements at December 28, 2014 Using:
		Total Carrying				Quoted Prices in				Significant Other			Significant
		Value at				Active Markets				Observable Inputs			Unobservable
		December 28, 2014				(Level 1)				(Level 2)			Inputs
													(Level 3)
		(In thousands)
	Cash	$	248			$	248			$	—		$	—
	Equity Securities:
	U.S. large-cap	1,644				1,644				—			—
	International large-cap value	1,449				1,449				—			—
	Emerging markets growth	748				748				—			—
	Domestic real estate funds	164				164				—			—
	Commodity funds	427				427				—			—
	Fixed income securities:
	Corporate debt instruments	8,499				3,094				5,405			—
	High yield bond funds	208				208				—			—
	Other types of investments:
	Multi-strategy hedge funds	1,341				—				—			1,341
	Total assets measured at fair value	$	14,728			$	7,982			$	5,405		$	1,341
						Fair Value Measurements at December 29, 2013 Using:
		Total Carrying				Quoted Prices in				Significant Other			Significant
		Value at				Active Markets				Observable Inputs			Unobservable
		December 29, 2013				(Level 1)				(Level 2)			Inputs
													(Level 3)
		(In thousands)
	Cash	$	167			$	167			$	—		$	—
	Equity Securities:
	U.S large-cap	1,831				1,831				—			—
	International large-cap value	1,480				1,480				—			—
	Emerging markets growth	672				672				—			—
	Domestic real estate funds	133				133				—			—
	Commodity funds	439				439				—			—
	Fixed income securities:
	Corporate debt instruments	7,126				2,426				4,700			—
	High yield bond funds	331				331				—			—
	Other types of investments:
	Multi-strategy hedge funds	1,217				—				—			1,217
	Total assets measured at fair value	$	13,396			$	7,479			$	4,700		$	1,217
Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets	A reconciliation of the beginning and ending Level 3 assets for fiscal years 2014, 2013, and 2012 is as follows:
		Fair Value Measurements Using
		Significant Unobservable Inputs
		(Level 3):
		Common				Venture				Multi-strategy			Total
		Collective				Capital				Hedge
		Trusts/Private Funds				Funds				Funds
		(In thousands)
	Balance at January 1, 2012	$	—			$	1			$	1,129		$	1,130
	Realized gains	68				—				—			68
	Unrealized gains	1				—				55			56
	Purchases	552				—				—			552
	Issuances, Sales and Settlements	(612		)		—				—			(612		)
	Balance at December 30, 2012	9				1				1,184			1,194
	Realized gains	—				—				—			—
	Unrealized (losses) gains	(1		)		(1		)		33			31
	Purchases	—				—				—			—
	Issuances, Sales and Settlements	(8		)		—				—			(8		)
	Balance at December 29, 2013	—				—				1,217			1,217
	Realized gains	—				—				—			—
	Unrealized gains	—				—				124			124
	Purchases	—				—				—			—
	Issuances, Sales and Settlements	—				—				—			—
	Balance at December 28, 2014	$	—			$	—			$	1,341		$	1,341
Schedule of Expected Benefit Payments	The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:
	Postretirement Medical Plan
		(In thousands)
	2015	$	167
	2016	174
	2017	182
	2018	192
	2019	200
	2020-2024	1,159

Warranty_Reserves_Tables

Warranty Reserves (Tables)	12 Months Ended
	Dec. 28, 2014
Product Warranties Disclosures [Abstract]
Warranty Reserve Activity	A summary of warranty reserve activity for the fiscal years ended December 28, 2014, December 29, 2013 and December 30, 2012 is as follows:
		(In thousands)
	Balance at January 1, 2012	$	10,412
	Provision charged to income	17,750
	Payments	(18,022		)
	Adjustments to previously provided warranties, net	801
	Foreign currency translation and acquisitions	62
	Balance at December 30, 2012	11,003
	Provision charged to income	17,291
	Payments	(17,116		)
	Adjustments to previously provided warranties, net	(693		)
	Foreign currency translation and acquisitions	49
	Balance at December 29, 2013	10,534
	Provision charged to income	17,447
	Payments	(16,750		)
	Adjustments to previously provided warranties, net	73
	Foreign currency translation and acquisitions	(521		)
	Balance at December 28, 2014	$	10,783

Stock_Plans_Tables

Stock Plans (Tables)	12 Months Ended
	Dec. 28, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Total Compensation Recognized Related to Outstanding Equity Awards	The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock options, restricted stock, restricted stock units, performance units and stock grants, net of estimated forfeitures, included in the Company’s consolidated statements of operations for fiscal years 2014, 2013, and 2012:
		December 28,			December 29,				December 30,
		2014			2013				2012
		(In thousands)
	Cost of product and service revenue	$	1,456		$	1,304			$	1,247
	Research and development expenses	546			853				747
	Selling, general and administrative expenses	12,462			11,896				18,631
	Continuing operations stock-based compensation expense	14,464			14,053				20,625
	Discontinued operations stock-based compensation expense	—			—				406
	Total stock-based compensation expense	$	14,464		$	14,053			$	21,031
Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model	The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows for the fiscal years ended:
		December 28,		December 29,			December 30,
		2014		2013			2012
	Risk-free interest rate	1.5	%	0.9	%		0.6	%
	Expected dividend yield	0.7	%	0.8	%		1.2	%
	Expected lives	5 years		5 years			4 years
	Expected stock volatility	30.9	%	38.5	%		38.7	%
Summary of Stock Option Activity	The following table summarizes stock option activity for the three fiscal years ended December 28, 2014:
		December 28, 2014						December 29, 2013					December 30, 2012
		Number		Weighted-				Number			Weighted-		Number		Weighted-
		of		Average Exercise				of			Average Exercise		of		Average Exercise
		Shares		Price				Shares			Price		Shares		Price
		(Shares in thousands)
	Outstanding at beginning of year	3,494		$	23.34			4,266			$	21.64	5,346		$	20.57
	Granted	520		43.12				518			33.62		756		26.28
	Exercised	(1,024	)	23.89				(947	)		21.45		(1,611	)	20.16
	Canceled	(4	)	20.97				(8	)		22.88		(210	)	22.34
	Forfeited	(158	)	35.33				(335	)		23.04		(15	)	21.98
	Outstanding at end of year	2,828		$	26.11			3,494			$	23.34	4,266		$	21.64
	Exercisable at end of year	1,900		$	21.13			2,392			$	20.66	2,677		$	20
Summary of Restricted Stock Award Activity	The following table summarizes restricted stock award activity for the three fiscal years ended December 28, 2014:
		December 28, 2014						December 29, 2013					December 30, 2012
		Number		Weighted-				Number			Weighted-		Number		Weighted-
		of		Average				of			Average		of		Average
		Shares		Grant-				Shares			Grant-		Shares		Grant-
				Date Fair							Date Fair				Date Fair
				Value							Value				Value
		(Shares in thousands)
	Nonvested at beginning of year	649		$	29.24			781			$	24.71	672		$	23.62
	Granted	261		42.61				289			33.87		358		25.86
	Vested	(258	)	27.64				(346	)		22.98		(184	)	23.19
	Forfeited	(94	)	33.58				(75	)		28.76		(65	)	24.03
	Nonvested at end of year	558		$	33.51			649			$	29.24	781		$	24.71

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 28, 2014
Stockholders' Equity Note [Abstract]
Components of Accumulated Other Comprehensive Loss	The components of accumulated other comprehensive income consisted of the following:
		Foreign			Unrecognized			Unrealized			Unrealized and Realized (Losses) Gains on Derivatives, net of tax			Accumulated
		Currency			Prior Service			(Losses)						Other
		Translation			Costs, net of			Gains on						Comprehensive
		Adjustment,			tax			Securities,						Income
		net of tax						net of tax
		(In thousands)
	Balance, January 1, 2012	$	56,164		$	2,169		$	(159	)	$	(4,088	)	$	54,086
	Current year change	11,363			(82		)	30			1,196			12,507
	Balance, December 30, 2012	67,527			2,087			(129		)	(2,892		)	66,593
	Current year change	8,756			(658		)	8			2,892			10,998
	Balance, December 29, 2013	76,283			1,429			(121		)	—			77,591
	Current year change	(52,951		)	146			14			—			(52,791		)
	Balance, December 28, 2014	$	23,332		$	1,575		$	(107	)	$	—		$	24,800

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 28, 2014
Fair Value Disclosures [Abstract]
Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis	The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of December 28, 2014 and December 29, 2013 classified in one of the three classifications described above:
					Fair Value Measurements at December 28, 2014 Using:
		Total Carrying			Quoted Prices in		Significant Other			Significant
		Value at			Active Markets		Observable Inputs			Unobservable Inputs
		December 28,			(Level 1)		(Level 2)			(Level 3)
		2014
		(In thousands)
	Marketable securities	$	1,568		$	1,568	$	—		$	—
	Foreign exchange derivative assets	3,205			—		3,205			—
	Foreign exchange derivative liabilities	(302		)	—		(302		)	—
	Contingent consideration	(91		)	—		—			(91		)
					Fair Value Measurements at December 29, 2013 Using:
		Total Carrying			Quoted Prices in		Significant Other			Significant
		Value at			Active Markets		Observable Inputs			Unobservable Inputs
		December 29,			(Level 1)		(Level 2)			(Level 3)
		2013
		(In thousands)
	Marketable securities	$	1,319		$	1,319	$	—		$	—
	Foreign exchange derivative assets	293			—		293			—
	Foreign exchange derivative liabilities, net	(396		)	—		(396		)	—
	Contingent consideration	(4,926		)	—		—			(4,926		)
Reconciliation of Beginning and Ending Level 3 Net Liabilities	A reconciliation of the beginning and ending Level 3 net liabilities for contingent consideration is as follows:
		(In thousands)
	Balance at January 1, 2012	$	(20,298	)
	Additions	(1,900		)
	Amounts paid and foreign currency translation	17,433
	Change in fair value (included within selling, general and administrative expenses)	1,748
	Balance at December 30, 2012	(3,017		)
	Additions	(1,100		)
	Amounts paid and foreign currency translation	135
	Change in fair value (included within selling, general and administrative expenses)	(944		)
	Balance at December 29, 2013	(4,926		)
	Additions	—
	Amounts paid and foreign currency translation	2,074
	Change in fair value (included within selling, general and administrative expenses)	2,761
	Balance at December 28, 2014	$	(91	)

Industry_Segment_and_Geographi1

Industry Segment and Geographic Area Information (Tables)	12 Months Ended
	Dec. 28, 2014
Segment Reporting [Abstract]
Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations	Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below for the fiscal years ended:
		December 28,			December 29,			December 30,
		2014			2013			2012
		(In thousands)
	Human Health
	Product revenue	$	996,767		$	957,022		$	926,733
	Service revenue	246,635			244,088			237,892
	Total revenue	1,243,402			1,201,110			1,164,625
	Operating income from continuing operations(1)	220,165			156,452			63,773
	Environmental Health
	Product revenue	543,308			541,048			547,941
	Service revenue	450,509			415,428			392,622
	Total revenue	993,817			956,476			940,563
	Operating income from continuing operations(1)	109,129			97,052			111,844
	Corporate
	Operating loss from continuing operations(2)(3)	(118,552		)	(25,710		)	(72,497		)
	Continuing Operations
	Product revenue	$	1,540,075		$	1,498,070		$	1,474,674
	Service revenue	697,144			659,516			630,514
	Total revenue	2,237,219			2,157,586			2,105,188
	Operating income from continuing operations	210,742			227,794			103,120
	Interest and other expense, net (see Note 5)	41,139			64,110			47,956
	Income from continuing operations before income taxes	$	169,603		$	163,684		$	55,164
	____________________________
	(1)	Pre-tax impairment charges have been included in the Human Health and Environmental Health operating income from continuing operations. The Company had no pre-tax impairment charges in fiscal year 2014. The Company recognized a $0.2 million pre-tax impairment charge in the Human Health segment in fiscal year 2013. The Company recognized $73.4 million of pre-tax impairment charges in the Human Health segment and also recognized $0.7 million of pre-tax impairment charges in the Environmental Health segment in fiscal year 2012.
	(2)	Activity related to the mark-to-market adjustment on postretirement benefit plans has been included in the Corporate operating loss from continuing operations, and in the aggregate constituted a pre-tax loss of $75.9 million in fiscal year 2014, pre-tax income of $17.6 million in fiscal year 2013, and a pre-tax loss of $31.8 million in fiscal year 2012.
	(3)	Includes expenses related to litigation with Enzo Biochem, Inc. and Enzo Life Sciences, Inc. (collectively, “Enzo”). Enzo filed a complaint in 2002 alleging that the Company separately and together with other defendants breached distributorship and settlement agreements with Enzo, infringed Enzo's patents, engaged in unfair competition and fraud, and committed torts against Enzo by, among other things, engaging in commercial development and exploitation of Enzo's patented products and technology. The Company entered into a settlement agreement with Enzo dated June 20, 2014 and during fiscal year 2014 paid $7.0 million into a designated escrow account to resolve this matter, of which $3.7 million had been accrued in previous years and $3.3 million was recorded during fiscal year 2014. In addition, $3.4 million of expenses were incurred and recorded in preparation for the trial during fiscal year 2014.
Schedule of Depreciation, Amortization and Capital Expenditures	Additional information relating to the Company’s reporting segments is as follows for the three fiscal years ended December 28, 2014:
		Depreciation and Amortization									Capital Expenditures
		Expense
		December 28,			December 29,			December 30,			December 28,		December 29,		December 30,
		2014			2013			2012			2014		2013		2012
		(In thousands)									(In thousands)
	Human Health	$	89,969		$	98,582		$	99,597		$	15,201	$	20,900	$	24,518
	Environmental Health	24,736			25,915			23,001			12,149		16,532		14,488
	Corporate	2,031			2,382			2,528			1,722		1,549		3,395
	Continuing operations	116,736			126,879			125,126			29,072		38,981		42,401
	Discontinued operations	$	339		$	1,590		$	1,741		$	213	$	10	$	7
Schedule of Total Assets by Segment
		Total Assets
		December 28,			December 29,			December 30,
		2014			2013			2012
		(In thousands)
	Human Health	$	2,645,411		$	2,692,809		$	2,700,565
	Environmental Health	1,453,683			1,213,801			1,153,444
	Corporate	34,981			34,271			33,952
	Net current and long-term assets of discontinued operations	—			5,831			13,801
	Total assets	$	4,134,075		$	3,946,712		$	3,901,762
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	The following geographic area information for continuing operations includes revenue based on location of external customer for the three fiscal years ended December 28, 2014 and net long-lived assets based on physical location as of December 28, 2014 and December 29, 2013:
		Revenue
		December 28,			December 29,			December 30,
		2014			2013			2012
		(In thousands)
	U.S.	$	849,356		$	826,991		$	812,934
	International:
	China	276,230			254,838			216,425
	United Kingdom	134,614			133,611			118,611
	Germany	107,081			99,153			105,735
	Japan	93,811			95,676			114,300
	Italy	85,433			78,120			69,599
	France	84,946			81,719			84,395
	Other international	605,748			587,478			583,189
	Total international	1,387,863			1,330,595			1,292,254
	Total sales	$	2,237,219		$	2,157,586		$	2,105,188
		Net Long-Lived Assets
		December 28,			December 29,			December 30,
		2014			2013			2012
		(In thousands)
	U.S.	$	198,675		$	214,721		$	200,539
	International:
	China	36,797			30,682			30,134
	United Kingdom	13,033			9,882			2,960
	Finland	12,758			13,635			11,851
	Singapore	7,041			6,812			6,366
	Italy	4,107			2,735			3,303
	Netherlands	3,614			4,037			3,900
	Germany	2,493			2,591			2,353
	Brazil	2,099			1,967			1,515
	Mexico	1,938			1,016			1,353
	Other international	8,627			8,062			8,889
	Total international	92,507			81,419			72,624
	Total net long-lived assets	$	291,182		$	296,140		$	273,163

Quarterly_Financial_Informatio1

Quarterly Financial Information (Unaudited) Quarterly Financial Information (Unaudited) (Tables)	12 Months Ended
	Dec. 28, 2014
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	Selected quarterly financial information is as follows for the fiscal years ended:
		First		Second		Third		Fourth			Year
		Quarter		Quarter		Quarter		Quarter(1)(2)
		(In thousands, except per share data)
	December 28, 2014
	Revenue	$	530,610	$	556,170	$	542,049	$	608,390		$	2,237,219
	Gross profit	235,713		247,984		243,309		277,602			1,004,608
	Restructuring and contract termination charges, net	2,135		742		11,092		(579		)	13,390
	Operating income from continuing operations	51,762		69,637		58,776		30,567			210,742
	Income from continuing operations before income taxes	40,473		60,673		47,810		20,647			169,603
	Income from continuing operations	34,951		52,003		42,898		31,314			161,166
	Net income	34,224		50,490		42,277		30,787			157,778
	Basic earnings per share:
	Income from continuing operations	$	0.31	$	0.46	$	0.38	$	0.28		$	1.43
	Net income	0.3		0.45		0.38		0.27			1.4
	Diluted earnings per share:
	Income from continuing operations	$	0.31	$	0.46	$	0.38	$	0.28		$	1.42
	Net income	0.3		0.44		0.37		0.27			1.39
	Cash dividends declared per common share	0.07		0.07		0.07		0.07			0.28
	December 29, 2013
	Revenue	$	502,943	$	540,673	$	522,100	$	591,870		$	2,157,586
	Gross profit	224,442		241,662		233,268		276,770			976,142
	Restructuring and contract termination charges, net	3,310		19,247		1,124		10,211			33,892
	Operating income from continuing operations	36,694		40,216		57,954		92,930			227,794
	Income from continuing operations before income taxes	24,654		27,351		45,614		66,065			163,684
	Income from continuing operations	32,775		27,274		40,763		73,455			174,267
	Net income	32,216		27,925		40,198		66,873			167,212
	Basic earnings per share:
	Income from continuing operations	$	0.29	$	0.24	$	0.36	$	0.65		$	1.55
	Net income	0.28		0.25		0.36		0.6			1.49
	Diluted earnings per share:
	Income continuing operations	$	0.29	$	0.24	$	0.36	$	0.65		$	1.54
	Net income	0.28		0.25		0.36		0.59			1.47
	Cash dividends declared per common share	0.07		0.07		0.07		0.07			0.28
	____________________________
	-1	The fourth quarter of fiscal year 2014 includes a pre-tax loss of $75.9 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy.
	-2	The fourth quarter of fiscal year 2013 includes pre-tax income of $17.6 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2013 also includes a tax benefit of $9.2 million related to discrete items primarily for lapses in statutes of limitations and audit settlements.

Nature_of_Operations_and_Accou2

Nature of Operations and Accounting Policies Nature of Operations and Accounting Policies (Narrative) (Details) (Details) (EUR €)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012	Jan. 03, 2016
	plan
	segments
Number of Stock-based Compensation Plans	1
Number of Operating Segments	2
Operating Cycle	52	52	52
License and services revenue as a percentage of total revenue	5.00%	5.00%	3.00%
Minimum [Member] | Building [Member]
Property, Plant and Equipment, Useful Life, Maximum	10 years 0 months
Maximum [Member] | Building [Member]
Property, Plant and Equipment, Useful Life, Maximum	40 years 0 months
Maximum [Member] | Tools, Dies and Molds [Member]
Property, Plant and Equipment, Useful Life, Maximum	3 years 0 months
Maximum [Member] | Machinery and Equipment [Member]
Property, Plant and Equipment, Useful Life, Maximum	7 years 0 months
Cash Flow Hedging [Member]
Derivative, Number of Instruments Held	5	0	2
Derivative, Notional Amount	238.2		50
Scenario, Forecast [Member]
Operating Cycle				53

Business_Combinations_and_Asse2

Business Combinations and Asset Purchases (Narrative) (Details) (USD $)	12 Months Ended			1 Months Ended
	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012	Nov. 30, 2012	Dec. 28, 2014	Jan. 01, 2012	Dec. 05, 2014	Oct. 21, 2014
Business Acquisition [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value	$91,000	$4,926,000	$3,017,000		$91,000	$20,298,000
Business Combination, Contingent Consideration Arrangements, Description	Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period. The earnout periods for each of these acquisitions does not exceed three years from the acquisition date, and the remaining weighted average earnout period at December 28, 2014 was one year.
Business Acquisition, Transaction Costs	3,100,000	100,000	1,200,000
Number of Years in Measurement Period from Acquisition Date to Change Underlying Assumptions	1 year
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	31,400,000				31,400,000
Perten Instruments Group AB [Member]
Business Acquisition [Line Items]
Business Acquisition, Goodwill, Expected Tax Deductible Amount							0
Fiscal Year 2014 Acquisitions (excluding Perten) [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid	17,898,000
Working capital and other adjustments	-151,000
Business Acquisition, Goodwill, Expected Tax Deductible Amount								0
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments	18,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt								4,287,000
Fiscal Year 2013 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid	400,000	11,400,000
Contingent consideration		1,100,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High		2,200,000
Human Health [Member] | Haoyuan Biotech Co. [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid				38,000,000
Working capital and other adjustments				2,729,000
Contingent consideration				1,900,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High				30,000,000
Human Health [Member] | Core Technology [Member] | Haoyuan Biotech Co. [Member]
Business Acquisition [Line Items]
Weighted average amortization period (in years)				8 years
Human Health [Member] | Trade Names [Member] | Haoyuan Biotech Co. [Member]
Business Acquisition [Line Items]
Weighted average amortization period (in years)				8 years
Environmental Health [Member] | Perten Instruments Group AB [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid					269,937,000
Working capital and other adjustments					0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt							$7,600,000
Environmental Health [Member] | Minimum [Member] | Perten Instruments Group AB [Member]
Business Acquisition [Line Items]
Weighted average amortization period (in years)					5 years
Environmental Health [Member] | Maximum [Member] | Perten Instruments Group AB [Member]
Business Acquisition [Line Items]
Weighted average amortization period (in years)					10 years

Business_Combinations_and_Asse3

Business Combinations and Asset Purchases (Fair Values of the Business Combinations and Allocations for the Acquisitions Completed) (Details) (USD $)	12 Months Ended	1 Months Ended
In Thousands, unless otherwise specified	Dec. 28, 2014	Nov. 30, 2012	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012	Oct. 21, 2014	Dec. 05, 2014
Business Acquisition [Line Items]
Goodwill	$2,284,077		$2,284,077	$2,143,120	$2,122,788
Fiscal Year 2014 Acquisitions (excluding Perten) [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid	17,898
Working capital and other adjustments	151
Less: cash acquired	124
Total	17,925
Current assets						1,965
Property, plant and equipment						125
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets						364
Goodwill						15,981
Deferred taxes						-3,072
Business Acquisition, Purchase Price Allocation, Current and Non-current Liabilities, Deferred Revenue						-589
Liabilities assumed						-2,333
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt						-4,287
Total						17,925
Core Technology [Member] | Fiscal Year 2014 Acquisitions (excluding Perten) [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles						1,705
Trade Names [Member] | Fiscal Year 2014 Acquisitions (excluding Perten) [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles						0
Customer Relationships [Member] | Fiscal Year 2014 Acquisitions (excluding Perten) [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles						6,800
In Process Research and Development [Member] | Fiscal Year 2014 Acquisitions (excluding Perten) [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles						1,266
Human Health [Member]
Business Acquisition [Line Items]
Goodwill	1,621,595		1,621,595	1,648,332	1,632,487
Human Health [Member] | Haoyuan Biotech Co. [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid		38,000
Contingent consideration		1,900
Working capital and other adjustments		-2,729
Less: cash acquired		175
Total		36,996
Current assets		2,389
Property, plant and equipment		2,906
Goodwill		19,682
Deferred taxes		-2,656
Liabilities assumed		-3,725
Total		36,996
Human Health [Member] | Core Technology [Member] | Haoyuan Biotech Co. [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		17,700
Human Health [Member] | Trade Names [Member] | Haoyuan Biotech Co. [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		400
Human Health [Member] | In Process Research and Development [Member] | Haoyuan Biotech Co. [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		300
Environmental Health [Member]
Business Acquisition [Line Items]
Goodwill	662,482		662,482	494,788	490,301
Environmental Health [Member] | Perten Instruments Group AB [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid			269,937
Working capital and other adjustments			0
Less: cash acquired			16,732
Total			253,205
Current assets							32,805
Property, plant and equipment							1,485
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets							0
Goodwill							164,164
Deferred taxes							-31,454
Business Acquisition, Purchase Price Allocation, Current and Non-current Liabilities, Deferred Revenue							0
Liabilities assumed							-16,195
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt							-7,600
Total							253,205
Environmental Health [Member] | Core Technology [Member] | Perten Instruments Group AB [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles							16,000
Environmental Health [Member] | Trade Names [Member] | Perten Instruments Group AB [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles							7,000
Environmental Health [Member] | Customer Relationships [Member] | Perten Instruments Group AB [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles							87,000
Environmental Health [Member] | In Process Research and Development [Member] | Perten Instruments Group AB [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles							$0

Discontinued_Operations_Narrat

Discontinued Operations Narrative (Details) (USD $)	12 Months Ended
	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
(Loss) gain on disposition of discontinued operations before income taxes	($260,000)	($1,810,000)	$2,405,000
(Benefit from) provision for income taxes on discontinued operations and dispositions	-1,831,000	-5,107,000	-823,000
Microarray-based diagnostic testing laboratory in the United States [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operations, Severance Costs	1,000,000
(Loss) gain on disposition of discontinued operations before income taxes	-90,000	0	0
Photoflash Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
(Loss) gain on disposition of discontinued operations before income taxes	-14,000	493,000	2,459,000
Technical Services Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
(Loss) gain on disposition of discontinued operations before income taxes	-156,000	-2,100,000	0
Other Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
(Loss) gain on disposition of discontinued operations before income taxes	$0	($203,000)	($54,000)

Discontinued_Operations_Schedu

Discontinued Operations Schedule Of Gains And Losses On Disposition Of Discontinued Operations (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
(Loss) gain on disposition of discontinued operations before income taxes	($260)	($1,810)	$2,405
Other Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
(Loss) gain on disposition of discontinued operations before income taxes	0	-203	-54
Technical Services Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
(Loss) gain on disposition of discontinued operations before income taxes	-156	-2,100	0
Microarray-based diagnostic testing laboratory in the United States [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
(Loss) gain on disposition of discontinued operations before income taxes	-90	0	0
Photoflash Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
(Loss) gain on disposition of discontinued operations before income taxes	($14)	$493	$2,459

Summary_Operating_Results_of_D

Summary Operating Results of Discontinued Operations for the Periods Prior to Disposition (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Operating Results of Discontinued Operations Prior to Disposition [Abstract]
Disposal Group, Including Discontinued Operation, Revenue	$348	$8,646	$10,017
Disposal Group, Including Discontinued Operations, Costs and Expenses	5,307	18,998	14,594
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax	($4,959)	($10,352)	($4,577)

Restructuring_and_Contract_Ter2

Restructuring and Contract Termination Charges, Net (Narrative) (Details) (USD $)	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
Restructuring and Related Activities [Abstract]
Accrued restructuring and contract termination costs	$23,830,000	$35,535,000	$27,747,000	$22,886,000
Accrued restructuring and contract termination costs	17,124,000	26,374,000
Restructuring Reserve, Noncurrent	$6,700,000	$9,100,000

Restructuring_and_Contract_Ter3

Restructuring and Contract Termination Charges, Net Restructuring and Contract Termination Charges, Net (Schedule of Initial Charges) (Details) (USD $)

3 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

In Thousands, unless otherwise specified

Dec. 28, 2014

Sep. 28, 2014

Jun. 29, 2014

Mar. 30, 2014

Dec. 29, 2013

Sep. 29, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 28, 2014

Dec. 29, 2013

Dec. 30, 2012

Dec. 30, 2012

Sep. 30, 2012

Jul. 01, 2012

Apr. 01, 2012

Sep. 30, 2012

employees

employees

employees

employees

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

($579)

$11,092

$742

$2,135

$10,211

$1,124

$19,247

$3,310

$13,390

$33,892

$25,051

Q3 2014 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated

152

Restructuring and contract termination charges, net

13,051

Q2 2014 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated

22

Restructuring and contract termination charges, net

735

Q1 2014 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated

17

Restructuring and contract termination charges, net

567

Q4 2013 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated

73

Restructuring and contract termination charges, net

11,179

Q3 2013 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated

29

Restructuring and contract termination charges, net

532

Q2 2013 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated

264

Restructuring and contract termination charges, net

18,704

Q1 2013 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated

62

Restructuring and contract termination charges, net

2,585

Q4 2012 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated

54

Restructuring and contract termination charges, net

2,936

Q3 2012 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated

61

Restructuring and contract termination charges, net

7,399

[1]

Q2 2012 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated

203

Restructuring and contract termination charges, net

4,218

Q1 2012 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated

112

Restructuring and contract termination charges, net

5,719

Contract Termination [Member] | 2014 Contract Termination Charges [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

1,545

Contract Termination [Member] | 2013 Contract Termination Charges [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

696

Contract Termination [Member] | 2012 Contract Termination Charges [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

1,470

Human Health [Member] | Severance [Member] | Q3 2014 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

6,863

Human Health [Member] | Severance [Member] | Q2 2014 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

460

Human Health [Member] | Severance [Member] | Q1 2014 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

370

Human Health [Member] | Severance [Member] | Q4 2013 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

902

Human Health [Member] | Severance [Member] | Q3 2013 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

394

Human Health [Member] | Severance [Member] | Q2 2013 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

600

9,395

[2]

Human Health [Member] | Severance [Member] | Q1 2013 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

2,340

Human Health [Member] | Severance [Member] | Q4 2012 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

523

Human Health [Member] | Severance [Member] | Q3 2012 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

3,671

[1]

Human Health [Member] | Severance [Member] | Q2 2012 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

2,100

3,976

[3]

3,200

Human Health [Member] | Severance [Member] | Q1 2012 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

5,252

Human Health [Member] | Facility Closing [Member] | Q3 2014 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

0

Human Health [Member] | Facility Closing [Member] | Q2 2014 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

0

Human Health [Member] | Facility Closing [Member] | Q1 2014 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

0

Human Health [Member] | Facility Closing [Member] | Q4 2013 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

7,271

Human Health [Member] | Facility Closing [Member] | Q3 2013 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

138

Human Health [Member] | Facility Closing [Member] | Q2 2013 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

522

Human Health [Member] | Facility Closing [Member] | Q1 2013 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

0

Human Health [Member] | Facility Closing [Member] | Q4 2012 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

0

Human Health [Member] | Facility Closing [Member] | Q3 2012 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

0

Human Health [Member] | Facility Closing [Member] | Q2 2012 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

0

Human Health [Member] | Facility Closing [Member] | Q1 2012 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

79

Human Health [Member] | Contract Termination [Member] | 2014 Contract Termination Charges [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

0

Human Health [Member] | Contract Termination [Member] | 2013 Contract Termination Charges [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

0

Human Health [Member] | Contract Termination [Member] | 2012 Contract Termination Charges [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

0

Environmental Health [Member] | Severance [Member] | Q3 2014 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

6,188

Environmental Health [Member] | Severance [Member] | Q2 2014 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

275

Environmental Health [Member] | Severance [Member] | Q1 2014 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

197

Environmental Health [Member] | Severance [Member] | Q4 2013 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

3,006

Environmental Health [Member] | Severance [Member] | Q3 2013 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

0

Environmental Health [Member] | Severance [Member] | Q2 2013 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

8,737

Environmental Health [Member] | Severance [Member] | Q1 2013 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

245

Environmental Health [Member] | Severance [Member] | Q4 2012 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

2,413

Environmental Health [Member] | Severance [Member] | Q3 2012 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

3,728

[1]

Environmental Health [Member] | Severance [Member] | Q2 2012 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

242

Environmental Health [Member] | Severance [Member] | Q1 2012 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

700

388

[4]

Environmental Health [Member] | Facility Closing [Member] | Q3 2014 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

0

Environmental Health [Member] | Facility Closing [Member] | Q2 2014 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

0

Environmental Health [Member] | Facility Closing [Member] | Q1 2014 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

0

Environmental Health [Member] | Facility Closing [Member] | Q4 2013 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

0

Environmental Health [Member] | Facility Closing [Member] | Q3 2013 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

0

Environmental Health [Member] | Facility Closing [Member] | Q2 2013 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

50

Environmental Health [Member] | Facility Closing [Member] | Q1 2013 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

0

Environmental Health [Member] | Facility Closing [Member] | Q4 2012 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

0

Environmental Health [Member] | Facility Closing [Member] | Q3 2012 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

0

Environmental Health [Member] | Facility Closing [Member] | Q2 2012 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

0

Environmental Health [Member] | Facility Closing [Member] | Q1 2012 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

0

Environmental Health [Member] | Contract Termination [Member] | 2014 Contract Termination Charges [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

1,545

Environmental Health [Member] | Contract Termination [Member] | 2013 Contract Termination Charges [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

696

Environmental Health [Member] | Contract Termination [Member] | 2012 Contract Termination Charges [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and contract termination charges, net

$1,470

[1]

Local law required some severance for the Q3 2012 Plan to be paid in monthly installments through the fourth quarter of fiscal year 2014.

[2]

Subsequent to the initial charge, during fiscal year 2013, the Company recorded an additional $0.6 million pre-tax restructuring charge in the Human Health segment for the Q2 2013 Plan for services that were provided for one-time termination benefits in which the employee was required to render service beyond the legal notification period.

[3]

Subsequent to the initial charge, during fiscal years 2013 and 2012, the Company recorded an additional $2.1 million and $3.2 million , respectively, pre-tax restructuring charges in the Human Health segment for the Q2 2012 Plan for services that were provided for one-time termination benefits in which the employee was required to render service beyond the legal notification period.

[4]

Subsequent to the initial charge, during fiscal year 2012, the Company recorded an additional $0.7 million pre-tax restructuring charge primarily in the Environmental Health segment for the Q1 2012 Plan for services that were provided for one-time termination benefits in which the employee was required to render service beyond the legal notification period.

Restructuring_and_Contract_Ter4

Restructuring and Contract Termination Charges, Net (Schedule of Restructuring Plan Activity) (Details) (USD $)	3 Months Ended									12 Months Ended
	Dec. 28, 2014	Sep. 28, 2014	Jun. 29, 2014	Mar. 30, 2014	Dec. 29, 2013	Sep. 29, 2013	Jun. 30, 2013		Mar. 31, 2013	Dec. 28, 2014		Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
Restructuring Reserve [Roll Forward]
Restructuring Charges and Changes in Estimates										$13,390,000		$33,892,000	$25,051,000
Amounts paid and foreign currency translation										-25,095,000		-26,104,000	-20,190,000
Ending balance	23,830,000				35,535,000					23,830,000		35,535,000	27,747,000	22,886,000
Restructuring and contract termination charges, net	-579,000	11,092,000	742,000	2,135,000	10,211,000	1,124,000	19,247,000		3,310,000	13,390,000		33,892,000	25,051,000
Employee Severance and Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Restructuring Charges and Changes in Estimates										11,845,000		33,196,000	23,581,000
Amounts paid and foreign currency translation										-23,554,000		-25,112,000	-17,249,000
Ending balance	23,526,000				35,235,000					23,526,000		35,235,000	27,151,000	20,819,000
Contract Termination [Member]
Restructuring Reserve [Roll Forward]
Restructuring Charges and Changes in Estimates										1,545,000		696,000	1,470,000
Amounts paid and foreign currency translation										-1,541,000		-992,000	-2,941,000
Ending balance	304,000				300,000					304,000		300,000	596,000	2,067,000
2014 Contract Termination Charges [Member] | Contract Termination [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net										1,545,000
Q3 2014 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net		13,051,000
Q3 2014 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring Charges and Changes in Estimates										13,051,000		0	0
Amounts paid and foreign currency translation										-2,992,000		0	0
Ending balance	10,059,000				0					10,059,000		0	0	0
Q2 2014 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net			735,000
Q2 2014 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring Charges and Changes in Estimates										735,000		0	0
Amounts paid and foreign currency translation										-484,000		0	0
Ending balance	251,000				0					251,000		0	0	0
Q1 2014 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net				567,000
Q1 2014 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring Charges and Changes in Estimates										567,000		0	0
Amounts paid and foreign currency translation										-475,000		0	0
Ending balance	92,000				0					92,000		0	0	0
2013 Contract Termination Charges [Member] | Contract Termination [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net												696,000
Q4 2013 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net					11,179,000
Q4 2013 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring Charges and Changes in Estimates										-121,000	[1]	3,908,000	0
Amounts paid and foreign currency translation										-1,541,000		-1,921,000	0
Ending balance	325,000				1,987,000					325,000		1,987,000	0	0
Q4 2013 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring Charges and Changes in Estimates										1,055,000	[1]	7,271,000	0
Amounts paid and foreign currency translation										-2,106,000		-417,000	0
Ending balance	5,803,000				6,854,000					5,803,000		6,854,000	0	0
Q3 2013 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net						532,000
Q3 2013 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring Charges and Changes in Estimates										0		394,000	0
Amounts paid and foreign currency translation										-137,000		-257,000	0
Ending balance	0				137,000					0		137,000	0	0
Q3 2013 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring Charges and Changes in Estimates										0		138,000	0
Amounts paid and foreign currency translation										0		-138,000	0
Ending balance	0				0					0		0	0	0
Q2 2013 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net							18,704,000
Q2 2013 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring Charges and Changes in Estimates										-796,000	[2]	18,704,000	0
Amounts paid and foreign currency translation										-10,373,000		-5,954,000	0
Ending balance	1,581,000				12,750,000					1,581,000		12,750,000	0	0
Q2 2013 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring Charges and Changes in Estimates										184,000	[2]	572,000	0
Amounts paid and foreign currency translation										-184,000		-572,000	0
Ending balance	0				0					0		0	0	0
Q1 2013 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net									2,585,000
Q1 2013 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring Charges and Changes in Estimates										-208,000	[3]	2,585,000	0
Amounts paid and foreign currency translation										0		-2,377,000	0
Ending balance	0				208,000					0		208,000	0	0
Previous restructuring and integration plans [Member]
Restructuring Reserve [Roll Forward]
Restructuring Charges and Changes in Estimates										-2,622,000	[4]	-376,000	23,581,000
Amounts paid and foreign currency translation										5,262,000		13,476,000	17,249,000
Ending balance	5,415,000				13,299,000					5,415,000		13,299,000	27,151,000	20,819,000
Human Health [Member] | 2014 Contract Termination Charges [Member] | Contract Termination [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net										0
Human Health [Member] | Q3 2014 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net		6,863,000
Human Health [Member] | Q3 2014 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net		0
Human Health [Member] | Q2 2014 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net			460,000
Human Health [Member] | Q2 2014 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net			0
Human Health [Member] | Q1 2014 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net				370,000
Human Health [Member] | Q1 2014 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net				0
Human Health [Member] | 2013 Contract Termination Charges [Member] | Contract Termination [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net												0
Human Health [Member] | Q4 2013 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Change in estimates										-100,000
Restructuring and contract termination charges, net					902,000
Human Health [Member] | Q4 2013 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net					7,271,000
Human Health [Member] | Q3 2013 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net						394,000
Human Health [Member] | Q3 2013 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net						138,000
Human Health [Member] | Q2 2013 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Change in estimates										-300,000
Restructuring and contract termination charges, net						600,000	9,395,000	[5]
Human Health [Member] | Q2 2013 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Change in estimates										100,000
Restructuring and contract termination charges, net							522,000
Human Health [Member] | Q1 2013 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Change in estimates										-200,000
Restructuring and contract termination charges, net									2,340,000
Human Health [Member] | Q1 2013 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net									0
Human Health [Member] | Previous restructuring and integration plans [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Change in estimates										-1,600,000
Human Health [Member] | Previous restructuring and integration plans [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Change in estimates										100,000
Environmental Health [Member] | 2014 Contract Termination Charges [Member] | Contract Termination [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net										1,545,000
Environmental Health [Member] | Q3 2014 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net		6,188,000
Environmental Health [Member] | Q3 2014 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net		0
Environmental Health [Member] | Q2 2014 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net			275,000
Environmental Health [Member] | Q2 2014 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net			0
Environmental Health [Member] | Q1 2014 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net				197,000
Environmental Health [Member] | Q1 2014 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net				0
Environmental Health [Member] | 2013 Contract Termination Charges [Member] | Contract Termination [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net												696,000
Environmental Health [Member] | Q4 2013 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net					3,006,000
Environmental Health [Member] | Q4 2013 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Change in estimates										1,100,000
Restructuring and contract termination charges, net					0
Environmental Health [Member] | Q3 2013 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net						0
Environmental Health [Member] | Q3 2013 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net						0
Environmental Health [Member] | Q2 2013 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Change in estimates										-500,000
Restructuring and contract termination charges, net							8,737,000
Environmental Health [Member] | Q2 2013 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Change in estimates										92,000
Restructuring and contract termination charges, net							50,000
Environmental Health [Member] | Q1 2013 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net									245,000
Environmental Health [Member] | Q1 2013 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net									0
Environmental Health [Member] | Previous restructuring and integration plans [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Change in estimates										($1,100,000)
[1]	During fiscal year 2014, the Company recorded a pre-tax restructuring reversal of $0.1 million in the Environmental Health segment related to lower than expected costs associated with the remaining severance payments for the Q4 2013 Plan and recorded an additional pre-tax restructuring charge of $1.1 million in the Human Health segment related to higher than expected costs associated with the closure of the excess facility for the Q4 2013 Plan.
[2]	During fiscal year 2014, the Company recorded pre-tax restructuring reversals of $0.3 million in the Human Health segment and $0.5 million in the Environmental Health segment related to lower than expected costs associated with the remaining severance payments for the Q2 2013 Plan. In addition during fiscal year 2014, the Company incurred an additional pre-tax restructuring charge of $0.1 million in each of the Human Health and Environmental Health segments related to higher than expected costs associated with the closure of the excess facility space for the Q2 2013 Plan.
[3]	During fiscal year 2014, the Company recorded a pre-tax restructuring reversal of $0.2 million in the Human Health segment related to lower than expected costs associated with the remaining severance payments for the Q1 2013 Plan.
[4]	During fiscal year 2014, the Company recognized pre-tax restructuring reversals of $1.6 million in the Human Health segment and $1.1 million in the Environmental Health segment related to lower than expected costs associated with workforce reductions for the previous restructuring plans. During fiscal year 2014, the Company recognized an additional pre-tax restructuring charge of $0.1 million in the Human Health segment related to higher than expected costs associated with the closure of the excess facility space for the previous restructuring plans.
[5]	Subsequent to the initial charge, during fiscal year 2013, the Company recorded an additional $0.6 million pre-tax restructuring charge in the Human Health segment for the Q2 2013 Plan for services that were provided for one-time termination benefits in which the employee was required to render service beyond the legal notification period.

Interest_and_Other_Expense_Inc2

Interest and Other Expense (Income), Net (Details) (USD $)	3 Months Ended	12 Months Ended
	Dec. 29, 2013	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012	30-May-08
Early Repayment of Senior Debt		$0	$150,000,000	$0
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax			4,800,000
Write off of Deferred Debt Issuance Cost	200,000
Payments of Debt Extinguishment Costs	-11,100,000	0	-11,119,000	0
Interest income		-667,000	-650,000	-747,000
Interest expense		36,270,000	49,924,000	45,787,000
Other expense, net		5,536,000	14,836,000	2,916,000
Total interest and other expense (income), net		41,139,000	64,110,000	47,956,000
2015 Notes [Member]
Unsecured senior notes, interest rate percent					6.00%
Early Repayment of Senior Debt	150,000,000
Interest Rate Contract [Member] | Interest Expense [Member]
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax	($2,800,000)		($2,000,000)	($2,000,000)

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended	12 Months Ended
	Dec. 29, 2013	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012	Nov. 30, 2011
Income Tax Contingency [Line Items]
Income Tax Holiday, Aggregate Dollar Amount		($7,100,000)	($7,400,000)	($5,200,000)
Valuation Allowance, Amount	63,139,000	55,460,000	63,139,000	67,800,000	82,300,000
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized tax benefits, beginning of period		39,410,000	58,110,000	51,740,000
Gross increases - tax positions in prior period		0	325,000	10,653,000
Gross decreases - tax positions in prior period		-1,809,000	-10,539,000	-4,665,000
Gross increases - current-period tax positions		239,000	2,222,000	3,343,000
Settlements		-1,400,000	-3,643,000	-2,822,000
Lapse of statute of limitations		-4,129,000	-6,495,000	-595,000
Foreign currency translation adjustments		31,000	-570,000	456,000
Unrecognized tax benefits, end of period	39,410,000	32,342,000	39,410,000	58,110,000
Interest on income taxes accrued		3,400,000
Interest on income taxes expense		-700,000	-3,900,000	1,100,000
Income tax penalties expense		-200,000	-3,700,000	-2,200,000
Income tax penalties accrued		200,000
Uncertain tax benefits if recognized that could affect the continuing operations effective tax rate		28,500,000
Unrecognized Tax Benefits Expected To Be Resolved With In A Year		5,300,000
Foreign earnings invested outside U.S.		675,000,000
Open Tax Years by Major Tax Jurisdiction, Begin Date		2007
Tax Adjustments, Settlements, and Unusual Provisions	-9,200,000	-7,000,000	-24,000,000	-7,000,000
General Business [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Tax Credit Carryforward, Amount		30,800,000
State and Local Jurisdiction [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards		197,400,000
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Tax Credit Carryforward, Amount		11,900,000
Foreign Tax Authority [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards		160,500,000
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Tax Credit Carryforward, Amount		12,400,000
Internal Revenue Service (IRS) [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards		45,800,000
Internal Revenue Service (IRS) [Member] | November 2011 Caliper Life Sciences [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards		$25,800,000				$223,400,000
Minimum [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Income Tax Holiday, Termination Date		2017
Maximum [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Income Tax Holiday, Termination Date		2018

Income_Taxes_Income_Before_Inc

Income Taxes Income Before Income taxes (Details) (USD $)	3 Months Ended										12 Months Ended
In Thousands, unless otherwise specified	Dec. 28, 2014		Sep. 28, 2014	Jun. 29, 2014	Mar. 30, 2014	Dec. 29, 2013		Sep. 29, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Income Tax Contingency [Line Items]
U.S.											($37,758)	($71,901)	($113,969)
Non-U.S.											207,361	235,585	169,133
Income from continuing operations before income taxes	$20,647	[1]	$47,810	$60,673	$40,473	$66,065	[2]	$45,614	$27,351	$24,654	$169,603	$163,684	$55,164
[1]	The fourth quarter of fiscal year 2014 includes a pre-tax loss of $75.9 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy.
[2]	The fourth quarter of fiscal year 2013 includes pre-tax income of $17.6 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2013 also includes a tax benefit of $9.2 million related to discrete items primarily for lapses in statutes of limitations and audit settlements.

Income_Taxes_Components_of_the

Income Taxes Components of the Provision (Benefits from) Income Tax (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Income Tax Contingency [Line Items]
Federal current	($262)	$2,331	($3,640)
Federal deferred expense (benefit)	-19,169	-29,961	-34,920
Federal total	-19,431	-27,630	-38,560
State current	2,416	1,968	2,752
State deferred expense (benefit)	-3,842	-2,147	-2,794
State total	-1,426	-179	-42
Non-U.S. current	39,634	15,025	50,314
Non-U.S.deferred expense benefit	-10,340	2,201	-27,837
Non-U.S. total	29,294	17,226	22,477
Total current	41,788	19,324	49,426
Total deferred expense (benefit)	-33,351	-29,907	-65,551
Total	8,437	-10,583	-16,125
Discontinued operations	-1,831	-5,107	-823
Total provision for income taxes	$6,606	($15,690)	($16,948)

Income_Taxes_Reconciliation_of

Income Taxes Reconciliation of Income Tax Expense (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Income Tax Contingency [Line Items]
Tax at statutory rate	$59,361	$57,289	$19,302
Non-U.S. rate differential, net	-36,616	-36,377	-26,652
U.S. taxation of multinational operations	2,367	3,658	1,727
State income taxes, net	1,970	-1,762	3,400
Prior year tax matters	-7,009	-23,534	3,389
Federal tax credits	-3,399	-5,452	-1,657
Change in valuation allowance	-7,679	-4,675	-14,446
Other, net	-558	270	-1,188
Total	$8,437	($10,583)	($16,125)

Income_Taxes_Components_of_Def

Income Taxes Components of Deferred Tax Assets and Liabilities (Details) (USD $)	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
Income Tax Contingency [Line Items]
Long-term deferred tax liabilities	$30,300,000	$45,300,000
Current deferred tax assets	62,000,000	78,300,000
Inventory	9,041,000	9,850,000
Reserves and accruals	30,641,000	30,269,000
Accrued compensation	22,915,000	15,920,000
Net operating loss and credit carryforwards	106,020,000	132,710,000
Accrued pension	44,342,000	23,353,000
Restructuring reserve	7,522,000	6,853,000
Deferred revenue	46,413,000	42,687,000
All other, net	824,000	1,666,000
Total deferred tax assets	267,718,000	263,308,000
Postretirement health benefits	-4,472,000	-3,894,000
Depreciation and amortization	-176,043,000	-163,269,000
Total deferred tax liabilities	-180,515,000	-167,163,000
Valuation allowance	-55,460,000	-63,139,000	-67,800,000	-82,300,000
Net deferred tax liabilities	31,743,000	33,006,000
Domestic Country [Member]
Income Tax Contingency [Line Items]
Net deferred tax liabilities	44,073,000	22,565,000
Foreign Tax Authority [Member]
Income Tax Contingency [Line Items]
Net deferred tax liabilities	($12,330,000)	$10,441,000

Income_Taxes_Summary_of_Loss_a

Income Taxes Summary of Loss and Tax Credit Carryforwards (Details) (USD $)	12 Months Ended
	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012	Nov. 30, 2011
Income Tax Contingency [Line Items]
Valuation Allowance, Amount	55,460,000	$63,139,000	$67,800,000	$82,300,000
State and Local Jurisdiction [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards	197,400,000
Tax Credit Carryforward, Amount	11,900,000
Foreign Tax Authority [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards	160,500,000
Tax Credit Carryforward, Amount	12,400,000
Internal Revenue Service (IRS) [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards	45,800,000
General Business [Member]
Income Tax Contingency [Line Items]
Tax Credit Carryforward, Amount	30,800,000
November 2011 Caliper Life Sciences [Member] | Internal Revenue Service (IRS) [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards	25,800,000				$223,400,000
Minimum [Member] | Foreign Tax Authority [Member]
Income Tax Contingency [Line Items]
Tax Credit Carryforward, Expiration Date	1-Jan-15
Minimum [Member] | November 2011 Caliper Life Sciences [Member] | Internal Revenue Service (IRS) [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards, Expiration Dates	1-Jan-15
Maximum [Member] | Foreign Tax Authority [Member]
Income Tax Contingency [Line Items]
Tax Credit Carryforward, Expiration Date	31-Dec-33
Maximum [Member] | November 2011 Caliper Life Sciences [Member] | Internal Revenue Service (IRS) [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards, Expiration Dates	31-Dec-31

Earnings_Per_Share_Schedule_of

Earnings Per Share (Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations) (Details)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Earnings Per Share [Abstract]
Number of common shares-basic	112,593	112,254	113,728
Effect of dilutive securities, Stock options	922	982	847
Effect of dilutive securities, Restricted stock	224	267	285
Number of common shares-diluted	113,739	113,503	114,860
Number of potentially dilutive securities excluded from calculation due to antidilutive impact	475	485	1,288

Accounts_Receivable_Net_Detail

Accounts Receivable, Net (Details) (USD $)	Dec. 28, 2014	Dec. 29, 2013
In Millions, unless otherwise specified
Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]
Reserves for doubtful accounts	$32.90	$28.30

Inventories_Net_Details

Inventories, Net (Details) (USD $)	Dec. 28, 2014	Dec. 29, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Raw materials	$96,169	$92,713
Work in progress	18,783	15,505
Finished goods	170,505	152,640
Total inventories, net	$285,457	$260,858

Property_Plant_and_Equipment_N2

Property, Plant and Equipment, Net (Details) (USD $)	12 Months Ended
	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$492,814,000	$498,111,000
Accumulated depreciation	-316,620,000	-314,923,000
Total property, plant and equipment, net	176,194,000	183,188,000
Depreciation expense	33,300,000	37,600,000	35,000,000
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	906,000	1,019,000
Building and leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	175,040,000	171,393,000
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$316,868,000	$325,699,000

Marketable_Securities_and_Inve2

Marketable Securities and Investments (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Schedule of Available-for-sale Securities [Line Items]
Unrealized (losses) gains on securities, net of tax	$14	$8	$30
Marketable securities	1,568	1,319
Marketable securities and investments	1,568	1,319
Equity Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	1,110	871
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	7	0
Market value	1,002	740
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	-115	-131
Fixed Income Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	88	308
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	0	0
Market value	88	308
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	0	0
Available-for-sale Securities, Other [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	541	334
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	0	0
Market value	478	271
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	-63	-63
Available-for-sale Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	1,739	1,513
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	7	0
Market value	1,568	1,319
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	($178)	($194)

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets, Net (Narrative) (Details) (USD $)	12 Months Ended			3 Months Ended
	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012	Dec. 30, 2012	Dec. 29, 2013	Sep. 28, 2014	Jan. 01, 2014
Goodwill and Intangible Assets Net [Line Items]
Reallocation of Goodwill Resulting from Realignment Within Operating Segments						$220,300,000
Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount	90.00%						11.00%
Goodwill							796,300,000
Change in any one of the input assumptions for the various reporting units	10.00%
Impairment of Intangible Assets (Excluding Goodwill)	0
Total amortization expense related to finite-lived intangible assets	83,400,000	89,300,000	90,100,000
Future Amortization Expense, Year One	80,400,000
Future Amortization Expense, Year Two	71,400,000
Future Amortization Expense, Year Three	61,900,000
Future Amortization Expense, Year Four	48,700,000
Future Amortization Expense, Year Five	37,200,000
Finite-Lived Intangible Assets, Net	419,681,000	389,846,000			389,846,000
Asset impairment	0	158,000	74,153,000
Minimum [Member]
Goodwill and Intangible Assets Net [Line Items]
Long-term terminal growth rates for reporting units	3.00%
Discount rates for reporting units	10.00%
Maximum [Member]
Goodwill and Intangible Assets Net [Line Items]
Long-term terminal growth rates for reporting units	6.00%
Discount rates for reporting units	11.50%
Trade Names And Trademarks [Member]
Goodwill and Intangible Assets Net [Line Items]
Remaining Fair Value After Impairment for Finite and Indefinite Lived Intangible Assets			6,100,000	6,100,000
Impairment of Intangible Assets (Excluding Goodwill)				74,200,000
Finite-Lived Intangible Assets, Net	23,133,000	19,601,000			19,601,000
Asset impairment			2,300,000
Trade Names And Trademarks [Member] | Minimum [Member]
Goodwill and Intangible Assets Net [Line Items]
Remaining Useful Life After Impairment for Finite and Indefinite Lived Intangible Assets			1 year
Trade Names And Trademarks [Member] | Maximum [Member]
Goodwill and Intangible Assets Net [Line Items]
Remaining Useful Life After Impairment for Finite and Indefinite Lived Intangible Assets			8 years
Trade Names And Trademarks [Member] | Weighted Average [Member]
Goodwill and Intangible Assets Net [Line Items]
Remaining Useful Life After Impairment for Finite and Indefinite Lived Intangible Assets				3 years
Licenses [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net	17,839,000	26,250,000			26,250,000
Human Health [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net	265,092,000	339,711,000			339,711,000
Human Health [Member] | Trade Names And Trademarks [Member]
Goodwill and Intangible Assets Net [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)				73,400,000
Finite-Lived Intangible Assets, Net	16,191,000	19,601,000			19,601,000
Human Health [Member] | Customer Lists [Member]
Goodwill and Intangible Assets Net [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)		200,000
Asset impairment					200,000
Human Health [Member] | Licenses [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net	17,839,000	25,745,000			25,745,000
Environmental Health [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net	154,589,000	50,135,000			50,135,000
Environmental Health [Member] | Trade Names And Trademarks [Member]
Goodwill and Intangible Assets Net [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)				700,000
Finite-Lived Intangible Assets, Net	6,942,000	0			0
Environmental Health [Member] | Licenses [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net	0	505,000			505,000
Other Asset Acquisitions [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net		7,000,000	6,800,000	6,800,000	7,000,000
Prepaid Royalties		40,300,000	25,000,000	25,000,000	40,300,000
Prepaid Royalties To Be Paid Within One Year	$10,000,000

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets, Net (Changes in the Carrying Amount of Goodwill) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013
Changes in the carrying amount of goodwill
Beginning balance	$2,143,120	$2,122,788
Foreign currency translation	-37,886	15,167
Acquisitions, earn outs and other	178,843	5,165
Ending balance	2,284,077	2,143,120
Human Health [Member]
Changes in the carrying amount of goodwill
Beginning balance	1,648,332	1,632,487
Foreign currency translation	-29,145	12,867
Acquisitions, earn outs and other	2,408	2,978
Ending balance	1,621,595	1,648,332
Environmental Health [Member]
Changes in the carrying amount of goodwill
Beginning balance	494,788	490,301
Foreign currency translation	-8,741	2,300
Acquisitions, earn outs and other	176,435	2,187
Ending balance	$662,482	$494,788

Goodwill_and_Intangible_Assets4

Goodwill and Intangible Assets, Net (Identifiable Intangible Asset Balances) (Details) (USD $)	Dec. 28, 2014	Dec. 29, 2013
In Thousands, unless otherwise specified
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Net amortizable intangible assets	$419,681	$389,846
Totals	490,265	460,430
Patents [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	39,953	39,591
Less: Accumulated amortization	-27,200	-24,207
Net amortizable intangible assets	12,753	15,384
Trade Names And Trademarks [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	40,069	35,809
Less: Accumulated amortization	-16,936	-16,208
Net amortizable intangible assets	23,133	19,601
Non-amortizing intangible assets	70,584	70,584
Licenses [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	59,631	79,180
Less: Accumulated amortization	-41,792	-52,930
Net amortizable intangible assets	17,839	26,250
Core Technology [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	298,491	302,070
Less: Accumulated amortization	-184,697	-169,326
Net amortizable intangible assets	113,794	132,744
Customer Relationships [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	402,185	321,395
Less: Accumulated amortization	-156,994	-132,833
Net amortizable intangible assets	245,191	188,562
In Process Research and Development [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	10,103	9,483
Less: Accumulated amortization	-3,132	-2,178
Net amortizable intangible assets	6,971	7,305
Human Health [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Net amortizable intangible assets	265,092	339,711
Totals	265,092	339,711
Human Health [Member] | Patents [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	36,760	36,791
Less: Accumulated amortization	-24,652	-22,205
Net amortizable intangible assets	12,108	14,586
Human Health [Member] | Trade Names And Trademarks [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	33,069	35,723
Less: Accumulated amortization	-16,878	-16,122
Net amortizable intangible assets	16,191	19,601
Non-amortizing intangible assets	0	0
Human Health [Member] | Licenses [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	59,631	71,580
Less: Accumulated amortization	-41,792	-45,835
Net amortizable intangible assets	17,839	25,745
Human Health [Member] | Core Technology [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	169,864	187,387
Less: Accumulated amortization	-98,798	-88,811
Net amortizable intangible assets	71,066	98,576
Human Health [Member] | Customer Relationships [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	292,627	305,038
Less: Accumulated amortization	-148,820	-127,397
Net amortizable intangible assets	143,807	177,641
Human Health [Member] | In Process Research and Development [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	5,079	4,257
Less: Accumulated amortization	-998	-695
Net amortizable intangible assets	4,081	3,562
Environmental Health [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Net amortizable intangible assets	154,589	50,135
Totals	225,173	120,719
Environmental Health [Member] | Patents [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	3,193	2,800
Less: Accumulated amortization	-2,548	-2,002
Net amortizable intangible assets	645	798
Environmental Health [Member] | Trade Names And Trademarks [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	7,000	86
Less: Accumulated amortization	-58	-86
Net amortizable intangible assets	6,942	0
Non-amortizing intangible assets	70,584	70,584
Environmental Health [Member] | Licenses [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	0	7,600
Less: Accumulated amortization	0	-7,095
Net amortizable intangible assets	0	505
Environmental Health [Member] | Core Technology [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	128,627	114,683
Less: Accumulated amortization	-85,899	-80,515
Net amortizable intangible assets	42,728	34,168
Environmental Health [Member] | Customer Relationships [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	109,558	16,357
Less: Accumulated amortization	-8,174	-5,436
Net amortizable intangible assets	101,384	10,921
Environmental Health [Member] | In Process Research and Development [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	5,024	5,226
Less: Accumulated amortization	-2,134	-1,483
Net amortizable intangible assets	$2,890	$3,743

Debt_Details

Debt (Details) (USD $)	3 Months Ended	12 Months Ended			1 Months Ended
	Dec. 29, 2013	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012	Oct. 25, 2011	Sep. 30, 2012
Early Repayment of Senior Debt		$0	$150,000,000	$0
Payments of Debt Extinguishment Costs	11,100,000	0	11,119,000	0
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax			4,800,000
Write off of Deferred Debt Issuance Cost	200,000
Discount on senior unsecured notes		-2,305,000
Maturities of Long-term Debt [Abstract]
2015		1,075,000
2016		1,120,000
2017		1,169,000
2018		1,367,000
2019		517,532,000
Thereafter		533,009,000
Long-term Debt Before Unamortized Discount		1,055,272,000
Total		1,052,967,000
Other Long-term Debt, Current	2,624,000	1,075,000	2,624,000
Line of Credit, Maturing January 8, 2019 [Member]
Unsecured revolving credit facility, amount		700,000,000
Unsecured revolving credit facility, expiry date		8-Jan-19
Line of Credit Facility, Remaining Borrowing Capacity		171,800,000
Letters of credit issued and outstanding		12,200,000
Interest rate terms under amended senior unsecured revolving credit facility		The interest rates under the new senior unsecured revolving credit facility are based on the Eurocurrency rate or the base rate at the time of borrowing plus a margin. The base rate is the higher of (i)B the rate of interest in effect for such day as publicly announced from time to time by JP Morgan Chase Bank, N.A. as its "prime rate," (ii)B the Federal Funds rate plus 50 basis points or (iii) one-month Libor plus 1.00%.
Weighted average interest rates under amended senior unsecured revolving credit facility		The Eurocurrency margin as of DecemberB 28, 2014 was 108 basis points. The weighted average Eurocurrency interest rate as of DecemberB 28, 2014 was 0.18%, resulting in a weighted average effective Eurocurrency rate, including the margin, of 1.26%.
Aggregate borrowings under the amended facility		516,000,000
Payments of Financing Costs		1,800,000
Discount on senior unsecured notes		0
Maturities of Long-term Debt [Abstract]
2015		0
2016		0
2017		0
2018		0
2019		516,000,000
Thereafter		0
Long-term Debt Before Unamortized Discount		516,000,000
Total		516,000,000
Line of Credit, Maturing January 8, 2019 [Member] | Base Rate Option Three [Member]
Basis spread on variable rate		1.00%
Line of Credit, Maturing January 8, 2019 [Member] | Eurocurrency Rate [Member]
Basis spread on variable rate		1.08%
Weighted average Eurocurrency interest rate		0.18%
Weighted average effective Eurocurrency rate, including the margin		1.26%
Line of Credit, Maturing January 8, 2019 [Member] | Base Rate Option Two [Member]
Basis spread on variable rate		0.50%
Line of Credit, Maturing December 16, 2016 [Member]
Unsecured revolving credit facility, amount	700,000,000		700,000,000
Unsecured revolving credit facility, expiry date			16-Dec-16
Aggregate borrowings under the amended facility	397,000,000		397,000,000
Line of Credit, Maturing December 16, 2016 [Member] | Eurocurrency Rate [Member]
Description of variable rate basis		Eurocurrency
Line of Credit, Maturing December 16, 2016 [Member] | Base Rate Option Two [Member]
Description of variable rate basis		Federal Funds
2021 Notes [Member]
Long-term Debt	497,400,000	497,700,000	497,400,000
Unsecured senior notes, interest rate percent					5.00%
Unsecured senior notes, face value		500,000,000			500,000,000
Gross proceeds from the issuance of debt instrument					496,900,000
Senior unsecured notes issuance as percentage of principal amount					99.37%
Discount on senior unsecured notes	-2,600,000	-2,305,000	-2,600,000		-3,100,000
Debt instrument maturity date					25-Nov-21
Percentage of redemption of senior notes on or after August 15, 2021					100.00%
Percentage of redemption upon a change of control and a contemporaneous downgrade of the Notes					101.00%
Maturities of Long-term Debt [Abstract]
2015		0
2016		0
2017		0
2018		0
2019		0
Thereafter		500,000,000
Long-term Debt Before Unamortized Discount		500,000,000
Total		497,695,000
2021 Notes [Member] | Treasury Rate [Member]
Basis spread on variable rate		0.45%
Financing Lease Obligations [Member]
Additional Financing Lease Obligations				11,500,000
Discount on senior unsecured notes		0
Maturities of Long-term Debt [Abstract]
2015		1,075,000
2016		1,120,000
2017		1,169,000
2018		1,367,000
2019		1,532,000
Thereafter		33,009,000
Long-term Debt Before Unamortized Discount		39,272,000
Total		39,272,000
Other Long-term Debt	40,300,000	39,300,000	40,300,000			29,300,000
Other Long-term Debt, Current	2,600,000	1,100,000	2,600,000
Other Long-term Debt, Noncurrent	$37,700,000	$38,200,000	$37,700,000

Accrued_Expenses_and_Other_Cur2

Accrued Expenses and Other Current Liabilities (Details) (USD $)	Dec. 28, 2014	Dec. 29, 2013
In Thousands, unless otherwise specified
Accounts Payable and Accrued Liabilities, Current [Abstract]
Payroll and incentives	$61,018	$52,865
Employee benefits	40,318	40,965
Deferred revenue	168,928	164,723
Federal, non-U.S. and state income taxes	9,801	11,783
Other accrued operating expenses	122,956	133,342
Total accrued expenses and other current liabilities	$403,021	$403,678

Employee_Benefit_Plans_Schedul

Employee Benefit Plans (Schedule of Net Benefit Costs, Pension Plans) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Defined Benefit Plan Disclosure [Line Items]
Net periodic benefit cost	$73,957	($16,839)	$34,361
Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Service cost	4,070	3,664	3,852
Interest cost	23,475	21,334	23,164
Expected return on plan assets	-25,007	-25,106	-20,768
Actuarial loss (gain)	71,700	-16,464	28,355
Amortization of prior service cost	($281)	($267)	($242)

Employee_Benefit_Plans_Schedul1

Employee Benefit Plans (Schedule of Net Funded Status, Pension Plans) (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 30, 2014	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Other Changes	$32,100,000
Defined Benefit Plan, Plans with Benefit Obligations in Excess of Plan Assets, Aggregate Benefit Obligation		156,867,000	151,391,000
Actuarial assumptions as of the year-end measurement date:
Defined Benefit Plan, Plans with Benefit Obligations in Excess of Plan Assets, Aggregate Fair Value of Plan Assets		0	0
Defined Benefit Plan, Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets, Aggregate Projected Benefit Obligation		153,239,000	148,235,000
Defined Benefit Plan, Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets, Aggregate Fair Value of Plan Assets		0	0
Foreign Pension Plans, Defined Benefit [Member]
Actuarial present value of benefit obligations: [Abstract]
Accumulated benefit obligations		291,640,000	277,125,000
Change in benefit obligations:
Projected benefit obligations at beginning of year	288,216,000	288,216,000	278,707,000
Service cost		2,670,000	2,589,000
Interest cost		10,575,000	9,834,000
Benefits paid and plan expenses		-12,280,000	-11,218,000
Participant's contributions		394,000	391,000
Defined Benefit Plan, Settlements, Benefit Obligation		0	-918,000
Actuarial loss (gain)		42,095,000	1,678,000
Effect of exchange rate changes		-27,861,000	7,153,000
Projected benefit obligations at end of year		303,809,000	288,216,000	278,707,000
Change in plan assets:
Fair value of plan assets at beginning of year	143,704,000	143,704,000	114,515,000
Actual return on plan assets		22,939,000	17,201,000
Benefits paid and plan expenses		-12,280,000	-11,218,000
Employer's contributions		11,195,000	20,200,000	10,900,000
Defined Benefit Plan, Settlements, Plan Assets		0	-918,000
Participant's contributions		394,000	391,000
Effect of exchange rate changes		-9,185,000	3,533,000
Fair value of plan assets at end of year		156,767,000	143,704,000	114,515,000
Net amounts recognized in the consolidated balance sheets consist of:
Net amounts recognized in the consolidated balance sheets		-147,042,000	-144,512,000
Defined Benefit Plan, Assets for Plan Benefits, Noncurrent		9,825,000	6,879,000
Current liabilities		-6,786,000	-7,360,000
Noncurrent liabilities		-150,081,000	-144,031,000
Net amounts recognized in accumulated other comprehensive income consist of:
Prior service cost		-1,371,000	-1,745,000
Net amounts recognized in accumulated other comprehensive income		-1,371,000	-1,745,000
Actuarial assumptions as of the year-end measurement date:
Discount rate		2.75%	3.77%	3.62%	4.91%
Rate of compensation increase		3.07%	3.23%	2.88%	3.22%
Expected rate of return on assets		5.30%	5.50%	5.40%
United States Pension Plans of US Entity, Defined Benefit [Member]
Actuarial present value of benefit obligations: [Abstract]
Accumulated benefit obligations		327,632,000	279,299,000
Change in benefit obligations:
Projected benefit obligations at beginning of year	279,299,000	279,299,000	301,770,000
Service cost		1,400,000	1,075,000
Interest cost		12,900,000	11,500,000
Benefits paid and plan expenses		-19,282,000	-17,817,000
Participant's contributions		0	0
Defined Benefit Plan, Settlements, Benefit Obligation		0	0
Actuarial loss (gain)		53,315,000	-17,229,000
Effect of exchange rate changes		0	0
Projected benefit obligations at end of year		327,632,000	279,299,000	301,770,000
Change in plan assets:
Fair value of plan assets at beginning of year	249,756,000	249,756,000	221,755,000
Actual return on plan assets		25,780,000	8,818,000
Benefits paid and plan expenses		-19,282,000	-17,817,000
Employer's contributions		0	37,000,000	17,000,000
Defined Benefit Plan, Settlements, Plan Assets		0	0
Participant's contributions		0	0
Effect of exchange rate changes		0	0
Fair value of plan assets at end of year		256,254,000	249,756,000	221,755,000
Net amounts recognized in the consolidated balance sheets consist of:
Net amounts recognized in the consolidated balance sheets		-71,378,000	-29,543,000
Defined Benefit Plan, Assets for Plan Benefits, Noncurrent		0	0
Current liabilities		0	0
Noncurrent liabilities		-71,378,000	-29,543,000
Net amounts recognized in accumulated other comprehensive income consist of:
Prior service cost		0	0
Net amounts recognized in accumulated other comprehensive income		$0	$0
Actuarial assumptions as of the year-end measurement date:
Discount rate		4.08%	4.77%	3.92%	4.10%
Rate of compensation increase		0.00%	0.00%	0.00%	3.50%
Expected rate of return on assets		7.25%	7.50%	7.75%

Employee_Benefit_Plans_Schedul2

Employee Benefit Plans (Schedule of Allocation of Plan Assets, Pension Plans) (Details)	12 Months Ended
	Jan. 03, 2016	Dec. 28, 2014	Dec. 29, 2013
Foreign Pension Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		100.00%	100.00%
United States Pension Plans of US Entity, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		100.00%	100.00%
Other Securities [Member] | Foreign Pension Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		1.00%	1.00%
Other Securities [Member] | United States Pension Plans of US Entity, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		0.00%	0.00%
Debt Securities [Member] | Foreign Pension Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		50.00%	48.00%
Debt Securities [Member] | United States Pension Plans of US Entity, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		61.00%	57.00%
Equity Securities [Member] | Foreign Pension Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		49.00%	51.00%
Equity Securities [Member] | United States Pension Plans of US Entity, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		39.00%	43.00%
Scenario, Forecast [Member] | Foreign Pension Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Target Allocation Percentage	1
Scenario, Forecast [Member] | United States Pension Plans of US Entity, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Target Allocation Percentage	1
Scenario, Forecast [Member] | Minimum [Member] | Equity Securities [Member] | Foreign Pension Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	45.00%
Scenario, Forecast [Member] | Minimum [Member] | Equity Securities [Member] | United States Pension Plans of US Entity, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	40.00%
Scenario, Forecast [Member] | Minimum [Member] | Debt Securities [Member] | Foreign Pension Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	45.00%
Scenario, Forecast [Member] | Minimum [Member] | Debt Securities [Member] | United States Pension Plans of US Entity, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	50.00%
Scenario, Forecast [Member] | Minimum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | Foreign Pension Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	0.00%
Scenario, Forecast [Member] | Minimum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | United States Pension Plans of US Entity, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	0.00%
Scenario, Forecast [Member] | Maximum [Member] | Equity Securities [Member] | Foreign Pension Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	55.00%
Scenario, Forecast [Member] | Maximum [Member] | Equity Securities [Member] | United States Pension Plans of US Entity, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	50.00%
Scenario, Forecast [Member] | Maximum [Member] | Debt Securities [Member] | Foreign Pension Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	55.00%
Scenario, Forecast [Member] | Maximum [Member] | Debt Securities [Member] | United States Pension Plans of US Entity, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	60.00%
Scenario, Forecast [Member] | Maximum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | Foreign Pension Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	5.00%
Scenario, Forecast [Member] | Maximum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | United States Pension Plans of US Entity, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	5.00%

Employee_Benefit_Plans_Schedul3

Employee Benefit Plans (Schedule of Changes in Fair Value of Plan Assets, Pension Plans) (Details) (Pension Plans, Defined Benefit, USD $)	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
In Thousands, unless otherwise specified
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$413,021	$393,460
Cash [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	4,971	4,458
Equity Securities, U.S. Large-cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	28,602	34,127
Equity Securities, International large-cap value[Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	25,202	27,595
Equity Securities, Emerging Markets Growth [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	13,010	12,517
Equity Securities, Equity Index Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	77,432	73,796
Equity Securities, Domestic Real Estate Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,860	2,471
Equity Securities, Commodity Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	7,423	8,179
Foreign Government Debt Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	22,025	18,344
Fixed Income Funds, Corporate Debt Instruments [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	147,834	132,828
Fixed Income Funds, Corporate Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	25,164	22,619
Fixed Income Funds, High Yield Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3,614	6,170
Other Types of Investments, Multi-strategy hedge funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	23,332	22,689
Other Types of Investments, Venture Capital Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1	8
Other Types of Investments, Non U.S. Government Index Linked Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	31,551	27,659
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	139,495	140,732
Fair Value, Inputs, Level 1 [Member] | Cash [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	4,971	4,458
Fair Value, Inputs, Level 1 [Member] | Equity Securities, U.S. Large-cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	28,602	34,127
Fair Value, Inputs, Level 1 [Member] | Equity Securities, International large-cap value[Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	25,202	27,595
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Emerging Markets Growth [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	13,010	12,517
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Equity Index Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Domestic Real Estate Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,860	2,471
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Commodity Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	7,423	8,179
Fair Value, Inputs, Level 1 [Member] | Foreign Government Debt Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	53,813	45,215
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, Corporate Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, High Yield Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3,614	6,170
Fair Value, Inputs, Level 1 [Member] | Other Types of Investments, Multi-strategy hedge funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 1 [Member] | Other Types of Investments, Venture Capital Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 1 [Member] | Other Types of Investments, Non U.S. Government Index Linked Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	250,193	230,031
Fair Value, Inputs, Level 2 [Member] | Cash [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Equity Securities, U.S. Large-cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Equity Securities, International large-cap value[Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Emerging Markets Growth [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Equity Index Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	77,432	73,796
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Domestic Real Estate Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Commodity Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Foreign Government Debt Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	22,025	18,344
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	94,021	87,613
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, Corporate Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	25,164	22,619
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, High Yield Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Other Types of Investments, Multi-strategy hedge funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Other Types of Investments, Venture Capital Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Other Types of Investments, Non U.S. Government Index Linked Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	31,551	27,659
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	23,333	22,697	20,431	19,292
Fair Value, Inputs, Level 3 [Member] | Cash [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Equity Securities, U.S. Large-cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Equity Securities, International large-cap value[Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Emerging Markets Growth [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Equity Index Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Domestic Real Estate Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Commodity Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Foreign Government Debt Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, Corporate Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, High Yield Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Other Types of Investments, Multi-strategy hedge funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	23,332	22,689	20,262	19,285
Fair Value, Inputs, Level 3 [Member] | Other Types of Investments, Venture Capital Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1	8	7	7
Fair Value, Inputs, Level 3 [Member] | Other Types of Investments, Non U.S. Government Index Linked Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$0	$0

Employee_Benefit_Plans_Schedul4

Employee Benefit Plans (Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets, Pension Plans) (Details) (Pension Plans, Defined Benefit, USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at end of year	$413,021	$393,460
Venture Capital Funds [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at end of year	1	8
Multi-strategy hedge funds [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at end of year	23,332	22,689
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	22,697	20,431	19,292
Realized gains (losses)	0	7	1,162
Unrealized gains (losses)	636	2,409	996
Fair value of plan assets at end of year	23,333	22,697	20,431
Fair Value, Inputs, Level 3 [Member] | Common Collective Trusts [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	0	162	0
Realized gains (losses)	0	7	1,162
Unrealized gains (losses)	0	-19	19
Fair value of plan assets at end of year	0	0	162
Fair Value, Inputs, Level 3 [Member] | Venture Capital Funds [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	8	7	7
Realized gains (losses)	0	0	0
Unrealized gains (losses)	-7	1	0
Fair value of plan assets at end of year	1	8	7
Fair Value, Inputs, Level 3 [Member] | Multi-strategy hedge funds [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	22,689	20,262	19,285
Realized gains (losses)	0	0	0
Unrealized gains (losses)	643	2,427	977
Fair value of plan assets at end of year	23,332	22,689	20,262
Defined Benefit Plan, Purchases [Member] | Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Purchases, issuances, and settlements	0		9,448
Defined Benefit Plan, Purchases [Member] | Fair Value, Inputs, Level 3 [Member] | Common Collective Trusts [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Purchases, issuances, and settlements	0		9,448
Defined Benefit Plan, Purchases [Member] | Fair Value, Inputs, Level 3 [Member] | Venture Capital Funds [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Purchases, issuances, and settlements	0		0
Defined Benefit Plan, Purchases [Member] | Fair Value, Inputs, Level 3 [Member] | Multi-strategy hedge funds [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Purchases, issuances, and settlements	0		0
Defined Benefit Plans, Sales and Settlements [Member] | Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Purchases, issuances, and settlements	0	-150	-10,467
Defined Benefit Plans, Sales and Settlements [Member] | Fair Value, Inputs, Level 3 [Member] | Common Collective Trusts [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Purchases, issuances, and settlements	0	150	10,467
Defined Benefit Plans, Sales and Settlements [Member] | Fair Value, Inputs, Level 3 [Member] | Venture Capital Funds [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Purchases, issuances, and settlements	0	0	0
Defined Benefit Plans, Sales and Settlements [Member] | Fair Value, Inputs, Level 3 [Member] | Multi-strategy hedge funds [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Purchases, issuances, and settlements	$0	$0	$0

Employee_Benefit_Plans_Schedul5

Employee Benefit Plans (Schedule of Expected Benefit Payments, Pension Plans) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
United States Pension Plans of US Entity, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
2015	$18,169
2016	18,268
2017	18,363
2018	18,657
2019	18,857
2020-2024	97,713
Defined Benefit Plan, Contributions by Employer	0	37,000	17,000
Foreign Pension Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
2015	11,320
2016	11,832
2017	12,028
2018	12,475
2019	13,067
2020-2024	70,926
Defined Benefit Plan, Contributions by Employer	11,195	20,200	10,900
United Kingdom Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Contributions by Employer		$10,000

Employee_Benefit_Plans_Schedul6

Employee Benefit Plans (Schedule of Net Benefit Costs, Other Postretirement Benefits) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Defined Benefit Plan Disclosure [Line Items]
Net periodic benefit cost	$73,957	($16,839)	$34,361
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	95	106	106
Interest cost	155	135	144
Expected return on plan assets	-964	-965	-877
Defined Benefit Plan, Amortization of Gains (Losses)	-384	-182	-929
Actuarial loss (gain)	141	-520
Net periodic benefit cost	($1,098)	($906)	($1,556)

Employee_Benefit_Plans_Schedul7

Employee Benefit Plans (Schedule of Net Funded Status, Other Postretirement Benefit Plans) (Details) (Other Postretirement Benefit Plans, Defined Benefit [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	4.77%	3.86%	4.00%
Change in benefit obligations:
Projected benefit obligations at beginning of year	$3,342	$3,810
Service cost	95	106	106
Interest cost	155	135	144
Benefits Paid	-157	-189
Actuarial loss (gain)	141	-520
Change in accumulated benefit obligations during the year	234	-468
Projected benefit obligations at end of year	3,576	3,342	3,810
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	13,396	12,958
Actual return on plan assets	1,332	438
Benefits Paid	-157	-189
Fair value of plan assets at end of year	14,728	13,396	12,958
Net amounts recognized in the consolidated balance sheets	11,152	10,054
Defined Benefit Plan, Assets for Plan Benefits, Noncurrent	11,152	10,054
Prior service cost	0	0
Net amounts recognized in accumulated other comprehensive income	0	0
Discount rate	4.10%	4.77%
Expected rate of return on assets	7.25%	7.50%	7.75%
Retirees [Member]
Change in benefit obligations:
Projected benefit obligations at end of year	1,033	1,159	1,331
Active Employees Eligible to Retire [Member]
Change in benefit obligations:
Projected benefit obligations at end of year	424	388	470
Other Active Employees [Member]
Change in benefit obligations:
Projected benefit obligations at end of year	$2,119	$1,795	$2,009

Employee_Benefit_Plans_Schedul8

Employee Benefit Plans (Schedule of Changes in Fair Value of Plan Assets, Other Postretirement Benefit Plans) (Details) (Other Postretirement Benefit Plans, Defined Benefit [Member], USD $)	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
In Thousands, unless otherwise specified
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$14,728	$13,396	$12,958
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	7,982	7,479
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	5,405	4,700
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,341	1,217	1,194	1,130
Cash [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	248	167
Cash [Member] | Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	248	167
Cash [Member] | Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Cash [Member] | Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, U.S. Large-cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,644	1,831
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,644	1,831
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, International large-cap value[Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,449	1,480
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,449	1,480
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Equity Index Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	748	672
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	748	672
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Domestic Real Estate Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	164	133
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	164	133
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Commodity Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	427	439
Equity Securities, Commodity Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	427	439
Equity Securities, Commodity Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Commodity Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fixed Income Funds, Corporate Debt Instruments [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	8,499	7,126
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3,094	2,426
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	5,405	4,700
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fixed Income Funds, High Yield Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	208	331
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	208	331
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Types of Investments, Multi-strategy hedge funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,341	1,217
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,341	1,217	1,184	1,129
Other Types of Investments, Venture Capital Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$0	$0	$1	$1

Employee_Benefit_Plans_Schedul9

Employee Benefit Plans (Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets, Other Postretirement Benefit Plans) (Details) (Other Postretirement Benefit Plan [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets at beginning of year	$13,396	$12,958
Realized gains (losses)	384	182	929
Fair value of plan assets at end of year	14,728	13,396	12,958
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets at beginning of year	1,217	1,194	1,130
Realized gains (losses)	0	0	68
Unrealized gains (losses)	124	31	56
Fair value of plan assets at end of year	1,341	1,217	1,194
Common Collective Trusts [Member] | Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets at beginning of year	0	9	0
Realized gains (losses)	0	0	68
Unrealized gains (losses)	0	-1	1
Fair value of plan assets at end of year	0	0	9
Venture Capital Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets at beginning of year	0	1	1
Realized gains (losses)	0	0	0
Unrealized gains (losses)	0	-1	0
Fair value of plan assets at end of year	0	0	1
Multi-strategy hedge funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets at end of year	1,341	1,217
Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets at beginning of year	1,217	1,184	1,129
Realized gains (losses)	0	0	0
Unrealized gains (losses)	124	33	55
Fair value of plan assets at end of year	1,341	1,217	1,184
Defined Benefit Plan, Purchases [Member] | Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Purchases, issuances, and settlements	0	0	552
Defined Benefit Plan, Purchases [Member] | Common Collective Trusts [Member] | Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Purchases, issuances, and settlements	0	0	552
Defined Benefit Plan, Purchases [Member] | Venture Capital Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Purchases, issuances, and settlements	0	0	0
Defined Benefit Plan, Purchases [Member] | Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Purchases, issuances, and settlements	0	0	0
Defined Benefit Plans, Sales and Settlements [Member] | Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Purchases, issuances, and settlements	0	-8	-612
Defined Benefit Plans, Sales and Settlements [Member] | Common Collective Trusts [Member] | Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Purchases, issuances, and settlements	0	-8	-612
Defined Benefit Plans, Sales and Settlements [Member] | Venture Capital Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Purchases, issuances, and settlements	0	0	0
Defined Benefit Plans, Sales and Settlements [Member] | Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Purchases, issuances, and settlements	$0	$0	$0

Recovered_Sheet1

Employee Benefit Plans (Schedule of Expected Benefit Payments, Other Postretirement Benefits) (Details) (USD $)	12 Months Ended
	Jan. 03, 2016	Dec. 28, 2014
United States Pension Plan of US Entity, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
2015		$18,169,000
2016		18,268,000
2017		18,363,000
2018		18,657,000
2019		18,857,000
2020-2024		97,713,000
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
2015		167,000
2016		174,000
2017		182,000
2018		192,000
2019		200,000
2020-2024		1,159,000
Foreign Pension Plan, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
2015		11,320,000
2016		11,832,000
2017		12,028,000
2018		12,475,000
2019		13,067,000
2020-2024		70,926,000
Subsequent Event [Member] | United States Pension Plan of US Entity, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plans, Estimated Future Employer Contributions in Next Fiscal Year	20,000,000
Subsequent Event [Member] | Foreign Pension Plan, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plans, Estimated Future Employer Contributions in Next Fiscal Year	$10,200,000

Employee_Benefit_Plans_Savings

Employee Benefit Plans (Savings Plan) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, 401(k) Savings Plan, Employer Contribution Match of Employees Eligible Compensation	100.00%
Defined Benefit Plan, 401(k) Savings Plan, Maximum Employee Match Percent for Employer Match	5.00%
Defined Benefit, 401(k) Savings Plan Expense	$12.20	$12.80	$12.30
November 2011 Caliper Life Sciences [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, 401(k) Savings Plan, Employer Contribution Match of Employees Eligible Compensation		100.00%	50.00%
Defined Benefit Plan, 401(k) Savings Plan, Maximum Employee Match Percent for Employer Match		5.00%	5.00%

Employee_Benefit_Plans_Supplem

Employee Benefit Plans (Supplemental Executive Retirement Plan) (Details) (Supplemental Employee Retirement Plans, Defined Benefit [Member], USD $)	12 Months Ended
	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Supplemental Employee Retirement Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Projected benefit obligation	$24,500,000	$21,100,000
Fair value of plan assets	500,000	300,000
Pension expense	$4,800,000	($400,000)	$2,500,000

Employee_Benefit_Plans_Nonqual

Employee Benefit Plans (Nonqualified Deferred Compensation Plans) (Details) (Management [Member], USD $)	Dec. 28, 2014	Dec. 29, 2013
In Millions, unless otherwise specified
Management [Member]
Defined Benefit Plan Disclosure [Line Items]
Deferred Compensation Arrangement with Individual, Recorded Liability	$1	$1

Contingencies_Details

Contingencies (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013
	years
Commitments and Contingencies Disclosure [Abstract]
Accrual for Environmental Loss Contingencies, Component Amount	($2.30)	$5.70
Management's estimate of total cost of ultimate disposition of known environmental matters	$12.30	$13.50
Number of years over which estimated environmental cost will be paid	10

Warranty_Reserves_Details

Warranty Reserves (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
	years
Warranty reserve activity
Period of warranty protection beyond date of sale (in years)	1
Balance beginning of period	$10,534	$11,003	$10,412
Provision charged to income	17,447	17,291	17,750
Payments	-16,750	-17,116	-18,022
Adjustments to previously provided warranties, net	73	-693	801
Foreign currency and acquisitions	-521	49	62
Balance end of period	$10,783	$10,534	$11,003

Stock_Plans_Narrative_Details

Stock Plans (Narrative) (Details) (USD $)	12 Months Ended			3 Months Ended
	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012	Sep. 30, 2012	Jan. 01, 2012
	plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Stock-based Compensation Plans	1
Total income tax benefit recognized for stock-based compensation	$5,400,000	$4,400,000	$6,800,000
Stock-based compensation costs capitalized as part of inventory	300,000	400,000
Options related excess tax benefit, classified as a financing cash activity	0	0	1,767,000
Aggregate intrinsic value for stock options outstanding	48,000,000
Weighted average remaining contractual term of options (in years)	3 years 5 months
Aggregate intrinsic value for stock options exercisable	41,700,000
Weighted average remaining contractual term of options exercisable (in years)	2 years 5 months
Number of shares vested and expected to vest in the future	2,800,000
Aggregate intrinsic value of vested and expected to vest stock options	47,700,000
Weighted average remaining contractual term for options vested and expected to vest	3 years 5 months
Total pre-tax stock-based compensation expense	14,464,000	14,053,000	21,031,000
Deferred compensation liability	4,100,000
Performance Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value of stock granted (per share)	$42.84	$34.06	$26.18
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	35,954	28,515	0
Total pre-tax stock-based compensation expense	1,600,000	1,400,000	7,100,000
Shares/units granted	79,463	98,056	122,675
Awards/units outstanding	235,725
Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value of stock granted (per share)	$42.14	$30.65	$27.87
Total pre-tax stock-based compensation expense	700,000	700,000	700,000
Shares/units granted	2,373	3,263	3,580	955
Stock award program for non-employees Directors, fair market value	100,000	100,000	100,000
Restricted Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value of stock granted (per share)	$42.61	$33.87	$25.86
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	94,000	75,000	65,000
Fair value of restricted stock awards vested	7,100,000	8,000,000	4,300,000
Total pre-tax stock-based compensation expense	7,100,000	7,500,000	8,200,000
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted	10,000,000
Shares/units granted	261,000	289,000	358,000
Awards/units outstanding	558,000	649,000	781,000		672,000
Weighted-average period for recognition of unrecognized compensation cost, years	1 year 2 months
Option vesting period (in years)	3 years 0 months
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized under plan	5,000,000
Weighted-average grant-date fair value of stock granted (per share)	$41.71	$30.51	$24.51
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date	95.00%
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate	10.00%
Shares/units granted	60,870	89,521	53,961
Shares available for grant under employee stock purchase plan	1,000,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value of options	$11.86	$10.82	$7.36
Total intrinsic value of options exercised	22,000,000	13,800,000	13,100,000
Cash received from option exercises	24,500,000	20,300,000	32,500,000
Total pre-tax stock-based compensation expense	5,000,000	4,400,000	5,100,000
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted	$5,600,000
Weighted-average period for recognition of unrecognized compensation cost, years	1 year 10 months
Option vesting period (in years)	3 years 0 months
Stock Options Expiration Period After Date of Grant	7 years 0 months
Two Thousand Nine Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized under plan	10,700,000

Stock_Plans_Summary_of_Total_C

Stock Plans (Summary of Total Compensation Recognized Related to Outstanding Stock Options) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$14,464	$14,053	$21,031
Discontinued Operations Stock Compensation Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	0	0	406
Cost of sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	1,456	1,304	1,247
Research and development expenses [Member ]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	546	853	747
Selling, general and administrative and other expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	12,462	11,896	18,631
Continuing Operations Stock Compensation Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$14,464	$14,053	$20,625

Stock_Plans_WeightedAverage_As

Stock Plans (Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model) (Details)	12 Months Ended
	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Risk-free interest rate	1.50%	0.90%	0.60%
Expected dividend yield	0.70%	0.80%	1.20%
Expected lives, years	5 years	5 years	4 years
Expected stock volatility	30.90%	38.50%	38.70%

Stock_Plans_Summary_of_Stock_O

Stock Plans (Summary of Stock Option Activity) (Details) (USD $)	12 Months Ended
	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Stock option activity
Shares outstanding at beginning of the year	3,494,000	4,266,000	5,346,000
Shares granted	520,000	518,000	756,000
Shares exercised	-1,024,000	-947,000	-1,611,000
Shares canceled	-4,000	-8,000	-210,000
Shares forfeited	-158,000	-335,000	-15,000
Shares outstanding at end of year	2,828,000	3,494,000	4,266,000
Shares exercisable at end of year	1,900,000	2,392,000	2,677,000
Number of shares vested and expected to vest in the future	2,800,000
Weighted-average price, outstanding at beginning of year (per share)	$23.34	$21.64	$20.57
Weighted-average price, granted (per share)	$43.12	$33.62	$26.28
Weighted-average price, exercised (per share)	$23.89	$21.45	$20.16
Weighted-average price, canceled (per share)	$20.97	$22.88	$22.34
Weighted-average price, forfeited (per share)	$35.33	$23.04	$21.98
Weighted-average price, outstanding at end of year (per share)	$26.11	$23.34	$21.64
Weighted-average price, exercisable at end of year (per share)	$21.13	$20.66	$20

Stock_Plans_Summary_of_Restric

Stock Plans (Summary of Restricted Stock Award Activity) (Details) (USD $)	12 Months Ended
	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Restricted Stock Units (RSUs) [Member]
Restricted stock award activity
Performance factor percentage minimum	0.00%
Performance factor percentage maximum	200.00%
Restricted Stock Awards [Member]
Restricted stock award activity
Nonvested at beginning of year	649,000	781,000	672,000
Shares, granted	261,000	289,000	358,000
Shares, vested	-258,000	-346,000	-184,000
Shares, forfeited	-94,000	-75,000	-65,000
Nonvested at end of year	558,000	649,000	781,000
Weighted-average grant-date fair value, nonvested at beginning of year (per share)	$29.24	$24.71	$23.62
Weighted-average grant-date fair value of stock granted (per share)	$42.61	$33.87	$25.86
Weighted-average grant-date fair value, vested (per share)	$27.64	$22.98	$23.19
Weighted-average grant-date fair value, forfeited (per share)	$33.58	$28.76	$24.03
Weighted-average grant-date fair value, nonvested at end of year (per share)	$33.51	$29.24	$24.71

Stockholders_Equity_Narrative_

Stockholders' Equity (Narrative) (Details) (USD $)	3 Months Ended								12 Months Ended			3 Months Ended
	Dec. 28, 2014	Sep. 28, 2014	Jun. 29, 2014	Mar. 30, 2014	Dec. 29, 2013	Sep. 29, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012	Mar. 29, 2015	Oct. 23, 2014	Oct. 24, 2012
Schedule of Stockholders' Equity [Line Items]
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax										$4,800,000
Stock repurchase program, number of shares authorized to be repurchased													8,000,000	6,000,000
Cash dividends (per share)	$0.07	$0.07	$0.07	$0.07	$0.07	$0.07	$0.07	$0.07	$0.28	$0.28
Aggregate cost of repurchased common stock to satisfy statutory tax withholding obligation requirements									4,300,000	4,400,000	2,100,000
Number of common stock repurchased in open market									1,400,000	3,600,000	0
Stock repurchase program, number of shares remained available for repurchase	7,400,000								7,400,000
Repurchases of common stock									61,300,000	123,000,000
Repurchased shares of common stock to satisfy statutory tax withholding obligation requirements									98,269	127,544	82,186
Dividends accrued	7,900,000								7,900,000
Other Comprehensive Loss (Income), Reclassification Adjustment from AOCI on Derivatives, Tax										1,900,000	800,000
Other Comprehensive Income (Loss), Amortization Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service (Cost) Credit, Net of Tax									146,000	-658,000	-82,000
Interest Rate Contract [Member] | Interest Expense [Member]
Schedule of Stockholders' Equity [Line Items]
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax					($2,800,000)					($2,000,000)	($2,000,000)
Subsequent Event [Member]
Schedule of Stockholders' Equity [Line Items]
Cash dividends (per share)												$0.07

Stockholders_Equity_Components

Stockholders' Equity (Components Of Accumulated Other Comprehensive Loss) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
Cumulative Translation Adjustment Summary [Roll Forward]
Foreign currency translation adjustment, net of tax, beginning of year	$76,283	$67,527	$56,164
Current year change	-52,951	8,756	11,363
Foreign currency translation adjustment, net of tax, end of year	23,332	76,283	67,527
Unrecognized prior service costs, net of tax	1,575	1,429	2,087	2,169
Unrecognized prior service costs, net of tax, current year change	146	-658	-82
Unrealized (losses) gains on securities, net of tax	-107	-121	-129	-159
Unrealized (losses) gains on securities, net of tax, current year change	14	8	30
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax	0	2,892	1,196
Unrealized and realized (losses) gains on derivatives, net of income tax	0	0	-2,892	-4,088
Other comprehensive income (loss)	-52,791	10,998	12,507
Accumulated other comprehensive income (loss)	$24,800	$77,591	$66,593	$54,086

Derivatives_And_Hedging_Activi1

Derivatives And Hedging Activities (Details)

1 Months Ended

12 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

31-May-08

Dec. 28, 2014

Dec. 29, 2013

Dec. 30, 2012

Jan. 01, 2012

Dec. 28, 2014

Dec. 29, 2013

Dec. 30, 2012

Dec. 28, 2014

Dec. 29, 2013

Dec. 30, 2012

Dec. 28, 2014

Dec. 29, 2013

Dec. 30, 2012

Dec. 29, 2013

Dec. 29, 2013

Dec. 30, 2012

Dec. 28, 2014

Dec. 29, 2013

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

European And Asian Currencies [Member]

European And Asian Currencies [Member]

European And Asian Currencies [Member]

Fair Value Hedging [Member]

Fair Value Hedging [Member]

Fair Value Hedging [Member]

Cash Flow Hedging [Member]

Cash Flow Hedging [Member]

Cash Flow Hedging [Member]

Interest Rate Contract [Member]

Interest Rate Contract [Member]

Interest Rate Contract [Member]

Fair Value, Measurements, Recurring [Member]

Fair Value, Measurements, Recurring [Member]

USD ($)

USD ($)

USD ($)

EUR (€)

EUR (€)

Interest Expense [Member]

Interest Expense [Member]

Interest Expense [Member]

Fair Value, Inputs, Level 2 [Member]

Fair Value, Inputs, Level 2 [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Derivative [Line Items]

Company's business conducted outside United States

60.00%

Maximum maturity period for foreign exchange contracts, in months

12 months

Duration of foreign currency derivative contract, days

30 days

30 days

30 days

Derivative, Number of Instruments Held

5

0

2

Derivative, Notional Amount

$95,000,000

$138,400,000

$64,300,000

€ 238,200,000

€ 50,000,000

Foreign Currency Contract, Asset, Fair Value Disclosure

-3,205,000

-293,000

Settlement of forward interest rate contracts with notional amounts

150,000,000

Accumulated derivative losses in other comprehensive (loss) income, net of taxes

8,400,000

Accumulated derivative losses in other comprehensive (loss) income, tax

5,400,000

Accumulated derivative losses related to effective cash flow hedges in accumulated other comprehensive loss, net of taxes

0

0

-2,892,000

-4,088,000

Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax

4,800,000

-2,800,000

-2,000,000

-2,000,000

Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months

$0

Fair_Value_Measurements_Narrat

Fair Value Measurements (Narrative) (Details) (USD $)	12 Months Ended			3 Months Ended
	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012	Dec. 30, 2012	Jan. 01, 2012	Oct. 25, 2011
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)	$0
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	31,400,000
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value	91,000	4,926,000	3,017,000	3,017,000	20,298,000
Asset impairment	0	158,000	74,153,000
Discount on senior unsecured notes	-2,305,000
Business Combination, Contingent Consideration Arrangements, Description	3 years
Business Combination, Contingent Consideration Arrangements, Weighted Average Period	1 year
Line of Credit, Maturing December 16, 2016 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unsecured revolving credit facility, amount		700,000,000
Revolving credit facility outstanding balance		397,000,000
Line of Credit, Maturing January 8, 2019 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unsecured revolving credit facility, amount	700,000,000
Revolving credit facility outstanding balance	516,000,000
Discount on senior unsecured notes	0
2021 Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unsecured senior notes, face value	500,000,000					500,000,000
Unsecured senior notes, carrying value	497,700,000	497,400,000
Long-term Debt	497,700,000	497,400,000
Discount on senior unsecured notes	-2,305,000	-2,600,000				-3,100,000
Unsecured senior notes, fair value	542,700,000	513,000,000
Financing Lease Obligations [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Discount on senior unsecured notes	0
Unsecured senior notes, fair value	39,300,000	40,300,000
Trade Names And Trademarks [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Asset impairment			71,900,000
Carrying Value of Impaired Finite-lived Intangible Assets			3,800,000
Fair Value of Impaired Finite-lived Intangible Assets			1,500,000
Impairment of Intangible Assets (Excluding Goodwill)				74,200,000
Carrying Value of Impaired Indefinite-lived Intangible Assets (Excluding Goodwill)			76,400,000
Fair Value of Impaired Indefinite-lived Intangible Assets (Excluding Goodwill)			4,500,000
Asset impairment			$2,300,000
Maximum [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value Inputs, Royalty Rate			1.00%
Fair Value Inputs, Discount Rate			12.00%
Maximum [Member] | Trade Names And Trademarks [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Remaining Useful Life After Impairment for Finite and Indefinite Lived Intangible Assets			8 years
Minimum [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value Inputs, Royalty Rate			0.50%
Fair Value Inputs, Discount Rate			11.00%
Minimum [Member] | Trade Names And Trademarks [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Remaining Useful Life After Impairment for Finite and Indefinite Lived Intangible Assets			1 year

Fair_Value_Measurements_Assets

Fair Value Measurements (Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis) (Details) (Fair Value, Measurements, Recurring [Member], USD $)	Dec. 28, 2014	Dec. 29, 2013
In Thousands, unless otherwise specified
Carrying Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	($1,568)	($1,319)
Foreign Currency Contract, Asset, Fair Value Disclosure	3,205	293
Foreign exchange derivative liabilities, net	-302	-396
Contingent consideration	-91	-4,926
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	-1,568	-1,319
Foreign Currency Contract, Asset, Fair Value Disclosure	0	0
Foreign exchange derivative liabilities, net	0	0
Contingent consideration	0	0
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0	0
Foreign Currency Contract, Asset, Fair Value Disclosure	3,205	293
Foreign exchange derivative liabilities, net	-302	-396
Contingent consideration	0	0
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0	0
Foreign Currency Contract, Asset, Fair Value Disclosure	0	0
Foreign exchange derivative liabilities, net	0	0
Contingent consideration	($91)	($4,926)

Fair_Value_Measurements_Reconc

Fair Value Measurements (Reconciliation of Beginning and Ending Level 3 Net Liabilities) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance beginning of period	($4,926)	($3,017)	($20,298)
Additions	0	-1,100	-1,900
Payments	2,074	135	17,433
Change in fair value (included within selling, general and administrative expenses)	2,761	-944	1,748
Balance end of period	($91)	($4,926)	($3,017)

Leases_Details

Leases (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012	Aug. 22, 2013
Sale Leaseback Transaction [Line Items]
Sale Leaseback Transaction, Description of Accounting for Leaseback		The lease is accounted for as an operating lease and the excess of the net proceeds over the net carrying amount of the property are being amortized on a straight-line basis over the initial lease term of 15 years.
Sale Leaseback Transaction, Date		8/22/13
Sale Leaseback Transaction, Gross Proceeds		$47.60
Sale Leaseback Transaction, Lease Terms		15 years 0 months
Sale Leaseback Transaction, Current Period Gain Recognized	1.8	0.6
Sale Leaseback Transaction, Deferred Gain, Gross				26.5
Sale Leaseback Transaction, Deferred Gain, Net	24.1	25.9
Rental expense charged to continiuing operations	54.8	52.6	60.2
Minimum rental commitments in next fiscal year	54.8
Minimum rental commitments due in two years	36.3
Minimum rental commitments due in three year	28.1
Minimum rental commitments due in four years	23.9
Minimum rental commitments due in five years	20.7
Minimum rental commitments due in six years and thereafter	$77.20

Schedule_of_Sales_and_Operatin

Schedule of Sales and Operating Income from Continuing Operations by Operating Segment (Details) (USD $)	3 Months Ended										12 Months Ended						3 Months Ended
	Dec. 28, 2014		Sep. 28, 2014	Jun. 29, 2014	Mar. 30, 2014	Dec. 29, 2013		Sep. 29, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 28, 2014		Dec. 29, 2013		Dec. 30, 2012		Dec. 30, 2012
											segments
Schedule of Segment Reporting Information, by Segment [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)											$0
Asset impairment											0		158,000		74,153,000
Number of Operating Segments											2
Sales Revenue, Goods, Net											1,540,075,000		1,498,070,000		1,474,674,000
Service revenue											697,144,000		659,516,000		630,514,000
Total revenue											2,237,219,000		2,157,586,000		2,105,188,000
Operating income from continuing operations	30,567,000	[1]	58,776,000	69,637,000	51,762,000	92,930,000	[2]	57,954,000	40,216,000	36,694,000	210,742,000		227,794,000		103,120,000
Interest and other expense (income), net											41,139,000		64,110,000		47,956,000
Income from continuing operations before income taxes	20,647,000	[1]	47,810,000	60,673,000	40,473,000	66,065,000	[2]	45,614,000	27,351,000	24,654,000	169,603,000		163,684,000		55,164,000
Defined Benefit Plan, Recognized Net Gain (Loss) on Mark-to-Market											75,900,000		-17,600,000		31,800,000
Payments for Legal Settlements											7,000,000
Loss Contingency Accrual						3,700,000							3,700,000
Enzo Biochem, Inc. Complaint [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Loss Contingency Accrual, Period Increase (Decrease)											3,300,000
Litigation Settlement, Expense											3,400,000
Human Health [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Sales Revenue, Goods, Net											996,767,000		957,022,000		926,733,000
Service revenue											246,635,000		244,088,000		237,892,000
Total revenue											1,243,402,000		1,201,110,000		1,164,625,000
Operating income from continuing operations											220,165,000	[3]	156,452,000	[3]	63,773,000	[3]
Environmental Health [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Sales Revenue, Goods, Net											543,308,000		541,048,000		547,941,000
Service revenue											450,509,000		415,428,000		392,622,000
Total revenue											993,817,000		956,476,000		940,563,000
Operating income from continuing operations											109,129,000	[3]	97,052,000	[3]	111,844,000	[3]
Corporate [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Operating income from continuing operations											-118,552,000	[4],[5]	-25,710,000	[4],[5]	-72,497,000	[4],[5]
Customer Lists [Member] | Human Health [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)													200,000
Asset impairment						200,000
Trade Names And Trademarks [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)																	74,200,000
Asset impairment															71,900,000
Asset impairment															2,300,000
Trade Names And Trademarks [Member] | Human Health [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)																	73,400,000
Trade Names And Trademarks [Member] | Environmental Health [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)																	$700,000
[1]	The fourth quarter of fiscal year 2014 includes a pre-tax loss of $75.9 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy.
[2]	The fourth quarter of fiscal year 2013 includes pre-tax income of $17.6 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2013 also includes a tax benefit of $9.2 million related to discrete items primarily for lapses in statutes of limitations and audit settlements.
[3]	Pre-tax impairment charges have been included in the Human Health and Environmental Health operating income from continuing operations. The Company had no pre-tax impairment charges in fiscal year 2014. The Company recognized a $0.2 million pre-tax impairment charge in the Human Health segment in fiscal year 2013. The Company recognized $73.4 million of pre-tax impairment charges in the Human Health segment and also recognized $0.7 million of pre-tax impairment charges in the Environmental Health segment in fiscal year 2012.
[4]	Includes expenses related to litigation with Enzo Biochem, Inc. and Enzo Life Sciences, Inc. (collectively, bEnzob). Enzo filed a complaint in 2002 alleging that the Company separately and together with other defendants breached distributorship and settlement agreements with Enzo, infringed Enzo's patents, engaged in unfair competition and fraud, and committed torts against Enzo by, among other things, engaging in commercial development and exploitation of Enzo's patented products and technology. The Company entered into a settlement agreement with Enzo dated June 20, 2014 and during fiscal year 2014 paid $7.0 million into a designated escrow account to resolve this matter, of which $3.7 million had been accrued in previous years and $3.3 million was recorded during fiscal year 2014. In addition, $3.4 million of expenses were incurred and recorded in preparation for the trial during fiscal year 2014.
[5]	Activity related to the mark-to-market adjustment on postretirement benefit plans has been included in the Corporate operating loss from continuing operations, and in the aggregate constituted a pre-tax loss of $75.9 million in fiscal year 2014, pre-tax income of $17.6 million in fiscal year 2013, and a pre-tax loss of $31.8 million in fiscal year 2012.

Industry_Segment_and_Geographi2

Industry Segment and Geographic Area Information Schedule of Depreciation, Amortization and Capital Expenditures (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Segment Reporting Information [Line Items]
Depreciation and amortization expense	$116,736	$126,879	$125,126
Human Health [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization expense	89,969	98,582	99,597
Capital expenditures	15,201	20,900	24,518
Environmental Health [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization expense	24,736	25,915	23,001
Capital expenditures	12,149	16,532	14,488
Corporate [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization expense	2,031	2,382	2,528
Capital expenditures	1,722	1,549	3,395
Continuing Operations [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization expense	116,736	126,879	125,126
Capital expenditures	29,072	38,981	42,401
Discontinued Operations [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization expense	339	1,590	1,741
Capital expenditures	$213	$10	$7

Industry_Segment_and_Geographi3

Industry Segment and Geographic Area Information Schedule of Total Assets by Segment (Details) (USD $)	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
In Thousands, unless otherwise specified
Schedule of Total Assets, by segment [Line Items]
Assets	$4,134,075	$3,946,712
Human Health [Member]
Schedule of Total Assets, by segment [Line Items]
Assets	2,645,411	2,692,809	2,700,565
Environmental Health [Member]
Schedule of Total Assets, by segment [Line Items]
Assets	1,453,683	1,213,801	1,153,444
Corporate [Member]
Schedule of Total Assets, by segment [Line Items]
Assets	34,981	34,271	33,952
Net current and long-term assets of discontinued operations [Member]
Schedule of Total Assets, by segment [Line Items]
Assets	0	5,831	13,801
Total assets [Member]
Schedule of Total Assets, by segment [Line Items]
Assets	$4,134,075	$3,946,712	$3,901,762

Industry_Segment_and_Geographi4

Industry Segment and Geographic Area Information Schedule of Revenue by Geographic Area (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
Sales by Geographic Area [Line Items]
Total sales	$2,237,219	$2,157,586	$2,105,188
UNITED STATES
Sales by Geographic Area [Line Items]
Total sales	849,356	826,991	812,934
CHINA
Sales by Geographic Area [Line Items]
Total sales	276,230	254,838	216,425
UNITED KINGDOM
Sales by Geographic Area [Line Items]
Total sales	134,614	133,611	118,611
GERMANY
Sales by Geographic Area [Line Items]
Total sales	107,081	99,153	105,735
FRANCE
Sales by Geographic Area [Line Items]
Total sales	84,946	81,719	84,395
JAPAN
Sales by Geographic Area [Line Items]
Total sales	93,811	95,676	114,300
ITALY
Sales by Geographic Area [Line Items]
Total sales	85,433	78,120	69,599
Other International [Member]
Sales by Geographic Area [Line Items]
Total sales	605,748	587,478	583,189
Total international [Member]
Sales by Geographic Area [Line Items]
Total sales	$1,387,863	$1,330,595	$1,292,254

Industry_Segment_and_Geographi5

Industry Segment and Geographic Area Information Schedule of Long-Lived Assets by Geographic Location (Details) (USD $)	Dec. 28, 2014	Dec. 29, 2013	Dec. 30, 2012
In Thousands, unless otherwise specified
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	$291,182	$296,140	$273,163
UNITED STATES
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	198,675	214,721	200,539
CHINA
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	36,797	30,682	30,134
FINLAND
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	12,758	13,635	11,851
UNITED KINGDOM
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	13,033	9,882	2,960
SINGAPORE
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	7,041	6,812	6,366
NETHERLANDS
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	3,614	4,037	3,900
ITALY
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	4,107	2,735	3,303
GERMANY
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	2,493	2,591	2,353
BRAZIL
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	2,099	1,967	1,515
MEXICO
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	1,938	1,016	1,353
Other International [Member]
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	8,627	8,062	8,889
Total international [Member]
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	$92,507	$81,419	$72,624

Quarterly_Financial_Informatio2

Quarterly Financial Information (Unaudited) (Details) (USD $)	3 Months Ended										12 Months Ended
	Dec. 28, 2014		Sep. 28, 2014	Jun. 29, 2014	Mar. 30, 2014	Dec. 29, 2013		Sep. 29, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 28, 2014		Dec. 29, 2013		Dec. 30, 2012
Quarterly Financial Data [Abstract]
Revenue	$608,390,000		$542,049,000	$556,170,000	$530,610,000	$591,870,000		$522,100,000	$540,673,000	$502,943,000	$2,237,219,000		$2,157,586,000
Gross profit	277,602,000		243,309,000	247,984,000	235,713,000	276,770,000		233,268,000	241,662,000	224,442,000	1,004,608,000		976,142,000
Restructuring and contract termination charges, net	-579,000		11,092,000	742,000	2,135,000	10,211,000		1,124,000	19,247,000	3,310,000	13,390,000		33,892,000		25,051,000
Operating income from continuing operations	30,567,000	[1]	58,776,000	69,637,000	51,762,000	92,930,000	[2]	57,954,000	40,216,000	36,694,000	210,742,000		227,794,000		103,120,000
Income from continuing operations before income taxes	20,647,000	[1]	47,810,000	60,673,000	40,473,000	66,065,000	[2]	45,614,000	27,351,000	24,654,000	169,603,000		163,684,000		55,164,000
Operating income from continuing operations	31,314,000	[1]	42,898,000	52,003,000	34,951,000	73,455,000	[2]	40,763,000	27,274,000	32,775,000	161,166,000		174,267,000		71,289,000
Net income	30,787,000	[1]	42,277,000	50,490,000	34,224,000	66,873,000	[2]	40,198,000	27,925,000	32,216,000	157,778,000		167,212,000		69,940,000
Basic earnings per share:
Continuing operations	$0.28	[1]	$0.38	$0.46	$0.31	$0.65	[2]	$0.36	$0.24	$0.29	$1.43		$1.55		$0.63
Net income	$0.27	[1]	$0.38	$0.45	$0.30	$0.60	[2]	$0.36	$0.25	$0.28	$1.40		$1.49		$0.61
Diluted earnings per share:
Continuing operations	$0.28	[1]	$0.38	$0.46	$0.31	$0.65	[2]	$0.36	$0.24	$0.29	$1.42		$1.54		$0.62
Net income	$0.27	[1]	$0.37	$0.44	$0.30	$0.59	[2]	$0.36	$0.25	$0.28	$1.39		$1.47		$0.61
Cash dividends per common share	$0.07		$0.07	$0.07	$0.07	$0.07		$0.07	$0.07	$0.07	$0.28		$0.28
Defined Benefit Plan, Recognized Net Gain (Loss) on Mark-to-Market											75,900,000		-17,600,000		31,800,000
Tax Adjustments, Settlements, and Unusual Provisions						-9,200,000					-7,000,000		-24,000,000		-7,000,000
Human Health [Member]
Quarterly Financial Data [Abstract]
Operating income from continuing operations											$220,165,000	[3]	$156,452,000	[3]	$63,773,000	[3]
[1]	The fourth quarter of fiscal year 2014 includes a pre-tax loss of $75.9 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy.
[2]	The fourth quarter of fiscal year 2013 includes pre-tax income of $17.6 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2013 also includes a tax benefit of $9.2 million related to discrete items primarily for lapses in statutes of limitations and audit settlements.
[3]	Pre-tax impairment charges have been included in the Human Health and Environmental Health operating income from continuing operations. The Company had no pre-tax impairment charges in fiscal year 2014. The Company recognized a $0.2 million pre-tax impairment charge in the Human Health segment in fiscal year 2013. The Company recognized $73.4 million of pre-tax impairment charges in the Human Health segment and also recognized $0.7 million of pre-tax impairment charges in the Environmental Health segment in fiscal year 2012.